id,paper_id,author_id,status,liked_num,tags,content,title,language,created_at,updated_at
1,24861879,1,Submitted,0,carcinogenesis; glioma; miR-124; N-Ras; R-Ras,"1. Downregulation of MiR-124 Expression in Human Gliomas; 2. MiR-124 Overexpression Inhibits Akt and Raf/ERK1/2 Signaling Pathways; 3. R-Ras and N-Ras Have Synergistic Effects to Restore MiR-124 inhibited VEGF Transcriptional Activation; 4. Overexpression of R-Ras Reverses the Inhibitory Effects of MiR-124; 5. Overexpression of MiR-124 Increases Chemosensitivity of Glioma Cells to Temozolomide and Its Apoptotic Induction Effect in the Presence of Temozolomide Through R-Ras and N-Ras; 6. MiR-124 Suppresses Tumor Angiogenesis in Nude Mice; 7. Overexpression of MiR-124 Inhibits Cell Proliferation, Invasion, and Tumor Growth;",MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
2,25190548,1,Submitted,0,MiR-454-3p; Glioma; Diagnosis; Prognosis,1. The expression levels of miR-454-3p in plasma were signiﬁcantly higher than that from healthy controls; 2. The expression levels of miR-4543p in the post-operative plasmas were signiﬁcantly downregulated when compared to the pre-operative plasmas; 3. The prognosis of glioma with high miR-454-3p expression was significantly worse compared with that of glioma with low miR-454-3p expression; 4. Plasma miR-454-3p could be a novel potential diagnostic biomarker for glioma;,Plasma miR-454-3p as a potential prognostic indicator in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
3,17233837,1,Submitted,0,NA,"1. Alb protein, peroxiredoxin 4 and SH3 domain-binding glutamic acid-rich-like protein 3 were upregulated in glioblastoma multiform versus non-tumor tissues; 2. Aldolase C fructose-biphosphate, creatine kinase, B chain dihydrolipoyl dehydrogenase, enolase 2, fumarate hydratase, HSP60, lactoylglutathione lyase, lucine aminopeptidase, Mu-crystallin homolog, NADH-UO 24, neurofilament triplet L protein, septin 2, stathmin and vacuolar ATP synthase subunit E were downregulated in glioblastoma multiform compared with non-tumor tissues;",Biomarker discovery: A proteomic approach for  brain cancer profiling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
4,30187121,1,Submitted,0,EGFR amplification; Chromosome 7 gain; Chromosome 10 loss; 7+/10; 7+/10q; TERT promoter mutation; Glioblastoma; Astrocytoma; Pleomorphic xanthoastrocytoma,"1. Our results demonstrate that EGFRamp and the 7/10 signature are closely associated with IDHwt GBM; 2. pTERTmut is less specifc for IDHwt GBM; 3. We conclude that, in the absence of endothelial proliferation and/or necrosis, the detection of EGFRamp is a very strong surrogate marker for the diagnosis of GBM in IDHwt diffuse astrocytic tumors; 4. A combination of any two of EGFRamp, the 7/10 signature and pTERTmut, is highly specifc for IDHwt GBM and the combination of all  three alterations is frequent and exclusively seen in IDHwt GBM;","Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
5,29558959,1,Submitted,0,Glioblastoma; Long noncoding RNA; HOTAIR; Biomarker; Cancer,1. HOTAIR expression is higher in serum isolated from GBM patients relative to controls; 2. Serum HOTAIR has good diagnostic value as a GBM biomarker; 3. The levels of HOTAIR are positively correlated in tumors and serum isolated from GBM patients; 4. Sequence of qRT-PCR products amplified from GBM serum maps to human HOTAIR locus;,Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
6,29076027,1,Submitted,0,Glioma; Serum; Exosome; Biomaker; miR-301a,1. Serum exosomes from GBM patients promote the proliferation and invasion of H4 cells; 2. Serum exosomal miR-301a serves as a diagnostic biomarker; 3. Serum exosomal miR-301a expression levels are higher in glioma patients than in other brain tumor patients; 4. Exosomal miR-301a levels reflect tumor dynamics in matched GBM serum samples; 5. Serum exosomal miR-301a expression levels are associated with clinicopatholigcal features; 6. ROC and Kaplan-Meier analyses reveal diagnostic and prognostic relevance of tumor-derived miR-301a levels; 7. miR-301a downregulates PTEN expression in glioma cells;,Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
7,22952195,1,Submitted,0,glioblastoma multiforme; interleukin-13 receptor; PET; radioimmunotherapy,"1. Interleukin 13 receptor alpha 2 (IL13Ra2) is an attractive GBM associated biomarker; 2. We designed a novel IL13Ra2-targeted quadruple mutant of IL13 (TQM13) to selectively bind the tumor-restricted IL13Ra2 with high affinity but not significantly interact with the physiologically abundant IL13Ra1/IL4Ra heterodimer that is also expressed in normal brain; 3. TQM13 bound strongly to recombinant IL13Ra2; 4. Radiolabeled TQM13 specifically bound IL13Ra2-expressing GBM cells and specimens but not normal brain; 5. TQM13 did not functionally activate IL13Ra1/IL4Ra in cells or bind to it in SPR binding assays, in contrast to wtIL13; 6. In vivo targeting of systemically delivered radiolabeled TQM13 to IL13Ra2-expressing subcutaneous tumors was demonstrated and confirmed non-invasively for the first time with 124I-TQM13 positron emission tomography imaging; 7. 131I-TQM13 demonstrated in vivo efficacy against subcutaneous IL13Ra2-expressing GBM tumors and in an orthotopic synergeic IL13Ra2- positive murine glioma model, as evidenced by statistically significant survival advantage;",A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
8,31908895,1,Submitted,0,ATRX; mutation; copy number variation; glioma; biomarkers,1. Comutation of ATRX with IDH1 and TP53 mainly occurs in LGG; 2. ATRX mutation is associated with glioma prognosis; 3. ATRX loss in different grades of glioma; 4. ATRX mutations are associated with multiple molecular events in LGGs;,Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
9,30196284,1,Submitted,0,TGFBI; Glioma; Proliferation; Migration; PI3K/Akt signaling pathway,"1. High TGFBI expression was found to be associated with poor prognosis in patients with glioblastoma multiforme; 2. Immunohistochemistry showed that TGFBI expression was significantly higher in glioma tissue than in normal human brain tissues; 3. The expression level of TGFBI showed no significant correlation with age, sex, lymph-node metastasis, or pathological grade; 4. sh-TGFBI could inhibit proliferation, invasion and migration and induce apoptosis in U87 and U251 cells in vitro; 5. The phosphorylation levels of AKT and mTOR declined significantly in sh-TGFBI transfected U81 and U251 cells when compared with control;",Enhanced Expression of TGFBI Promotes the Proliferation and Migration of Glioma Cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
10,29099300,1,Submitted,0,glioma; glioblastoma; biomarkers; neutrophil lymphocyte ratio; lymphocyte monocyte ratio; oncology,"1. Compared with healthy controls and patients with acoustic neuroma, meningioma, or nonlesional epilepsy, the patients with glioma had higher values of preoperative NLR and dNLR as well as lower values of LMR and PNI, whereas PLR was higher in glioma patients than in healthy controls and patients with nonlesional epilepsy; 2. Subgroup analysis revealed a positive correlation between NLR, dNLR, PLR, and tumor grade but a negative correlation between LMR, PNI, and tumor grade in glioma; 3. The best diagnostic performance was obtained with the combination of NLR+LMR and dNLR+LMR, with AUCs of 0.777 and 0.778, respectively; 4. For the paired combinations, NLR+LMR demonstrated the highest accuracy;",Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
11,30214229,1,Submitted,0,miR-361-5p; glioma; SND1; migration; invasion,1. MiR-361-5p is decreased in gliomas and correlates with grades; 2. SND1 correlates with grades and its overexpression in glioma is associated with mir-361-5p downregulation; 3. mir-361-5p expression in glioma cell lines at various levels is negatively correlated with snD1 expression; 4. SND1 is a direct target of mir-361-5p in human glioma cells; 5. mir-361-5p inhibits the migration and invasion of gBM cell lines; 6. SND1 could induce the expression of MMP-2 via gene transcription activation; 7. SND1 reverses the tumor-suppressive effects of mir-361-5p;,mir-361-5p inhibits glioma migration and invasion by targeting snD1,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
12,29258767,1,Submitted,0,Glioma; GFAP; MAP - 2; NOGO - A; OLIG - 2; WT - 1; Astrocytoma; Oligodendroglioma; Ependymoma; Tissue microarrays  ,"1. GFAP expression decreases with tumour malignancy, oligodendroglial differentiation and IDH wildtype status in astrocytoma; 2. MAP-2 IRS is increased in astrocytomas with IDH1 mutation, oligodendroglial lineage and higher proliferation rate; 3. NOGO-a expression is lower in cases with ATRX loss, IDH mutation and higher patients' age; 4. OLIG-2 expression is predominantly seen in oligodendrogliomas and astrocytomas and OLIG-2 IRS is increased with higher proliferation rate and in IDH-mutant diffuse gliomas; 5. WT-1 expression significantly decreases in astrocytomas with ATRX loss and IDH1 mutation;","Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 expression in WHO 2016 classiﬁed neuroepithelial tumours and their prognostic value",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
13,27837435,1,Submitted,0,Exosome; Glioma; MiR-221; DNM3; RELA; Drug resistance,"1. In GBM, aberrant miRNA expression is closely associated with enhanced tumor proliferation,  invasion  and metastasis and consequently can be used as an indicator of cancer malignancy; 2. An increased drug resistance coincides with increased secretion of exosomes; 3. Elevated tissue and exosomal miR-221 levels is positively correlated with glioma grades; 4. Inhibiting endogenous miR-221 expression and incubation with U87MG-derived exosome exerted opposite efect on glioma proliferation, migration and TMZ resistance; 5. Exosomal miR-221 directly targets and inhibits DNM3 expression; 6. Overexpression of DNM3 reverses the stimulative efects of miR-221; 7. RELA mediates exosomal miR-221 expression; 8. MiR-221 upregulation promotes tumor growth in vivo;",Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
14,28367610,1,Submitted,0,Glioma; miR-122; Diagnose; Prognosis; Biomarker,1. Plasma miR-122 expression might act as a diagnostic and prognostic biomarker for gliomas; 2. miR-122 in the glioma group was lower than that in the control group; 3. The expression of miR-122 was signiﬁcantly correlated with WHO grade; 4. miR-122 expression decreased as the gliomas developed; 5. miR-122 expression and extent of resection are independent prognostic parameters for indicating poor prognosis for gliomas;,Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
15,31933806,1,Submitted,0,Glioblastoma; exosomes; miR-29b; prognosis,1. Serum exosomal miR-29b might be a promising biomarker for predicting prognosis of GBM; 2. Serum exosomal miR-29b could effectively distinguish GBM patients from AA patients or normal controls; 3. Low serum exosomal miR-29b expression was strongly associated with aggressive clinical findings and shorter survival; 4. Serum exosomal miR-29b was an independent prognostic indicator;,Serum miR-29b as a novel biomarker  for glioblastoma diagnosis and prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
16,31611998,1,Submitted,0,microRNA-193b; diagnosis; prognosis; tumor progression; glioma,"1. Increased expression of miR-193b was observed in serum, tissues and cells of patients with glioma compared with the corresponding controls; 2. miR-193b expression was associated with the World Health Organization grading and the Karnofsky Performance Scale of the patients; 3. High expression of miR-193b was associated with poor overall survival rate in patients; 4. The overexpression of this miR in glioma cells led to increased proliferation, migration and invasion, whereas its inhibition resulted in the opposite effects on these cell behaviors;",Diagnostic and prognostic value of microRNA-193b in patients with glioma and its effect on tumor progression ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
17,31410219,1,Submitted,0,extracellular vesicle; glioma; liquid biopsy; EGFR; NLGN3,1. We demonstrated that EGFR+EVs are effective diagnostic and prognostic markers of glioma; 2. High expression of EGFR in the EVs derived from glioma cells; 3. EGFR+EVs as a diagnostic marker for glioma; 4. EGFR in serum EVs correlates with the malignancy of glioma;,Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of  glioma.,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
18,25817794,1,Submitted,0,Cell cycle; CDK; Cyclin; Glioblastoma; miR-340,"1. miR-340 is downregulated in ~89% of glioblastoma tumor samples examined and 100% of examined glioblastoma cell lines; 2. miR-340 plays an oncosuppressive role in glioblastoma, and that its ectopic expression causes significant defect in glioblastoma cell growth; 3. miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2; 4. miR-340 plays a tumor-suppressive role in glioblastoma and may be useful as a diagnostic biomarker and/or a therapeutic avenue for glioblastoma;","miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
19,31485019,1,Submitted,0,GBM; miR-1246,1. H-GDEs induce M2 macrophage polarization in vitro and in vivo; 2. MiR-1246 is highly expressed in H-GDEs and the CSF of GBM patients and is delivered to macrophages via exosomes; 3. MiR-1246 induces M2 macrophage polarization in vitro and in vivo; 4. MiR-1246 directly targets TERF2IP in macrophages; 5. Exosomal miR-1246 targets TERF2IP and induces M2 macrophage polarization by activating the STAT3 pathway and inhibiting the NF-κB pathway;,Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
20,30197535,1,Submitted,0,microRNA-200b; down-regulation; glioma; grade; meta-analysis,"1. Compared with non-neoplastic brain tissues, the expression level of miR-200b was signicantly decreased in glioma tissues; 2. The glioma tissues from high-grade tumors had much lower miR-200b expression than glioma tissues from low-grade tumors;",MicroRNA-200b expression level is negatively associated with pathological grading in human gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
21,30279734,1,Submitted,0,ceRNA network; micNETs; TGFBR2; mesenchymal subtype,"1. We characterized mesenchymal glioblastoma at the mRNA-miRNA level and reported a ceRNA network that could separate the mesenchymal subtype from other subtypes; 2. Identification of a ceRNA network enriched in the mesenchymal subtype; 3. Six micNETs, TGFBR2, RUNX1, PPARG, GIT2, ACSL1 and RAP1B, predict the GBM mesenchymal subtype; 4. The TGF-β pathway is a potential therapeutic target for the GBM mesenchymal subtype;",Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
22,30995921,1,Submitted,0,Glioma; MicroRNA; hsa-let-7b-5p; Biomarker; Bioinformatics analysis,"1. Based on crosstalk genes in the KEGG, PPI network, and WGCNA analyses, PLK1, CCNA2, cyclin B2 (CCNB2), and AURKA were screened as candidate diagnostic marker genes; 2. The survival analysis revealed that high mRNA expression of PLK1, CCNA2, and AURKA was significantly associated with poor overall survival; 3. Furthermore, hsa-let-7b-5p was identified as a core miRNA in the regulation of candidate genes involved in glioma development; 4. We confirmed that hsa-let-7b-5p could inhibit the migration, invasion, and cell cycle of glioma cells;",Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
23,31138312,1,Submitted,0,Glioblastoma; Biomarker; Diagnosis; Prognosis; Diferentially expressed gene,1. CBX3 overexpression in human GBM samples was shown by immunohistochemical staining and qPCR; 2. Knockdown of CBX3 inhibits U373 cell growth; 3. Knockdown of CBX3 induced G2/M cell cycle arrest in U373 cells;,Integrated analysis of 34 microarray datasets  reveals CBX3 as a diagnostic and prognostic  biomarker in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
24,31784096,1,Submitted,0,MGMT promoter methylation; MS-PCR; Illumina methylome bead chip array; High density DNA; methylation array; Glioma; Glioblastoma,"1. MGMT promoter methylation status is an important biomarker predicting survival and response to chemotherapy in patients suffering from glioblastoma; 2. MGMT promoter methylation analysis are definitively higher than those generated by MS-PCR, but the array-based profiling also provides additional information about distinct molecular brain tumor classes and genomewide copy number information; 3. In our hands, the prediction of the MGMT promoter methylation status via STP-27/HM450 K seems to have slight advantages over MSPCR;",High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
25,20223881,1,Submitted,0,Hedgehog; pediatric brain tumor; pilocytic astrocytoma.,1. PTCH mRNA expression levels in Pilocytic Astrocytomas correlate lnversely with age; 2. PTCH and GLI1 protein staining indices in Pilocytic Astrocytomas correlate with that of a cellular marker for proliferation; 3. Hh pathway modulation can be measured in primary cells cultured from Pilocytic Astrocytomas;,Activation of the Hedgehog pathway in pilocytic astrocytomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
26,32008867,1,Submitted,0,DEAD box helicase 5; DEAD box helicase 17; Glioma; Radiotherapy; Prognosis,1. The expression of Ddx5 and Ddx17 were both upregulated in glioma tissues compared to normal brain tissues; 2. A significant positive correlation between Ddx5 and Ddx17 expression was identified by statistical analysis; 3. Immunohistochemical staining verified the expression of Ddx5 and Ddx17 in peritumoral zone was lower than that in core zone but higher than normal brain tissues; 4. The increased expression of Ddx5 and Ddx17 was markedly correlated with WHO Grade and histological type; 5. High Ddx5 and Ddx17 were found to be significantly associated with the worse overall survival of glioma patients; 6. Higher expression of both Ddx5 and Ddx17 predicted shorter clinical survival time for high-grade glioma patients with radiotherapy or with chemotherapy;,Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
27,15696972,1,Submitted,0,SOX6; Brain tumor; Undifferentiated cell; Neural stem/progenitor cell ,"1. Immunohistochemical analysis revealed that astrocytic and oligodendroglial tumors expressed SOX6; 2. Neuronal-glial cell tumors (central neurocytoma) and embryonal tumors (medulloblastoma), which arise from multipotential stem cell precursors, also showed a high intensity of SOX6 staining; 3. Ependymal tumors (ependymoma and subependymoma), meningioma, and schwannoma, which are all well differentiated tumors, showed either no staining or only faint staining for SOX6; 4. SOX6 may be expressed in bipotential or multipotential cells capable of neuronal and glial differentiation, but not in fully differentiated cells; 5. SOX6 may be a useful marker for the diagnosis of tumors arising from immature bipotential cells that may differentiate into neuronal and glial cells;",Immunohistochemical analysis of SOX6 expression in human brain tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
28,7523604,1,Submitted,0,Tenascin; cerebrospinal fluid; brain tumour,"1. An increase of tenascin in CSF (>100 ng/ml) was found in patients with an astrocytic tumour; 2. The concentration was significantly higher (>300 ng/rn) in high grade astrocytoma (anaplastic astrocytoma and glioblastoma) and a further increase(>1000 ng/ml) was found in cases of CSF dissemination of high grade astrocytoma; 3. Tenascin concentrations were less than 100 ng/ml in nonastrocytic tumours and non-neoplastic neurological diseases, except meningeal dissemination of tumour cells, meningeal stimulation by infection, and subarachnoid haemorrhage; 4. In cases of treated astrocytomas in remission, tenascin was negligible (<100 ng/ml) in the CSF; 5. The measurement of tenascin in CSF is useful for differential diagnosis of brain tumours and monitoring of astrocytic tumours;",Tenascin in cerebrospinal fluid is a useful biomarker for the diagnosis of brain tumour,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
29,28204824,1,Submitted,0,caspase-8; glioma; DNA methylation; gene silencing; anti-apoptosis,1. Downregulated mRNA expression of caspase-8 correlates with the grade of human malignant glioma; 2. Methylation of caspase-8 gene promoter is rare in human cancer cell lines; 3. Anti-apoptotic activity and expression at the mRNA level are highly relevant to caspase-8 gene methylation in human cancer cells; 4. The caspase-8 gene methylation status may be used as an indicator for the early diagnosis of human malignant glioma;,DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
30,20041315,1,Submitted,0,FRAT1; Astrocytoma; Proliferation; Apoptosis; Immunohistochemistry; TUNEL,"1. All grades and most subtypes of astrocytomas expressed high level of FRAT1; 2. Expression levels of FRAT1 in human astrocytomas were significantly positively correlated with increasing WHO grades; 3. PI in FRAT1-positive specimens was significantly higher than it in FRAT1-negative specimens, and FRAT1 IRS was positively correlated with the PI; 4. Though there was no significant difference between AI in FRAT1-positive specimens and that in FRAT1-negative specimens, FRAT1 IRS was inversely correlated with AI; 5. FRAT1 may play a key role in tumorigenesis and malignancy progression of astrocytomas under certain pathological conditions by promoting proliferation and reducing apoptosis;","FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
31,20219352,1,Submitted,0,microRNA; Astrocytoma; Survival,"1. The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease; 2. Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival; 3. Cox proportional hazard regression analysis revealed that this prognostic impact was independent of other clinicopathological factors; 4. Upon completing this multivariable analysis, old age, high WHO grade, high hsa-miR-21 expression level and low hsa-miR-181b expression level were all independently associated with decreased survival, while hsa-miR-21 showed a prognostic impact on patient survival as significantly as age;","The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
32,30794970,1,Submitted,0,Cell-free miR-214; Circulating miRNAs; Glioma; Noninvasive diagnosis; Prognostic factor,"1. Extracellular miR-214 levels were significantly overexpressed in preoperative serum from glioma patients with glioma, whereas its expression significantly decreased in matched postoperative serum; 2. Upregulated cell-free miR214 in serum was significantly associated with higher tumor grade, absence of isocitrate dehydrogenase, and unmethylated methylguanine methyltransferase promoter; 3. Extracellular miR-214 in serum could effectively distinguish patients with glioma from healthy control; 4. Serum cell-free miR-214 was an independent prognostic indicator of overall survival for patients with glioma;",Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
33,29076001,1,Submitted,0,MiRNAs; Circulating biomarkers; Gliomas; Exosomes,"1. Selection of candidate miRNAs overexpressed in glioma tissues; 2. The expression levels of miR-21, miR-222 and miR-124-3p in serum exosomes of patients with high grade gliomas were significantly higher than those of low grade gliomas and healthy controls; 3. The expression levels of miR-21, miR-222 and miR-124-3p were sharply decreased in samples obtained after surgery;",A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
34,28780604,1,Submitted,0,Glioma; MiR-338-5p; TSHZ3; MMP2; Invasion,"1. The expression of miR-338-5p, normalized to hsnRNA U6, was significantly higher in grade III and IV gliomas and glioblastoma cell lines compared to that in NNB and grade II gliomas, whereas TSHZ3 expression, normalized to GAPDH, was inversely related to miR-338-5p (R = -0.636, P<0.01); 2. TSHZ3 is a direct target gene of microRNA-338-5p; 3. MiR-338-5p promotes MMP2 expression; 4. Contrasting roles of miR-338-5p and TSHZ3 on regulating glioma cell invasiveness;",MiR-338-5p Promotes Glioma Cell Invasion by Regulating TSHZ3 and MMP2,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
35,30015879,1,Submitted,0,microRNA-500a-5p; proliferation; migration; chromodomain helicase DNA binding protein 5; glioblastoma,"1. MiR-500a-5p is significantly upregulated in glioblas toma tissues; 2. MiR-500a-5p enhances glioblastoma cell proliferation, migration and invasion in vitro; 3. MiR-500a-5p delayed tumor growth in vivo; 4. MiR-500a-5p specifically targeted CHD5 3-UTR in glioblastoma;","MiR-500a-5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
36,25922553,1,Submitted,0,NA,"1. FRAT1 Is Overexpressed in Glioma; 2. FRAT1 Is Associated with the Pathologic Grade, Proliferative Index, Invasive Index, and Microvessel Density of Glioma; 3. FRAT1 Expression Status Correlates with the Prognosis of GBM;",Overexpression of FRAT1 Is Associated with Malignant Phenotype and Poor Prognosis in Human Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
37,24847385,1,Submitted,0,glioma malignancy grade; NDRG2; DNA methylation; protein and mRNA expression; patient survival,1. Promoter methylation of NDRG2 is tumor-specific and is associated with the aggressiveness of glioma tumor; 2. NDRG2 expression is significantly downregulated in glioblastomas at both mRNA and protein levels; 3. Expression of this gene is negatively associated with tumor progression; 4. NDRG2 gene promoter methylation does not represent as being the major mechanism of gene silencing in gliomas; 5. NDRG2 epigenetic alterations and downregulation of expression are associated with the aggressive behavior of glioma in terms of tumor spread and poor patient survival;,Glioma Malignancy-Dependent NDRG2 Gene Methylation and Downregulation Correlates with Poor Patient Outcome,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
38,29050344,1,Submitted,0,glioblastoma; proliferation; TMZ resistance; microRNA; p53,1. MiR-141-3p is increased in human glioma tissues; 2. MiR-141-3p activates glioma cell growth in vitro; 3. MiR-141-3p knockdown sensitizes resistant GBM cells to TMZ in vitro; 4. p53 is a direct target of miR-141-3p in glioma cells; 5. Reintroduction of p53 could attenuate the oncogenic effect of miR-141-3p; 6. Reintroduction of p53 rescues the TMZ resistant effect of miR-141-3p; 7. MiR-141-3p knockdown inhibits tumor growth and sensitizes cells to TMZ in vivo;,MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
39,27981547,1,Submitted,0,miR-199a-3p;Diagnosis;Prognosis;Biomarkers;Glioma,"1. The qRT-PCR results showed that the miR-199a-3p expression was significantly downregulated in glioma tissues compared with the adjacent non-tumor tissues (p<0.01); 2. Plasma miR-199a-3p level was significantly lower in glioma patients when compared with healthy controls (p<0.01); 3. ROC curve analysis showed that plasma miR-199a-3p was a useful marker for discriminating cases from healthy controls, with an area under the ROC curve (AUC) of 0.8466 (95% confidence interval (CI) 0.772 to 0.9211, p<0.001); 4. MiR-199a-3p expression was associated with various clinicopathological parameters, including WHO grade (p=0.001) and KPS score (p=0.008); 5. Glioma patients with low miR-199a-3p expression level had distinctly shorter overall survival than patients with high miR-199a-3p expression level (p=0.0067); 6. Univariate and multivariate analysis suggested that miR-199a-3p expression was an independent predictor of poor prognosis;",Circulating miR-199a-3p in plasma and its potential diagnostic and prognostic value in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
40,27673330,1,Submitted,0,NA,1. miR210HG could be an important biomarker for the diagnosis of glioma; 2. miR210HG levels were significantly higher in tumor tissue than in tumor-adjacent normal tissue in participating glioma patients; 3. Serum miR210HG levels were also significantly higher in glioma patients than in healthy controls; 4. The receiver operating characteristic curve showed that serum miR210HG was a specific diagnostic predictor of acute pulmonary embolism with an area under the curve of 0.8323 (95% confidence inter); 5. Plasma miR210HG levels were upregulated in the glioma patient group compared to the healthy volunteer controls;,Long Noncoding RNA miR210HG as a Potential Biomarker for the Diagnosis of Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
41,21835431,1,Submitted,0,Nogo-A; Olig-2; Oligodendroglioma; 1p/19q; FISH,"1. Among the markers herein considered, Nogo-A was positive in oligodendroglial tumor cells with an elevated sensitivity and specificity (76.6% and 80.6%, respectively); 2. Olig-2 antibody stained most of the oligodendroglial tumors, thus showing a sensitivity even higher than Nogo-A (89.4%), but it also stained a large number of astrocytic tumors, including PA. Therefore, the specificity of Olig-2 was very low (25%); 3. Nogo-A is more useful and specific than Olig-2 in differentiating oligodendrogliomas from other gliomas; 4. Using a Nogo-A-driven fluorescence in situ hybridization analysis, it is possible to identify a larger number of 1p19q codeletions in gliomas;",Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
42,32220051,1,Submitted,0,glioma; miR-155-3p; resistance; Six1; temozolomide,1. Increase in miR-155-3p level in glioma tissues of humans; 2. In vitro analysis shows that miR-155-3p activates the growth of glioma cells; 3. Knock-down of miR-155-3p increases sensitivity of TMZ-resistant glioma cells; 4. miR-155-3p directly targets Six1 in glioma cells; 5. The oncogenic effect of miR-155-3p was abrogated by reintroducing Six1; 6. Six1 reintroduction rescues miR-155-3p- mediated TMZ resistant; 7. Knock-down of miR-155-3p inhibits the growth of tumours and increases TMZ sensitivity;,MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
43,31081101,1,Submitted,0,miR-126; Glioma; PTEN/PI3K/Akt pathway; MDM2-p53 pathway; Prognosis,1. Expression of miR-126 was Abnormally Low in Glioma Cells; 2. MiR-126 Inhibited in-vitro Proliferation of Glioma Cells; 3. MiR-126 Induced Apoptosis of Glioma Cells; 4. MiR-126 Inhibited in-vitro Migration of Glioma Cells; 5. MiR-126 Inhibited in-vitro Invasion of Glioma Cells; 6. MiR-126 Inhibited Glioma via Targeted Regulation of PTEN/PI3K/Akt and MDM2-p53 Pathways; 7. Prognosis of Patients with a Low miR-126 Level Was Poor;,Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2-p53 pathways,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
44,26207187,1,Submitted,0,Glioblastoma multiforme; Astrocytoma; 2D-DIGE; Mass spectrometry; Proteomics; Microarray,"1. GRP78 has long been recognized as a molecular chaperone in the endoplasmic reticulum (ER) and can be induced by the ER stress response; 2. Besides its location in the ER, GRP78 has been found in cell plasma membrane, cytoplasm, mitochondria, nucleus and other cellular secretions; 3. GRP78 is implicated in tumor cell proliferation, apoptosis resistance, immune escape, metastasis and angiogenesis, and its elevated expression usually correlates with a variety of tumor microenvironmental stresses, including hypoxia, glucose deprivation, lactic acidosis and inflammatory response; 4. GRP78 protein acts as a centrally located sensor of stress, which senses and facilitates the adaptation to the tumor microenvironment;",Identification of the Transmembrane Glucose Regulated Protein 78 as a Biomarker for the Brain Cancer Glioblastoma Multiforme by Gene Expression and Proteomic Studies.,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
45,22369735,1,Submitted,0,Single nucleotide polymorphism (SNP); Glioma; IL4R; TREH; CCDC26; Case-control study,"1. This study provides evidence for three glioma susceptibility genes-TREH, IL4R and CCDC26-in a Chinese population; this may shed light on molecular markers of glioma susceptibility and could therefore be used as a diagnostic and prognostic marker for glioma patients in clinical study; 2. The allele ""G"" of rs1801275 in the IL4R gene can predict 0.71- and 0.67-fold glioma susceptibility by the allele model and dominant model respectively; 3. The allele ""T"" of rs17748 is downstream ofthe TREH gene and the 3'UTR region ofthe PHLDB1 gene, and only predicts 0.48-fold glioma susceptibility by the recessive model; 4. The third protective allele ""G"" of rs6470745 in the CCDC26 gene only predicts a 0.48-fold glioma risk by the recessive model;","Polymorphisms of TREH, IL4R and CCDC26 genes associated with risk of glioma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
46,25140035,1,Submitted,0,Astrocytoma; diagnosis; prognosis; serum microRNA,"1. Nine serum miRNAs were significantly increased in the astrocytoma patients; 2. The biomarker composed of these 9 miRNAs had high sensitivity, specificity, and accuracy; 3. These 9 miRNAs were markedly decreased in the serum after operation; 4. The upregulation of miR-20a-5p, miR-106a-5p, and miR-181b-5p was associated with advanced clinical stages of astrocytoma; 5. Kaplan-Meier survival analysis showed that the high expression of miR-19a-3p, miR-106a-5p, and miR-181b 5p was significantly associated with poor patient survival; 6. The combined 3-miRNAs panel was an important prognostic predictor, independent of other clinicopathological factors;",Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
47,23494632,1,Submitted,0,Glioblastoma; Glioma; IDH; Malignant progression,"1. The median overall survival time of patients with sGBMMut was significantly longer than that of patients with sGBM-Wt (68.2 vs. 25.3 months); 2. The median time from initial diagnosis to sGBM diagnosis was also significantly longer for sGBM-Mut than for sGBM-Wt (50.1 vs. 13.4 months); 3. There was no difference in the median survival time from the sGBM diagnosis between sGBM-Mut and sGBM-Wt (6.75 vs. 6.8 months); 4. All sGBM-Mut (7 of 7) and 6 of 9 sGBM-Wt had TP53 mutations, and the remaining one-thirds of sGBM-Wt had neither TP53 mutations nor 1p/19q codeletion; 5. IDH1/2 mutations have an impact on the glioma history of sGBM with different genetic pathway; 6. The aggressive progression to sGBM-Wt suggests the need for more intense treatment to the IDH1/2 wild-type tumors;",Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
48,18096722,1,Submitted,0,Glioma; Human hematopoietic stem cells; Malignancy; Nervous system; Somatic stem cells,"1. The levels of membrane particle-associated prominin-1/CD133 declined during childhood and remained constant thereafter, with a remarkably narrow range in healthy adults; 2. Glioblastoma patients showed elevated levels of membrane particle-associated prominin-1/CD133, which decreased dramatically in the final stage of the disease; 3. Analysis of CSF for membrane particles carrying the somatic stem cell marker prominin-1/CD133 offers a novel approach for studying human central nervous system disease;",The Stem Cell Marker Prominin-1/CD133 on Membrane Particles in Human Cerebrospinal Fluid Offers Novel Approaches for Studying Central Nervous System Disease,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
49,10533725,1,Submitted,0,Telomerase; Telomerase activity,"1. Telomerase activity was detectable in almost all of the gliomas, but not in any of the meningiomas, neurinomas, or normal brain tissues; 2. The relative telomerase activity of the glioma showed a clear association with the pathological grade of glioma; 3. Most of the tumors with high telomerase activity were pathologically of high grade; 4. The relative level of telomerase activity could be correlated with the survival time of the patients; 5. These results suggest that the level of telomerase activity in brain tumors is a diagnostic marker indicating the prognosis of the patient as well as the malignant potential of the tumor;",Correlation of Clinical Features and Telomerase Activity in Human Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
50,28731165,1,Submitted,0,homeobox-containing protein 1; glioma; diagnostic marker,1. HMBOX1 was expressed in the nucleus and cytoplasm of normal and tumor tissues; 2. HMBOX1 expression was significantly decreased in WHO grade IV compared with WHO grade II and III glioma; 3. HMBOX1 expression significantly correlates with Ki‐67; 4. HMBOX1 expression in high-grade glioma was decreased compared with low‐level;,Homeobox‐containing protein 1 loss is associated with clinicopathological performance in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
51,31422498,1,Submitted,0,MiRNA; Glioblastoma multiform; Prognosis; Response,"1. Expression of investigated miR-221 and miR-222 were significantly increased in GBM cases as compared to healthy individuals (F=12.9, at P<0.001, F=28.78, at P<0.0001, respectively); 2. Among GBM patients (n=20), mean expression level miR-221 reported significant increase with elder GBM (>60 years) at F=5.7, P=0.028 3. both miR-221 and miR-222 showed significant difference in performance status (ECGO) at P=0.036 and 0.007, patients with primary lesion at P=0.001 and 0.005, surgically treatment strategy at P<0.001 and 0.004, respectively; 4. Patients were grouped according to their outcomes into response (complete [CR] or partial [PR]), stable disease[SD] and progressive disease [PD], miR-221 and miR-222 showed increase expression with PD and patients with worse PFS and OS were those with high miRs expression;",Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
52,21696415,1,Submitted,0,BRAF; isocitratedehydrogenase1; KIAA1549; pilocyticastrocytoma,"1. Fusion transcripts were present in 79% of tumours diagnosed in the first decade of life, but only in 51% of patients aged 11-20 years, 42% of patients aged 21-30 years, 30% of patients aged 31-40 years and 7% of patients older than 40 years; 2. The frequency of BRAF-KIAA1549 fusion transcripts is significantly lower in adult patients with pilocyticastrocytoma, weakening the sensitivity of this specific diagnostic marker in that age group;",BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
53,23041135,1,Submitted,0,Oligodendroglioma; FISH; 1p LOH; Proteomics; iTRAQ; Biomarkers,"1. We utilized a quantitative proteomics strategy that combined 8-plex isobaric tags for relative and absolute quantitation (iTRAQ) labeling and two-dimensional liquid chromatographytandem mass spectrometry (2D-LC/MS/MS) to identify molecular signatures, reveal mechanisms, and develop predictive markers of OG patients with 1p loss of heterozygosity (LOH); 2. Differential expression analyses of the proteomes of OGs with and without 1p LOH identified 13 candidate proteins that warranted further investigation; 3. The differential expression of four of the 13 candidates (UBA1, ubiquitin-like modifier activating enzyme 1, ATP6V1E1, ATPase, H+ transporting, lysosomal 31 kDa, V1 subunit E1, MAP2, microtubule-associated protein 2, and HMGB1, high-mobility group protein B1) was validated in 39 additional OG samples using immunohistochemistry; 4. These markers may provide insights into the feature of chemosensitivity in 1p LOH OGs, but may also represent useful predictive markers of 1p LOH with decision tree models;",iTRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
54,28133515,1,Submitted,0,TMEM39a; Multiple sclerosis; Systemic lupus erythematosus; Glioma,1. Upregulation of TMEM39A expression in glioblastoma cell lines; 2. TMEM39A transcription is enhanced in U87-MG cells and U251-MG cells; 3. Subcellular localization of TMEM39A in U251-MG cells; 4. TMEM39A is expressed in GBM tissue; 5. Differential TMEM39A mRNA expression and validation of the prognostic value of this observation in the REMBRANDT cohort;,Recognition of Transmembrane Protein 39A as a Tumor-Specific Marker in Brain Tumor,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
55,24966945,1,Submitted,0,Glioma; tumor antigen; melanoma-associated antigen D4; gene expression; immunogenicity,"1. Quantitative RTPCR analysis revealed that MAGE-D4 mRNA expression was overall up-regulated in 41 glioma specimens compared with that in 14 normal brain tissues; 2. Immunohistochemistry analysis showed that 78% (21/27) glioma tissues expressed MAGE-D4 protein, which was predominantly located in the cytoplasm of tumor cells, but absent in any neuroglia cell of normal brain tissues; 3. ELISA analysis demonstrated that humoral response against MAGE-D4 was  detected in 17% (7/41) of glioma patients' sera but not in 77 healthy donors; 4. MAGE-D4 is highly expressed in glioma and can develop specifically humoral response in glioma patients, which supports that it may be a promising biomarker for glioma diagnosis and immunotherapy;",High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
56,22855780,1,Submitted,0,NA,"1. An inverse association between IgE levels and risk of glioma was detected, the association was present at least 20 years before tumor diagnosis; 2. Elevated levels of prediagnostic allergen-specific IgE and total IgE are associated with reduced risk of both glioblastoma and glioma; 3. However, the association between testing positive for allergen-specific IgE and decreased tumor risk was restricted to women; 4. In addition, our findings suggest that for both sexes combined, the simultaneous presence of elevated levels of both allergen-specific IgE and total IgE may be associated with a lower risk of glioblastoma and glioma than are negative levels for both types of IgE;",Association Between Prediagnostic IgE Levels and Risk of Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
57,15289301,1,Submitted,0,Anaplastic Oligodendrogliomas;  High-Grade Astrocytomas;Medulloblastomas;PIK3CA,"1. Mutations in PIK3CA, a member of the family of phosphatidylinositol 3- kinase catalytic subunits, were identified in a significant fraction (25-30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers; 2. PIK3CA mutational analysis was performed on exon 9 and exon 20 of PIK3CA by PCR of genomic DNA from brain tumor samples followed by direct sequencing; 3. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas; 4. No mutations were identified in ependymomas or low-grade astrocytomas; 5. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers;","Mutations of PIK3CA in Anaplastic Oligodendrogliomas,  High-Grade Astrocytomas, and Medulloblastomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
58,31468534,1,Submitted,0,apoptosis; glioma; H19; miR‐675; VDR,"1. CUR decreased the expression of H19 and miR-675, but increased the expression of VDR; 2. VDR was a virtual target gene of miR-675; 3. H19, miR-675, and VDR formed a regulatory feedback loop, which could be involved in the development of glioma; 4. CUR could affect the prognosis of glioma; 5. CUR downregulated the expression of H19 and miR-675, but upregulated the expression of VDR; 6. The protein level of VDR in the CUR-loaded NP group was much higher than that in the NP group; 7. The involvement of a negative feedback loop of H19/miR-675/VDR has been demonstrated in the development of glioma; 8. H19 might serve as a new biomarker for the diagnosis and treatment of glioma;",A negative feedback loop of H19/miR‐675/VDR mediates therapeutic effect of cucurmin in the treatment of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
59,31628293,1,Submitted,0,lipopolysaccharide-binding protein; OKN-007; high-grade gliomas; GBM; glioblastoma; F98 rat glioma; oncology,"1. OKN-007 was effective in significantly decreasing F98 glioma tumor volumes as well as significantly increasing animal survival, compared with survival of untreated tumor-bearing rats; 2. The gene for LBP was significantly downregulated by OKN-007; 3. OKN-007 decreased the levels of LBP; 4. LBP could be detected not only in glioma tissue but also in blood serum of F98 glioma-bearing rats; 5. LBP could potentially be used as a serum diagnostic marker of treatment response in high-grade gliomas;",Association of decreased levels of lipopolysaccharide-binding protein with OKN-007-induced regression of tumor growth in an F98 rat glioma model,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
60,27154922,1,Submitted,0,2-hydroxyglutarate; glioma; glutamate; IDH1 mutation; MR spectroscopy,"1. The IDH1 mutant gliomas showed a significantly higher accumulation of 2HG; 2. Glutamate levels were significantly decreased in IDH1 mutant gliomas; 3. Through an analysis of metabolic enzyme genes in glutamine pathways, it was shown that the expressions of branched-chain amino acid transaminase 1 were reduced and glutamate dehydrogenase levels were elevated in IDH1 mutant gliomas; 4. Conventional MRS detection of glutamate and 2HG resulted in a high diagnostic accuracy (sensitivity 72%, specificity 96%) for IDH1 mutant glioma; 5. Combined biomarkers using glutamate and 2HG improved diagnostic performance;",Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
61,20472885,1,Submitted,0,Biomarkers; Genomics; Proteomics; and Gene Regulation,1. Quantitative PCR analysis showed that miR-182 was significantly increased by up to 32-fold in glioma tumors compared with the adjacent nontumor brain tissues obtained from the same patient; 2. Elevated expression of miR-182 was further identified by in situ hybridization in 248 of 253 (98%) archived human glioma biopsies tested; 3. A significant correlation between miR-182 expression and World Health Organization glioma grading (P < 0.001); 4. MiR-182 expression was an independent prognostic indicator for the survival of glioma patients;,miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
62,23035067,1,Submitted,0,NA,"1. The IDH1R 132H mutation is both a strong prognostic predictor and a diagnostic hallmark of gliomas and therefore has major clinical relevance; 2. The IDH1R 132H mutation was detected by a combination of coamplification at lower denaturation temperature and digital PCR; 3. The IDH1R 132H mutation was detected in 15 out of 25 plasma DNA mixtures (60%) from patients with mutated tumors and in none of the 14 patients with a nonmutated tumor; 4. With a specificity of 100% and a sensitivity related to the tumor volume and contrast enhancement, IDH1R 132H identification has a valuable diagnostic accuracy in patients not amenable to biopsy;",Detection of IDH1 mutation in the plasma of patients with glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
63,12577293,1,Submitted,0,oligodendrogliomas; MR spectroscopy; brain tumors; metabolism,1. Five main metabolites found in brain MR spectra were quantified and expressed as ratios of tumor to contralateral white matter tissue; 2. The metabolic profile of oligodendrogliomas showed a decreased level of N-acetylaspartate and increased levels of choline-containing compounds and glutamine plus glutamate compared with white matter; 3. The level of glutamine plus glutamate was significantly higher in low-grade oligodendrogliomas than in low-grade astrocytomas and may serve as a metabolic marker in diagnosis and treatment planning; 4. In high-grade oligodendrogliomas large resonances of lipids plus lactate were observed in contrast to low-grade tumors;,Characterization of oligodendrogliomas using short echotime HMR spectroscopic imaging,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
64,21303223,1,Submitted,0,Plasma netrin-1; diagnostic biomarker; human  cancers,"1. Netrin-1 levels in the circulation is significantly increased in renal, liver, prostate, meningioma of brain, pituitary adenoma, glioblastoma and breast cancer but not in colon, pancreatic and lung adenocarcinoma; 2. Netrin-1 can be used as a biomarker of many human cancers and may be useful as a prognostic tool as well;",Plasma netrin-1 is a diagnostic biomarker of human  cancers,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
65,31890049,1,Submitted,0,metallothionein 1J; pseudogene; glioma; proliferation; invasion; microRNA-24,1. MT1JP is downregulated in glioma; 2. Overexpression of MT1JP suppresses glioma cell proliferation and invasion; 3. MiR-24 expression was significantly upregulated in the glioma cell lines; 4. MT1JP is a direct target of miR‐24; 5. Inhibitory effect of MT1JP on glioma cell proliferation and invasion is dependent on miR‐24;,MT1JP inhibits glioma progression via negative regulation of miR‐24,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
66,25038272,1,Submitted,0,Brain tumors; Bcl-6; Glioma; Tumor progression,"1. A frequency of 36.6% of Bcl-6 translocation in GBM patients and a decreased expression in low-grade glioma patients, correlated with the severity of the disease; 2. Bcl-6 translocation induced an overexpression of both Bcl-6 protein and messenger in GBM, inhibiting apoptotic processes and caspases 3 expression; 3. On the contrary, in low-grade gliomas and meningiomas Bcl-6 expression was reduced, resulting in an increase of apoptotic processes; 4. Finally, p53 expression levels in brain tumors were comparable to Bcl-6 levels; 5. Overall, these data demonstrate, for the first time, that the Bcl-6 gene translocates in GBM patients and that its translocation and expression are correlated with apoptosis inhibition, indicating a key role for this gene in the control of cellular proliferation;",Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
67,23486687,1,Submitted,0,anaplastic gliomas; 1p/19q; IDH1/2; prognosis; stratification,"1. AOA could be classified into 2 subgroups with different prognoses based on 1p/19q codeletion and IDH1/2 mutation; 2. One subgroup with 1p/19q codeletion and/or IDH1/2 mutation was termed as AOA1, and the other one without either biomarkers was termed as AOA2; 3. AOA1 with 1p/19q codeletion and/or IDH1/2 mutation showed similar Kaplan-Meier plots with AO; 4. AOA2 without either biomarker showed similar Kaplan-Meier plots with AA; 5. Patients with AO and AOA1 had significantly longer PFS and OS than did patients with AA and AOA2;",1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
68,26191177,1,Submitted,0,miR-221; astrocytoma; cell proliferation; apoptosis,1. High expression of miR-221 in astrocytoma tissues; 2. Expression of miR-221 in U251 cells is up-regulated by miR-221 mimic; 3. U251 cell proliferation promoted by miR-221 mimic; 4. U251 cell cycle progression promoted by miR-221 mimic; 5. U251 cell apoptosis inhibited by miR-221 mimic;,Overexpression of miR-221 inhibits proliferation and promotes apoptosis of human astrocytoma cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
69,23606081,1,Submitted,0,Glioma; miR-30a-5p; Expression,1. MiR-30a-5p is overexpressed in glioma cell lines and glioma samples ascompared to the normal brain tissues (NBTs); 2. MiR-30a-5p expression level is positively correlated with tumor grade of malignancy; 3. MiR-30a-5p may have the potential as a diagnostic or prognostic marker of gliomas;,Analysis of hsa-miR-30a-5p Expression in Human Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
70,28107674,1,Submitted,0,Mitochondrial serine hydroxymethyltransferase 2 (SHMT2); Glioma; Oncology; Prognosis,"1. The expression of SHMT2 in glioma was signifificantly increased compared to normal brain tissue; 2. The proportion of SHMT2-positive cells gradually increased with increasing WHO grade; 3. As determined by the log-rank test, the PFS and OS of patients with low SHMT2 expression was significantly longer than that of patients with high SHMT2 expression; 3. SHMT2 promoted tumour proliferation; 4. SHMT2 expression and the WHO grade were independent prognostic indicators for glioma patients;",Mitochondrial serine hydroxymethyltransferase 2 is a potential diagnostic and prognostic biomarker for human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
71,31884342,1,Submitted,0,RAD21; MIR4697HG; Glioma; ceRNA,1. MIR4697HG inhibits glioma progression; 2. RAD21 suppresses MIR4697HG transcription; 3. MIR4697HG functions as a sponge for miR-766-5p; 4. MIR4697HG regulates glioma by modulating PRR12 expression; 5. Restored miR-766-5p or knockdown of PRR12 reverses the effects on cell proliferation and metastasis caused by MIR4697HG overexpression;,RAD21 inhibited transcription of tumor suppressor MIR4697HG and led to glioma tumorigenesis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
72,28112756,1,Submitted,0,NA,1. Upregulated Expression of FTX in Glioma Tissues; 2. Knockdown of FTX Inhibited Glioma Cell Proliferation and Invasion; 3. MiR-342-3p Expression was Directly Regulated by FTX; 4. MiR-342-3p Inhibited Proliferation and Invasion of Glioma Cells; 5. Inhibition of miR-342-3p Abrogated the Suppression of Proliferation and Invasion of Glioma Cells Induced by Depletion of FTX; 6. MiR-342-3p Directly Targeted AEG-1; 7. FTX Regulated AEG-1 Expression Through miR-342-3p;,Long noncoding RNA FTX is upregulated in gliomas and promotes proliferation and invasion of glioma cells by negatively regulating miR-342-3p,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
73,9002714,1,Submitted,0,basic fibroblast growth factor; brain tumor;  immunoassay;  tumor marker,"1. Upper limit of plasma bFGF in the normal subjects was 1.6 pg/ml; 2. Elevated plasma bFGF levels were observed in 28 patients including 13 of 17 glioma patients, eight of 19 benign tumor patients, and seven of 19 malignant tumor patients; 3. Twelve of 14 malignant glioma patients had elevated plasma bFGF levels; 4. There was a good correlation (r = 0.42, p < 0.05) between the elevated plasma bFGF level and the tumor volume;",Elevated Plasma Basic Fibroblast Growth Factor in Brain Tumor Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
74,21933631,1,Submitted,0,nerve growth factor; astrocytoma; cell nucleus; prognosis,"1. NGF-positive immunoreactive products were distributed in both the cytoplasm and nucleus of astrocytoma, but were only located in the cytoplasm of traumatic brain injury (TBI) tissue; 2. NGF nuclear-positive rate (NPR) of grades III-IV astrocytomas (70.0%) was higher than that of grades I-II astrocytoma (28.6%, P <0.05); 3. NGF-NP expression positively correlated with the NGF concentration in cerebrospinal fluid (CSF) (r=0.755, P <0.01); 4. Kaplan-Meier survival analysis indicated that the median survival time was 25 months for NGF-NP astrocytoma grade I-II patients and 42 months in NGF nuclear negative (NGF-NN) astrocytoma grade I-II patients (P <0.05); 5. In astrocytoma III-IV patients, the median survival was 7 months for NGF-NP patients and 24 months for NGF-NN patients (P <0.01); 6. Two types of NGF with molecular weights of 13 and 36 kDa were present in astrocytoma, but only the 36 kDa NGF was found in the CSF; 7. NGF expression elevated as the malignancy increased;",Nerve growth factor expression in astrocytoma and cerebrospinal fluid: a new biomarker for prognosis of astrocytoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
75,24238516,1,Submitted,0,glioma; plasma; biomarker; tissue inhibitor of metalloproteinase 1; metalloproteinase 9,"1. Both plasma TIMP-1 and MMP-9 levels were significantly increased in glioma patients; 2. Plasma TIMP-1 level was associated with glioblastoma multiforme (GBM) patients' better survival; 3. The survival time for GBM patients with higher-than-median TIMP-1 levels was significantly longer than those with lower TIMP-1 levels; 4. Plasma TIMP-1 was higher in male patients than female patients in Grade II gliomas, but the difference was not significant in high-grade (Grade III and IV) gliomas;",Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
76,32194691,1,Submitted,0,glioma; exosome; biomarker; microRNA-210; hypoxia,1. Serum exo-miR-210 was abnormally overexpressed in the serum of patients with glioma and increased with increasing grades of glioma; 2. Expression levels of exo-miR-210 in the serum are associated with specific clinicopathological features; 3. Serum exo-miR-210 levels reflect the dynamics of GBM; 4. Expression of serum exo-miR-210 as a potential diagnostic and prognostic biomarker for glioma; 5. Expression levels of serum exo-miR-210 are associated with hypoxia;,Exosomal microRNA-210 is a potentially non-invasive biomarker  for the diagnosis and prognosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
77,25785017,1,Submitted,0,MicroRNA-128; glioma; serum; biomarker; diagnosis,"1. Serum miR-128 levels were down-regulated in human glioma; 2. Serum miR-128 levels could reliably discriminate glioma patients from control subjects; 3. Serum miR-128 levels of glioma patients would elevate after surgery; 4. Similar to expression in serum, tissue miR-128 levels were significantly lower in glioma compared with normal cohorts (mean ± SD: 4.89 ± 0.87 versus 7.15 ± 1.24, P < 0.001), corresponding to glioma WHO grades; 5. Serum miR-128 levels were significantly correlated with tissue miR-128 levels;",Serum microRNA-128 as a biomarker for diagnosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
78,28959170,1,Submitted,0,glioma; lncRNA; LOC285758; over-expression; epigenetics; DNA methylation; MS-HRM; MLPA; IDH1; 1p/19q,1. In all glioma subtypes levels of LOC285758 were significantly higher in comparison to normal brain reference RNA; 2. LOC285758 expression was inversely associated with promoter methylation; 3. LncRNA LOC285758 Methylation is also distinctive between astrocytoma I-III and other glioma subtypes and may thus serve as an additional biomarker in glioma diagnosis; 4. Elevated expression of LOC285758 and its association to loss of cytosine methylation and higher malignancy grade suggest to an oncogenic function of this lncRNA in glioma biogenesis;,"Expression of LOC285758, a potential long non-coding biomarker, is methylationdependent and correlates with glioma malignancy grade",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
79,24412320,1,Submitted,0,MiRNA; Expression; RT-PCR; Glioma; Grade; Signaling pathways,"1. Expression of two prooncogenic miRNAs (miR-21 and miR-23a) was gradually up-regulated along with the tumor grade; 2. Expression of miR-7 and miR-137 was decreased depending on the glioma grade; 3. MDR, ABCG2, and p21/CDKN1A levels were significantly up regulated while expression of PTEN was down-regulated in tumor samples compared to the normal brain tissue;",Analysis of expression of microRNAs and genes involved in the control of 2 key signaling mechanisms that support or inhibit development of brain 3 tumors of different grades,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
80,21438658,1,Submitted,0,ALA; PpIX; biophotonics; brain tumor; fluorescence-guided resection; optical spectroscopy; oncology; light-transport modeling; glioma,"1. Qualitative fluorescence of protoporphyrin IX (PpIX), synthesized endogenously following d-aminolevulinic acid (ALA)  administration; 2. A significant difference in the quantitative measurements of PpIX concentration occurred in all tumor  groups compared with normal brain tissue; 3. Receiver operating characteristic (ROC) curve analysis of PpIX concen tration as a diagnostic variable for detection of neoplastic tissue yielded a classification efficiency of 87% (AUC =  0.95, specificity = 92%, sensitivity = 84%) compared with 66% (AUC = 0.73, specificity = 100%, sensitivity = 47%)  for conventional fluorescence imaging (p < 0.0001); 4. More than 81% (57 of 70) of the quantitative fluorescence measurements that were below the threshold of the surgeon's visual perception were classified correctly in an analysis  of all tumors; 5. This study is the first to measure quantitative ALA-induced PpIX concentrations in vivo, and the results have broad implications for guidance during resection of  intracranial tumors;",Quantitative fluorescence in intracranial tumor: implications  for ALA-induced PpIX as an intraoperative biomarker,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
81,29166921,1,Submitted,0,Epidermal growth factor receptor (EGFR); Targeted superparamagnetic iron oxide (SPIO) nanoparticle;  Magnetic resonance imaging (MRI); Glioblastoma; Lipid-encapsulated nanoparticle,"1. EGFR overexpression is a poor prognostic factor and is correlated with decreased overall survival in GBM patients; 2. In this study, a rapid and noninvasive method of molecular MRI was established to identify EGFR-positive GBM  by using novel EGFR-SPIO nanoparticles with a lipid  coating; 3. Te results indicate that T2 MR images from  EGFR-SPIO nanoparticles can be used for identifying  EGFR-positive GBM in  vitro; 4. The lipid-encapsulated EGFR-SPIO nanoparticles can specifcally target cells  with elevated EGFR expression in the three tested human glioblastoma cell lines; 5. The results of this study can be used  for noninvasive molecular MR image diagnosis in the future;",Identifcation of epidermal growth  factor receptor-positive glioblastoma using  lipid-encapsulated targeted superparamagnetic  iron oxide nanoparticles in vitro,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
82,30530966,1,Submitted,0,Glioblastoma; serum miR-100; prognosis; biomarker,"1. Serum miR-100 levels were significantly decreased in GBM patients compared with the healthy controls; 2. MiR-100 upregulation and subsequent elevated expression of SMRT/NCOR2 reduced cell proliferation and stimulated cell apoptosis in vitro; 3. The serum miR-100 levels in all participants were detected by qRT-PCR; 4. Serum miR-100 levels were significantly increased following gtreatment,indicating that serum miR-100 levels might be sensitive to treatment response;",Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
83,31083169,1,Submitted,0,biomarker; diagnostic; glioma; ROC; ROCK1,"1. ROCK1 mRNA was significantly increased in serum samples collected from glioma patients compared to the controls (P<.05); 2. High ROCK1 mRNA expression was tightly related with Karnofsky Performance Status (KPS) score (P=.024) and World Health Organization (WHO) grade (P=.029); 3. However, there was no association between ROCK1 expression and gender, neurological disorders, family history and cigarette smoking (all, P>.05); 4. The AUC was 0.881, indicating that ROCK1 was a diagnostic biomarker for glioma patients (P<.0001, 95% CI=0.829-0.933);",Serum ROCK1 mRNA is of great diagnostic value for glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
84,32147765,1,Submitted,0,glial fibrillary acidic protein (GFAP); glioblastoma; neurological diseases o the brain; diagnosis; prognosis,"1. A significant increase in the basal level of GFAP was typical of patients with glioblastomas in comparison with other groups (patients with astrocytomas, cerebral metastases, benign tumors, non-tumor diseases, and healthy subjects); 2. An association of GFAP levels with unfavorable prognosis of overall survival in patients with glioblastoma was revealed;",Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial Tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
85,26232108,1,Submitted,0,Glioma; antibody microarray; CRP; IL1β; microglia; endothelialcell; biomarker; stromal cell; brain tumor.,"1. Serum levels of LYAM1, BHE40 and CRP distinguish GBM sera from that of healthy individuals; 2. Elevated levels of CRP protein are present in GBM without a concomitant increase in CRP mRNA; 3. CRP promotes endothelial cells survival; 4. IL1β present in the microglial secretome is a novel mediator of CRP-induced endothelial cell survival; 5. Serum CRP is a marker for poor prognosis;",Definition of a serum marker panel for glioblastomadiscrimination and identification of Interleukin 1β in the microglial secretome as a novel mediator of endothelial cell survival  induced by C-Reactive Protein,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
86,31607471,1,Submitted,0,Gliomas; 11C-METPET; Molecularpathology; Noninvasivepredictor,"1. In the whole cohort analysis, SUVmax, SUVmean and texture features (SD and median) of oligodendroglioma, IDH-mutant and 1p/19q codeleted patients were lower than these values of other patients; 2. In WHO grade II subgroup analysis, no statistical difference of conventional features was observed between groups; 3. Texture analysis displayed higher diffEntropy, diffVariance, and entropy in oligodendroglioma, IDH-mutant and 1p/19q-codeleted patients; 4. Receiver operating characteristic analysis suggested AUCs of some conventional features and texture features ranged from 0.722 to 0.892 that are effective for diagnosis, determining LGGs with IDH-mutant and 1p/19qcodeleted in this cohort and WHO II grade glioma subgroup analysis respectively;",11C-Methionine Integrated PET/MRI-Based Texture Analysis Features May Have a Potential Ability to Distinguish Oligodendroglioma (IDH-Mutant and 1p/19q-Codeleted) From Varied Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
87,30932289,1,Submitted,0,NA,"1. The maximum and mean CBVa (CBVa_max and CBVa_mean) values were calculated in the tumor and normalized to the contralateral thalamus (nCBVa_max and nCBVa_mean); 2. Both CBVa_max and nCBVa_max increased with tumor grade (P < 0.001); 3. Grade II gliomas showed CBVa_max < 0.78 ml /100 ml in 10/17 cases and nCBVa_max <1.20 in 11/17 cases; 4. Grade III gliomas showed both CBVa_max > 0.78 ml / 100 ml and nCBVa_max > 1.20 in 13/14 cases, and CBVa_max < 2.06 ml / 100 ml in 13/14 cases and nCBVa_max < 2.33 in 11/14 cases; 5. Grade IV gliomas showed CBVa_max > 2.06 ml / 100 ml in 9/14 cases and nCBVa_max > 2.33 in 13/14 cases; 6. The areas under the ROC curve, sensitivity, and specificity were 0.839 (P < 0.001), 92.9% (26/28), and 64.7% (11/17) for CBVa_max, and 0.883 (P < 0.001), 92.9% (26/28), and 70.6% (12/17) for nCBVa_max in the discrimination between grade II and high-grade (grade III and grade IV) tumors, respectively;",Association of Glioma Grading With Inflow-Based Vascular-Space-Occupancy MRI: A Preliminary Study at 3T,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
88,26884942,1,Submitted,0,Glioblastoma; molecular subtypes; MGMT; P53; prognosis,1. The expression of MGMT was lower in proneural-like subtype GBM; 2. MGMT was negatively correlated with P53 expression; 3. Lower MGMT expression predicts better prognosis in proneural-like GBM; 4. The expression of MGMT in proneural subtype was lower and the prognosis was better in TCGA database;,Lower MGMT expression predicts better prognosis in  proneural-like glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
89,31897212,1,Submitted,0,microRNA‐769‐3p; zinc finger e‐box binding homeobox 2; progression; Wnt/β-catenin pathway; glioma,"1. MiR-769-3p was significantly downregulated in glioma tissues and serum, as well as in glioma cell lines (P<0.001); 2. MiR-769-3p expression was significantly associated with the World Health Organization grade and Karnofsky performance score; 3. The ROC curves demonstrated that serum miR-769-3p level reliably distinguished patients with glioma from healthy individuals; 4. High tissue miR-769-3p expression predicted poor overall survival in patients with glioma (log-rank P=0.001) and was identified  as an independent prognostic factor; 5. Zinc finger E-box binding homeobox 2 (ZEB2) was demonstrated to be a direct target of miR-769-3p in glioma cells using a luciferase assay 6. miR-769-3p upregulation suppressed the activity of the Wnt/β-catenin signaling pathway in glioma cells;",MicroRNA‐769‐3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‐catenin signaling pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
90,21435336,1,Submitted,0,Biomarker; Carcinogenesis; Glioma; Leucine-rich repeat C4; hsa-miR-381,1. Hsa-miR-381 is highly expressed in brain tumors; 2. Overexpression of hsa-miR-381 promotes the in vitro proliferation of glioblastoma cells and in vivo growth of xenograft tumors; 3. Peripheral blood hsa-miR-381 can be used as a potential diagnostic biomarker for brain tumors; 4. Hsa-miR-381 is a potential target for glioma therapy; 5. Overexpression of LRRC4 inhibits endogenous expression of hsa-miR-381 in U251 cells; 6. Overexpression of hsa-miR-381 targets the 3′ UTR of LRRC4; 7. Direct injection of hsa-miR-381 increases the growth of U251/LRRC4+ cells by downregulating LRRC4 and this action is associated with inducing MEK/ERK and AKT signaling;,Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
91,32111444,1,Submitted,0,Glioma; miR-129-5p; HOXC10; Proliferation,"1. MiR‐129-5p is downregulated in glioma tissues and cell lines; 2. MiR-129-5p acts as a tumor suppressor gene in glioma; 3. HOXC10 is a direct target of miR-129-5p in glioma cells; 4. MiR-129-5p suppressed cell growth, migration and invasion by inhibiting HOXC10; 5. MiR‐129-5p suppressed glioma growth in vivo; 6. HOXC10 was upregulated in glioma cancer; 7. HOXC10 knockdown inhibited cell proliferation,migration and invasion;",MircoRNA-129-5p suppresses the development of glioma by targeting HOXC10,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
92,15788675,1,Submitted,0,NA,1. Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas; 2. YKL-40 Immunohistochemistry Distinguishes Anaplastic Oligodendrogliomas from Glioblastomas; 3. Tumor cell staining intensity was also markedly different: 84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+; 4. YKL-40 Is a Stronger Marker than Glial Fibrillary Acidic Protein for Distinguishing Histologic Subtypes of High-Grade Glioma;,YKL-40 Is a Differential Diagnostic Marker for Histologic Subtypes of High-Grade Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
93,17934521,1,Submitted,0,microarray; array-CGH; methylation; astrocytoma; oligodendroglioma,"1. Total 1p deletions were rare (2%), however partial deletions involving 1p36 were frequently identified in anaplastic astrocytomas (22%) and glioblastomas (34%); 2. Multivariate analysis showed that patients with total 1p deletions had significantly longer survival; 3. In nine glioblastomas homozygous deletions at 1p36 were identified; 4. No somatic mutations were found among the five genes located in the homozygously deleted region; 5. The CpG island of TNFRSF9 was hypermethylated in 19% of astrocytic tumours and 87% of glioma cell lines; 6. TNFRSF9 expression was upregulated after demethylation of glioma cell lines; 7. Akt3 amplifications were found in four glioblastomas;",1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
94,25001988,1,Submitted,0,Glioma; Immunohistochemistry; MK; PTN; Prognosis; Survival,"1. The expression levels of MK and PTN proteins in glioma tissue were both significantly higher (both p < 0.001) than those in paratumor tissues on immunohistochemistry analysis, which was confirmed by qRT-PCR analysis; 2. Additionally, the overexpression of either MK or PTN was significantly associated with the World Health Organization Grade (p = 0.001 and 0.034, respectively), low Karnofsky Performance Status (KPS) score (p = 0.022 and 0.001, respectively), time to recurrence (p = 0.043 and 0.011, respectively) and poor overall survival (p = 0.018 and 0.001, respectively); 3. Multivariate Cox proportional-hazards regression analysis revealed that increased expressions of MK and PTN were both independent prognostic factors for poor overall survival (p = 0.030 and 0.022, respectively); 4. The co-expression of MK and PTN was more significantly (p = 0.003) associated with adverse prognosis in patients with gliomas than the respective expression of MK or PTN alone;",Co-expression of midkine and pleiotrophin predicts poor survival in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
95,2545843,1,Submitted,0,oncogene; cell cycle; flow cytometry; glial cell; glioblastoma; brain neoplasm,"1. Flow cytometric analysis revealed that the c-myc oncoprotein was highly expressed in neoplastic cell lines and in glioblastoma tumor specimens; 2. Anti-c-myc oncoprotein staining was not present in a nonneoplastic glial cell line or in a benign brain tissue specimen; 3. In the malignant cultured cells, c-myc oncoprotein underwent an approximate two fold increase as the cells progressed from G1/G0 to G2/M in the cell cycle;",Quantification of the c-myc oncoprotein in human  glioblastoma cells and tumor tissue,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
96,22763625,1,Submitted,0,Biomarker; Glioma; Meningioma; Metastasis; Plasma,"1. GFAP plasma detectability was strongly associated with a diagnosis of GBM (p<0.001); 2. Plasma GFAP and plasma placental growth factor (PlGF) showed promising moderate potential in the differential diagnosis of unifocal GBM versus unifocal supratentorial ICM (area under the curve=0.73, p<0.05);",Exploratory investigation of eight circulating plasma markers in brain tumor patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
97,20236756,1,Submitted,0,Astrocyte elevated gene-1; Oligodendroglioma; Tumor progression; Survival,1. Western blotting and RT-PCR showed that AEG-1 mRNA and protein were elevated in the oligodendroglioma cell line and significantly upregulated in primary oligodendrogliomas compared with the adjacent non-cancerous brain tissues; 2. Immunohistochemical analysis showed that 51 of 75 (68.0%) paraffin-embedded archival oligodendroglioma samples exhibited high expression of AEG-1; 3. Statistical analysis suggested that upregulation of AEG-1 was significantly correlated with the histological grade of oligodendroglioma (p = 0.000) and that patients with high AEG-1 level exhibited shorter survival time (p = 0.000); 4. Multivariate analysis revealed that AEG-1 upregulation might be an independent prognostic indicator for the survival of patients with oligodendroglioma;,Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
98,26662803,1,Submitted,0,Gene expression; Notch genes; Glioblastoma; Biomarker; Real-time PCR,"1. Using real-time PCR, we assessed the expression of Notch genes including receptors (Notch1, Notch2, Notch3, and Notch4), ligands (JAG1, JAG2, and DLL3), downstream targets (HES1 and HEY2), regulator Deltex1 (DTX1), inhibitor NUMB along with transcriptional co-activator MAML1, and a component of gamma-secretase complex APH1A in 15 formalin-fixed paraffin-embedded (FFPE) patient samples; 2. The data revealed aberrant expressionof Notch genes in glioblastoma compared to normal brain; 3. Seventy-three percent (11/15) of GBM samples studied showed elevated Notch1 expression; 4. HES1 showed low expression compared to the calibrator in 93.33 % (14/15) of samples studied (P=0.011); 5. DTX1, a transcription factor that regulates the Notch pathway through ubiquitin ligase activity, showed extremely low expression in all 13 samples studied (P=0.0001);","Aberrant expression of Notch1, HES1, and DTX1 genes in glioblastoma formalin-fixed paraffin-embedded tissues",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
99,31914615,1,Submitted,0,cell proliferation; cyclin D1; glioma; Par6,1. Par6 overexpression promotes cell proliferation in glioma cells; 2. Regulation of Par6 expression is involved in the tumorigenicity of glioma cells; 3. Par6 regulates the G1/S cell cycle transition in glioma cells; 4. The TGF-β-Par6 pathway is involved in the Par6-mediated tumorigenicity of glioma cells; 5. Activation of the Akt/PI3K/GSK-3β signaling pathway is associated with Par6-induced cell proliferation and cell cycle progression in glioma cells; 6. Par6 expression is associated with malignancy and prognosis in patients with glioma;,Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
100,16061654,1,Submitted,0,NA,"1. BEHAB/brevican mRNA expression is dramatically upregulated in glioma; 2. The protein analysis disclosed not only an increased expression of the full-length and cleaved forms of BEHAB/brevican but also the presence of additional, unique isoforms in glioma; 3. Characterize two novel glioma-specific isoforms, B/bsia and B/bDg, which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies; 4. B/bsia is an oversialylated isoform expressed by about half the high- and low-grade gliomas analyzed; 5. B/bDg lacks most of the carbohydrates typically present on BEHAB/brevican and is the major up-regulated isoform of this protein in high-grade gliomas but is absent in a specific subset of low-grade, indolent oligodendrogliomas; 6. B/bDg is detected on the extracellular surface, where it binds to the membrane by a mechanism distinct from the other BEHAB/brevican isoforms; 7. The glioma-specific expression of B/bDg, its restricted membrane localization, and its expression in all high-grade gliomas tested to date suggest that it may play a significant role in glioma progression and make it an important new potential therapeutic target;",Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
101,29605294,1,Submitted,0,MiR-615; EGFR; GBM; Suppressor,"1. MiR-615 is down-regulated in GBM tissues and cells; 2. EGFR is over-expressed in GBM tissues and cells; 3. MiR-615 negatively correlated with WHO grade (P=0.044), while EGFR mRNA and protein expressions were positively associated with WHO grade (P=0.049, 0.038); 4. MiR-615 might be a potential marker for prognosis of GBM patients; 5. MiR-615 inhibits GBM cell growth both in vitro and in vivo; 6. Ectopic expression of miR-615 inhibits migration and invasion of GBM cells; 7. MiR-615 directly targets EGFR expression; 8. EGFR overexpression reverses inhibitory effects of miR-615; 9. Inhibited EGFR affects proliferation, migration and invasion of GBM cells;","MiR-615 inhibits cell proliferation, migration and invasion by  targeting EGFR in human glioblastoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
102,29502292,1,Submitted,0,High-grade glioma ; Microarray ; WEE1 ; EMP3 ; IGF2BP3,"1. Three prognostic-related genes (WEE1, IGF2PB3, and EMP3) were demonstrated to separate HGG patients into two different survival subgroups; 2. The area under receiver operating characteristic curve of WEE1 was higher than that of IGF2BP3, EMP3, age, IDH status, 1p/19q status, and MGMT promoter status; 3. WEE1 is an independent prognostic biomarker in survival analysis and has potential diagnostic value for HGG patients; 4. WEE1 can induce HGG cell migration and invasion in vitro;",Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
103,23664694,1,Submitted,0,Glioma; PTX3; Cancer-associated inflammation; Macrophage; Immunohistochemistry,"1. In glioblastoma, most neoplastic cells were PTX3 positive and usually with a strong immunostaining; 2. PTX3 is expressed in neuroepithelial tumors; 3. PTX3 is differentially expressed in low and high-grade tumors and in tumors of astrocytic or oligodendroglial origin, reflecting malignancy and histological origin;",The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
104,19240607,1,Submitted,0,Glioma; Methylation; p16; Serum,"1. A more frequent detection of p16 promoter methylation in the serum of patients with astrocytic tumor than in the serum of those with oligodendroglial tumor; 2. No methylated p16 sequences were detected in the peripheral serum of the patients having tumors without these methylation changes or in the 10 healthy controls; 3. P16 promoter methylation in the serum was observed in all brainstem astrocytoma cases, but not in other cases;",p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
105,19521960,1,Submitted,0,MIC-1/GDF15; prognostic biomarker; cerebrospinalfluid; glioblastoma,1. MIC-1/GDF15 CSF concentrations are increased in glioblastoma patients; 2. Enhanced CSF concentrations of MIC-1/GDF15 are associated with worse outcome in glioblastoma patients; 3. MIC-1/GDF15 expression in glioblastoma and monocyte-macrophage differentiation; 4. The MIC-1/GDF15 promoter is methylated in glioblastoma and most glioblastoma cell lines;,Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
106,24729345,1,Submitted,0,astrocytic tumour; oligodendroglial tumour; miR-210; glioma; real-time quantitative RT-PCR,"1. MiR-210 presents a differential expression depending on the origin of the glioma; 2. Oligodendroglial tumours exhibit a significantly reduced level of miR-210 as compared with normal brain tissue; 3. In contrast, astrocytic tumours demonstrate significantly increased levels of miR-210; 4. The expression of miR-210 is positively correlated with the grade of astrocytic tumour, in the following order: grade IV > grade III > grade II > normal brain tissue (p < 0.05);",Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
107,30266404,1,Submitted,0,DIRAS3; Glioma; EGFR; Akt,"1. DIRAS3 is up-regulated in gliomas and is correlated with poor prognosis of glioma patients; 2. DIRAS3 promotes proliferation and invasion of glioma cells; 3. DIRAS3 expression level is higher in Classical and Mesenchymal subtypes glioma, and is positively correlated with EGFR -AKT signaling activation; 4. DIRAS3 promotes glioma malignance by activating EGFR-AKT signaling cascade at the downstream of EGFR; 5. DIRAS3 could serve as a potential diagnostic marker and a promising therapeutic target of gliomas;",Oncogenic DIRAS3 promotes malignant phenotypes of glioma byactivating EGFR-AKT signaling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
108,23524267,1,Submitted,0,Glioblastoma; Glioma stem cells; Nestin; c-Secretase,1. Cell surface Nestin expression in human primary GBM specimens and GSCs; 2. Cell surface Nestin may be one of the reliable GSC markers and may serve as an unique GSC marker in GBMs that are devoid of CD133-positive and CD15-positive GSCs; 3. Cell surface Nestin-positive cells have robust tumorsphere-forming ability; 4. R-Secretase regulates the generation of cell surface Nestin in human GSCs;,Cell surface Nestin is a biomarker for glioma stem cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
109,31603255,1,Submitted,0,glioblastoma; long noncoding RNA; PKCα; Smad2; tumorigenicity,"1. TCONS_00020456 expression level correlated with glioma grades; 2. TCON decreased significantly in GBM, and showed a coexpressional relationship with Smad2 and protein kinase C α (PKCα); 3. Decreased TCONS_00020456 expression indicated a short life span and was a prognostic factor when combined with WHO grade; 4. TCONS_00020456 regulated epithelial-mesenchymal transition‐related proteins and signal pathways; 5. TCONS_00020456 negatively promotes glioma progression in vivo; 6. TCON, regarded as oncosuppressor, targeting the Smad2/PKCα axis plays a novel role in inhibiting the malignant progression of glioma;",Identification of novel LncRNA targeting Smad2/PKCα signal pathway to negatively regulate malignant progression of glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
110,31690954,1,Submitted,0,Glioma; Tumor-associated macrophages; CD163; CCL3; PD-1,"1. We observed an increase in the pool of M2 macrophages in high-grade gliomas, as confirmed by their CD68 and CD163 double-positive phenotype; 2. Less M1 macrophages were noticed in high-grade gliomas, as evidenced by the down-regulation in the expression of CCL3 marker; 3. Higher gene expression ratio of CD163/CCL3 is associated with glioma progression; 4. The Kaplan-Meier survival plots indicate that glioma patients with lower expression of M2c marker (CD163), and higher expression of M1 marker (CCL3) had better survival; 5. We examined the systemic immune response in the peripheral blood and noted a predominance of M2 macrophages, myeloid-derived suppressor cells and PD-1+ CD4 T cells in glioma patients; 6. A high gene expression ratio of CD163/CCL3 in high-grade gliomas as compared to low-grade gliomas and significantly elevated frequency of M2 macrophages and PD-1+ CD4 T cells in the blood of tumor patients;",Predominance of M2 macrophages in gliomas leads to the suppression  of local and systemic immunity,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
111,26518540,1,Submitted,0,Glioblastoma; GFAP; Serum; Diagnostic marker; Biomarker,"1. Serum GFAP levels in GBM patients were positively correlated with tumor volume and histopathological tumor characteristics; 2. GBM patients with high GFAP levels showed more in vivo GFAP expression as well as more necrosis and perilesional edema compared to GBM patients having low or non-detectable GFAP levels; 3. GFAP serum concentrations differentiated between patients with GBM and patients with cerebral mass lesions of other entities with a moderate diagnostic accuracy; 4. In the low GFAP serum group, 80% of the patients had no MGMT promoter methylation, while 20% revealed inconclusive results; 5. In the high GFAP serum group, 40% had a positive MGMT promoter methylation, whereas 60% showed no methylation;",Prospective evaluation of serum glial fibrillary acidic protein(GFAP) as a diagnostic marker for glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
112,19755387,1,Submitted,0,IDH1 Mutations;  Molecular Signature; Predictive Factor; Secondary Glioblastomas,"1. IDH1 mutations were detected in 36 of 407 glioblastomas (8.8%); 2. Glioblastoma patients with IDH1 mutations were younger (mean, 47.9 years) than those with EGFR amplification (60.9 years) and were associated with significantly longer survival (mean, 27.1 versus 11.3 months, P < 0.0001); 3. IDH1 mutations were frequent in glioblastomas diagnosed as secondary (22 of 30, 73%), but rare in primary glioblastomas (14 of 377, 3.7%: P < 0.0001); 4. IDH1 mutations as genetic marker of secondary glioblastoma corresponded to the respective clinical diagnosis in 95% of cases; 5. Glioblastomas with IDH1 mutation diagnosed as primary had clinical and genetic profiles similar to those of secondary glioblastomas, suggesting that they may have rapidly progressed from a less malignant precursor lesion that escaped clinical diagnosis and were thus misclassified as primary; 6. Conversely, glioblastomas without IDH1 mutations clinically diagnosed as secondary typically developed from anaplastic rather than low-grade gliomas, suggesting that at least some were actually primary glioblastomas, that may have been misclassified, possibly due to histologic sampling error;",IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
113,15696967,1,Submitted,0,Glioma; Transcriptional factor; SOX6,"1. SOX6 gene was more highly expressed in glioma tissues and fetal brain than in normal adult brain and other cancer cells, except melanoma cells; 2. Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex;","Expression of a transcriptional factor, SOX6, in human gliomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
114,28881623,1,Submitted,0,positron emission tomography (PET); high-grade glioma; doxycycline; biodistribution; IL13RA2,1. The radiolabeled peptide [64Cu]Pep-1L was used without any additional purication for both in vitro and in vivo studies; 2. [64Cu]Pep-1L has good serum stability and suitable for in vivo use; 3. These in vitro uptake data demonstrate binding and specicity of [64Cu]Pep-1L towards IL-13RA2-expressing cancer cells; 4. [64Cu]Pep-1L specically binds doxycycline induced B16F10-Tet-hIL13RA2 tumors in vivo;,Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
115,16487366,1,Submitted,0,brain tumour; differential diagnosis; immunohistochemistry; NeuN,"1. We found no NeuN expression in pilocytic astrocytoma, whereas all other investigated tumour subtypes showed focal or widespread expression in varying proportions of cases; 2. Comparing NeuN expression in clear cell tumours, widespread NeuN expression had a positive predictive value of 76.9% (95% confidence interval 46.2, 95.0) for central neurocytoma; 3. Lack of NeuN expression had a positive predictive value of 87.3% (76.5, 94.4) for oligodendroglioma;",Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
116,24386117,1,Submitted,0,NA,"1. In this study, MRI contrast agents or fluorescent probes linked to RGD-peptides were used, in a glioma model, to assess the relation between RGD uptake/signal improvement/cell density and consequently tumor invasiveness; 2. RGDpeptide internalization appeared, in vitro, as a marker of cellular density; 3. The combination of these peptides with contrast agents associated to more sensitive MRI techniques could improve the MRI signal allowing the characterization of cellular density for tumor diagnosis;",Cellular Density Effect on RGD Ligand Internalization in Glioblastoma for MRI Application,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
117,27047250,1,Submitted,0,Biomarkers; Blood; Diagnosis; Glioma; Microarrays; miRNAs.,"1. By quantitative real time reverse-transcriptase polymerase chain reaction (qRT-PCR), we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas; 2. ROC analysis of miR-15b biomarker levels allowed to differentiate patients with tumour from patients without glioma; 3. Combined expression analyses of miR15b and miR-21 distinguished between patients with and without glioma (90% sensitivity and 100% specificity); 4. A decrement in the expression levels of miR-16 characterized glioblastomas compared to low grade and anaplastic gliomas; 5. It's possible to identify the disease state by meaning miR-15b and miR-21 markers in blood; 6. miR-16 can be used to distinguish glioblastoma from other grade gliomas;",miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
118,21881830,1,Submitted,0,Free DNA; Serum; Cerebrospinal fluid (CSF); Glioma,"1. With two primers sets amplifying short and long free DNA fragments (ALU115 and ALU247), free DNA integrity was determined by ratio of the concentration of ALU247 over ALU115 (ALU247/115); 2. There was no significant difference in serum DNA concentration with the long fragment assay (ALU247bp segment) between the glioma patients (mean 78.73±63.64 ng/ml, range 7.923-308.14 ng/ml) and the healthy controls (mean 57.72±55.86 ng/ml, range 6.16-191.97 ng/ml, p=0.058); 3. The results revealed that the mean serum DNA integrity value was not significantly different between glioma patients and controls (p=0.067); 4. The CSF DNA integrity index in both glioma and nonneoplastic control specimens varied widely; 5. CSF-free DNA concentration and integrity may serve as a new marker for the diagnosis of glioma;",Prognostic Value of Free DNA Quantification in Serum and Cerebrospinal Fluid in Glioma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
119,22037800,1,Submitted,0,HDGF; Glioma; Tumorigenesis; Prognostic factor; Adenovirus-mediated siRNA gene delivery,"1. HDGF expressed at a higher level in malignant gliomas when compared with normal brain and low-grade gliomas, suggesting that the expression levels correlated with glioma malignancy grade; 2. Increased expression of nuclear HDGF predicts short survival for GBM patients after surgery; 3. After knocking down nuclear HDGF expression in human GBM cells, cell growth and cell invasion and induction on apoptosis by caspase-3 activation were significantly inhibited; 4. We conclude that HDGF is a mitogenic growth factor in glioma progression and can be a useful prognostic marker for GBM and therapeutic target for clinical management of glioma in the future;",Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
120,17460461,1,Submitted,0,caveolin; brain tumors; glioblastoma; oligodendroglioma; marker,"1. In all glioblastomas and gliosarcomas, cav-1 staining was extremely intense, typically localized at the cell membrane and recognized a variable percentage of cells, including the majority of spindle cells and palisade-oriented perinecrotic cells; 2. In anaplastic astrocytomas, a less intense membrane staining or a cytoplasmic dotlike immunoreactivity were present, the latter being almost the exclusive pattern observed in diffuse astrocitomas grade II; 3. In contrast to astroglial tumors, the striking totality of grade II oligodendrogliomas and the large majority of grade III were lacking cav-1 expression; 4. The lack of cav-1 immunoreactivity in oligodendrogliomas suggests its concrete application as a useful diagnostic marker;",Caveolin-1 Expression is Variably Displayed in Astroglial-derived Tumors and Absent in Oligodendrogliomas: Concrete Premises for a New Reliable Diagnostic Marker in Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
121,28717243,1,Submitted,0,NA,"1. LOC441204, a novel non-coding RNA gene displaying high expression in clinical specimens of brain tumor and significant upregulation in glioma cell lines in microarray analyses; 2. High expression of LOC441204 is correlated with brain tumor progression; 3. LOC441204 is associated with brain tumor cell proliferation; 4. LOC441204 depletion suppresses brain tumor cell proliferation; 5. LOC441204 depletion promotes β-catenin degradation; 6. LOC441204 interacts with β-catenin in brain tumor cell; 7. LOC441204 bound to β-catenin preventing its degradation, resulting in downstream p21 repression and cdk4 activation to enhance glioma cell proliferation;",The long non-coding RNA LOC441204 enhances cell growth in  human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
122,22002423,1,Submitted,0,α-Internexin; 1p/19q; Diagnostic marker; Glioma; Oligodendroglioma; LOH; Proliferation,"1. INA was found in only 20% of cases with isolated/partial 1p aberrations and 36% of cases without 1p/19q deletions, it was also found in 63% (10/16) of cases with isolated/partial 19q aberrations; 2. α-Internexin expression was more specific in high-grade than in lowgrade gliomas (66% vs 31%); 3. Only no or weak INA expression was seen in OMTs; 4. INA is a useful marker to differentiate OTs from astrocytic tumors and OMTs, but INA expression is not exclusively linked to OTs harboring the 1p/19q codeletion;",α-Internexin in the Diagnosis of Oligodendroglial Tumors and Association With 1p/19q Status,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
123,30726924,1,Submitted,0,cystathionine; MRS; brain glioma; 1p/19q codeletion; MEGA-PRESS,"1. Statistically significant higher cystathionine levels were detected in IDH-mutated 1p/19q-codeleted gliomas, compared with IDH-mutated non-codeleted gliomas; 2. Selective accumulation of cystathionine was observed in codeleted gliomas in vivo, in brain tissue samples, as well as in cells harboring heterozygous deletions for serine- and cystathionine-pathway genes located on 1p: phosphoglycerate dehydrogenase (PHGDH) and cystathionine gammalyase (CTH); 3. QPCR analyses showed 40-50% lower expression of both PHGDH and CTH in 1p/19q-codeleted gliomas compared to their non-codeleted counterparts;",Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic  resonance spectroscopy,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
124,27600094,1,Submitted,0,embryonic stem cell marker;glioma stem-like cell;glioma progression;glioma recurrence,"1. Embryonal and neural stem cell markers are expressed on mRNA level in astrocytomas of different WHO grades, and primary and recurrent glioblastomas; 2. While OCT4 and MYC expression was elevated with increasing malignancy of astrocytomas, MYC expression was slightly reduced in recurrent tumors compared to the corresponding primary tumor; 3. Correlation analysis revealed distinct positive correlation between distinct stem cell markers, and this effect was most prominent in the recurrent glioblastoma cohort; 4. In situ, embryonic stem cell factors were found also in more differentiated tumor regions; 5. Upon exposure to temozolomide, increased expression of KLF4 (and lesser Nanog and OCT4) was observed;",Stem cell markers in glioma progression and recurrence,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
125,26464658,1,Submitted,0,SPRY4-IT1; glioma; proliferation; metastasis; epithelial-mesenchy,"1. Higher expression levels of SPRY4-IT1 were observed in glioma tissues than in the adjacent normal brain tissues; 2. The mRNA expression of SPRY4-IT1 was higher in glioma cell lines than in NHA; 3. SPRY4-IT1 could promote proliferation, metastasis and EMT of glioma cells and its knockdown could inhibit glioma cell growth, migration and EMT; 4. Downregulation of SPRY4-IT1 could reduce proliferation of glioma cells; 5. Downregulation of SPRY4-IT1 obviously blocked the EMT process;","Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
126,24582746,1,Submitted,0,HOXB9; Glioma; Transforming growth factor-b1; Proliferation,"1. HOXB9 expression in glioma tissues was significantly higher than that in nontumor tissues; 2. Higher HOXB9 expression was also significantly associated with advanced clinical stage in glioma patients; 3. HOXB9 overexpression stimulated the proliferation, migration, and sphere formation of glioma cells, whereas HOXB9 knockdown elicited an opposite effect; 4. HOXB9 overexpression also increased the tumorigenicity of glioma cells in vivo; 5. The activation of transforming growth factor-b1 contributed to HOXB9-induced oncogenic activities;",Overexpressed homeobox B9 regulates oncogenic activities by transforming growth factor-b1 in gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
127,29590424,1,Submitted,0,Lower grade glioma; T2-FLAIR; imaging marker;IDH-mutant astrocytoma,"1. There was substantial interrater agreement for the T2-FLAIR mismatch sign [κ = 0.75 (0.64, 0.87)], but only fair agreement for T2 homogeneity [κ = 0.38 (0.25-0.52)]; 2. The T2-FLAIR mismatch sign was present in 38 cases (25%) and had a positive predictive value of 100%, negative predictive value of 68%, a sensitivity of 51% and a specificity of 100%; 3. Our study confirms that among non-enhancing LGG the T2-FLAIR mismatch sign represents a highly specific imaging marker for IDH-mutant astrocytoma;","The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower grade glioma: A validation study",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
128,30072578,1,Submitted,0,NA,1. Large HLA peptidomes are identified from tumors and plasma of GBM patients; 2. The GBM HLA peptidomes include many peptides from multiple Tumor Antigens; 3. The levels of potential biomarker plasma-sHLA peptides are reduced following surgical removal of the tumors; 4. The plasma-sHLA and tumor-mHLA peptidomes of the same patients are highly correlated; 5. The HLA peptidomes do not correlate with the proteomes of the tumors; 6. Some HLA allomorphs present larger diversity of peptides in both tumors and plasma; 7. Peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass;,Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
129,27538656,1,Submitted,0,TLR9; NFKBIA; Glioma; Survival; IHC; PCR; Patient; Biomarker ,"1. TLR9 mRNAs is markedly expressed in glioma tissues than in non-neoplastic tissues (mean ± SD: 3.26 ± 0.40 vs. 0.71 ± 0.36, P <0.001); 2. There was also a significant difference between TLR9 mRNAs and high grade glioma (P < 0.001); 3. NFKBIA mRNAs was significantly identified in nonneoplastic tissues compared with glioma specimens (mean ± SD: 2.76 ± 0.30 vs. 0.94 ± 0.35, P <0.001); 4. Lower levels of NFKBIA mRNA were significantly related to advanced grade of gliomas (P < 0.001); 5. Immunoreactivity for high expression of TLR9 was detected in 65% of cases (26/40) that was associated with high grade glioma (P= 0.001); 6. Immunoreactivity for high expression of NFKBIA was observed in 32.5% (13/40) of cases and NFKBIA expression was decreased in patients with high grad glioma (P = 0.014); 7. The Kaplan-Meier analysis indicated that patients with high expression of TLR9 and low expression of NFKBIA are significantly related to poorer OS (P<0.001);",Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
130,30154718,1,Submitted,0,glioma;prognostic biomarkers;grades;gender;IDH mutations,"1. The ROC curve analysis showed that NLR had the highest diagnostic value for distinguishing GBM from grade II to III [0.684 (0.645-0.723)] and predicting the GBM IDH-1 wt molecular subtype [0.672 (0.631-0.71)]; 2. NLR was the best single hematological marker for distinguishing glioblastoma; 3. Combinations of age with PNI and age with AGR were the best predictors of GBM [0.750 (0.713-0.786)] and IDH-wt GBM [0.759 (0.719-0.798)], respectively;",Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
131,30992025,1,Submitted,0,Exosomes; LncRNA-SBF2-AS1; Temozolomide-resistance; Glioblastoma,1. LncSBF2-AS1 is upregulated in GBM cell lines and tissues after TMZ treatment; 2. LncSBF2-AS1 overexpression confers TMZ resistance; 3. Knockdown of lncSBF2-AS1 sensitizes TMZ-resistant GBM cells to TMZ; 4. Transcription factor ZEB1 regulates lncSBF2-AS1 and is associated with TMZ resistance in GBM cells; 5. LncSBF2-AS1 functions AS a ceRNA and sponges miR-151a-3p in GBM cells; 6. LncSBF2-AS1 regulates DNA damage rapair through miR-151a-3p/XRCC4 axis; 7. Intercellular transfer of lncSBF2-AS1 by exosomes spreads TMZ resistance in vitro; 8. Exosomal lncSBF2-AS1 spreads TMZ resistance in vivo; 9. Circulating exosomal lncSBF2-AS1 may act as a promising diagnostic biomarker for TMZ-resistant GBM patients;,Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
132,20187195,1,Submitted,0,diffusion MRI;brain tumor;glioma;functional diffusion maps;fDM,1. Glioma cell density Is inversely correlated With ADC measurement; 2.	 A measure of normal ADC variability across scan days must be determined to properly set the thresholds for fDMs; 3. fDMs created with different DADC thresholds reﬂect different sensitivity and speciﬁcity to brain tumor progression; 4. This study suggests fDMs are valid biomarkers for brain tumor cellularity;,Validation of Functional Diffusion Maps (fDMs) as a Biomarker for Human Glioma Cellularity,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
133,28362236,1,Submitted,0,glioblastoma;DWI;high b-value;peritumoral region;diffusion restriction;oncology,"1. In 25% of glioblastoma patients, Definite-NePDHL was present, while it was conspicuously absent in patients with malignant lymphoma and metastatic brain tumors; 2. The specificity and positive predictive value were 100%; 3. Patients with Definite-NePDHL had significantly early local (p = 0.0467) and distant/dissemination recurrence (p < 0.0001) and poor prognosis (p = 0.0007); 4. The presence of Definite-NePDHL is very specific for glioblastoma and indicates poor prognosis; 5. Definite-NePDHL is a significant indicator of early local and distant/dissemination recurrence in patients with glioblastoma;",Nonenhancing peritumoral hyperintense lesion on  diffusion-weighted imaging in glioblastoma: a novel  diagnostic and specific prognostic indicator,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
134,27028997,1,Submitted,0,NA,1. The cfDNA from glioma patients showed lower levels of Alu methylation than the controls (P<0.01); 2. Glioma patient survival correlates positively with Alu methylation levels; 3. Alu methylation correlated positively with survival (P<0.01); 4. Methylation level of Alu in cfDNA is of diagnostic value;,Alu methylation serves as a biomarker for non-invasive diagnosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
135,30008924,1,Submitted,0,MMP-26; astrocytic glioma; immunohistochemistry; prognosis,"1. MMP-26 expression was significantly assocaited with the World Health Organization grade (P<0.05); 2. Additionally, it was identified that MMP-26 expression was an effective predictor of the overall survival of patients with astrocytic glioma (P<0.05); 3. Analyses of univariate and multivariate Cox regression confirmed that MMP-26 expression was an independent factor for evaluating the prognosis of astrocytic glioma patients (P<0.05);",High MMP-26 expression in glioma is correlated with poor clinical outcome of patients ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
136,16002321,1,Submitted,0,LNX gene; Glioma; cDNA microarray; PDZ; Notch,"1. Human LNX was downregulated in 100% of gliomas including low- and high-grade ones, which was confirmed by Northern blot; 2. In situ hybridization analysis revealed that LNX was lowly expressed in cytoplasm of glioma cells; 3. LNX might act as a diagnostic marker and a potential therapeutic target for glioma; 4. Human LNX interacted with Ski interacting protein (SKIP) via PDZ domains;","Characterization of human LNX, a novel ligand of Numb protein X that is downregulated in human gliomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
137,31395792,1,Submitted,0,NA,1. Key markers including C1orf61 and FAM50B were selected with a Pearson correlation coefficient greater than 0.75; 2. We chose the 20 CpG methylation sites of above two genes in unsupervised clustering analysis using the Euclidean distance; 3. We found that the prognosis of the hypomethylated group was significantly better than that in the hypermethylated group (log-rank test p-value = 0.011);,Integrative analysis of DNA methylation and gene expression to  identify key epigenetic genes in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
138,26671581,1,Submitted,0,Papillary glioneuronal tumor; SLC44A1-PRKCA; MAPK; BRAF; FGFR1; KIAA-BRAF; rosette-forming glioneuronal tumors of the fourth ventricle; ganglioglioma; angiocentric neuroepithelial tumors,"1. Fluorescence in situ hybridization analysis revealed a constant SLC44A1-PRKCA fusion signal in all PGNTs; 2. None of PGNT mimics showed the SLC44A1-PRKCA fusion signal pattern; 3. All PGNTs were negative for BRAF V600E and FGFR1 mutation, and KIAA1549-BRAF fusion; 4. These results suggest that PGNT belong to low grade glioma with MAPK signaling pathway deregulation; 5. SLC44A1-PRKCA fusion seems to be a specific characteristic of PGNT with a high diagnostic value and detectable by FISH;",Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
139,20084020,1,Submitted,0,Astrocytoma; AIII-tubulin; Diagnostic marker; Glioblastoma; Immunohistochemistry; Neuronal marker; PROX1,"1. We found that PROX1 exhibited a strikingly positive and statistically significant correlation with glioma tumor grade; 2. Gliomas, on average, express a 4-fold increase of the PROX1 mRNA compared with normal brain tissue; 3. Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other tumor cells but are still mitotically active; 4. Double immunolabeling showed that PROX1+ cells in glioblastomas frequently coexpressed early neuronal proteins MAP2 and βIII-tubulin but not the mature neuronal marker protein NeuN;",Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
140,27871448,1,Submitted,0,Serum vitronectin; Glioma; Prognosis; Diagnosis,1. Serum vitronectin levels were significantly elevated in glioma patients as compared with other groups; 2. High Wealth Health Organization grade was independently associated with high vitronectin levels; 3. Serum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate highgrade glioma from low-grade glioma; 4. Vitronectin levels markedly predicted 5-year progression and 5-year mortality; 5. Serum vitronectin was identified as an independent predictor for 5-year overall survival and 5-year progression-free survival as well as 5-year mortality and 5-year progression 6. Serum vitronectin might be a prognostic and diagnostic biomarker for human glioma;,Diagnostic and prognostic value of serum vitronectin levels in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
141,30655743,1,Submitted,0,telomerase reverse transcriptase promoter; α thalassemia/mental retardation syndrome X-linked; isocitrate  dehydrogenase; mutation; proliferation marker protein Ki-67; glioma,"1. TERT promoter mutations are positively associated with age and WHO grade, but negatively associated with ATRX mutations; 2. ATRX mutations are positively associated with age and IDH mutations; 3. TERT wild-type and ATRX wild-type tumors exhibit high Ki-67 protein expression, however the wild-type TERT promoter with ATRX mutations exhibits low Ki-67 protein expression;",Significance of TERT and ATRX mutations in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
142,29695934,1,Submitted,0,glioblastoma; O6 -methylguanine-DNA methyltransferase; miR-142-3p; carmustine;  temozolomide,"1. MiR-142-3p was expressed at lower levels in the cell lines with higher levels of MGMT protein expression; 2. Overexpression of miR-142-3p marginally enhanced methylation of the MGMT promoter compared with the control (shLuc); 3. Overexpression of miR-142-3p does not affect MGMT mRNA, but decreases MGMT protein level; 4. miR-142-3p binds MGMT 3'-UTR directly to regulate MGMT gene; 5. MiR-142-3p overexpression inhibits GBM-cell viability after treatment with alkylating agents;",MicroRNA-142-3p is involved in regulation of  MGMT expression in glioblastoma cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
143,26230475,1,Submitted,0,glioma miR-205 serum biomarker; oncology; diagnosis; progression,1. Serum miR-205 expression level as a potential diagnostic biological marker; 2. Patients with a glioma specimen in which serum miR-205 expression was decreased tended to have a higher pathological grade and lower KPS score; 3. Serum miR-205 Is a prognostic marker in patients with malignant glioma; 4. We found that serum miR-205 is a novel and valuable biomarker for the diagnosis of glioma and an independent prognostic parameter for OS in advanced-grade cancers;,Downregulation of serum microRNA-205 as a potential diagnostic and prognostic  biomarker for human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
144,31934080,1,Submitted,0,miR-145-5p; prognosis; serum; glioblastoma,1. Serum miR-145-5p levels were significantly decreased in GBM patients; 2. Serum miR-145-5p could effectively discriminate GBM patients from healthy controls and grade I/II glioma patients; 2. Serum miR-145-5p expression were independent prognostic factors for OS; 3. Downregulation of miR-145-5p might result in upregulation of many targeted genes; 4. Decreased serum miR-145-5p is a promising diagnostic and prognostic biomarker for GBM;,Diagnostic and prognostic significance of serum  miR-145-5p expression in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
145,25756397,1,Submitted,0,glioma; microRNA-210; diagnosis; prognosis; biomarker,"1. An approximately seven-fold increase in miR-210 expression was detected in serum samples from glioblastoma patients relative to healthy controls; 2. The OR of 28.19 indicated that increased serum miR-210 levels were strongly linked to a diagnosis of glioma in patients; 3. MiR-210 expression might potentially also be linked to prognosis as higher-grade gliomas generally portend a worse  survival in patients than lower-grade cases; 4. When Kaplan-Meier analysis was performed with these values for high and low miR-210 expression (low < 2.259 < high), high  expression of serum miR-210 was found to be associated with  worse OS; 5. No  significant associations were found for OS and sex, age at diagnosis, or tumour size; 6. Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma;",Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
146,30817682,1,Submitted,0,glioblastoma; MEK/ERK signaling pathway; RNA interference; sperm-associated antigen 4,1. High expression of SPAG4 involves poor overall survival in GBM; 2. SPAG4 is overexpressed in GBM cell lines and repressible by siRNA; 3. Silencing of SPAG4 inhibits proliferation of GBM cells; 4. Silencing of SPAG4 reduces cell migration; 5. Silencing of SPAG4 suppresses MEK/ERK signaling pathway;,Human sperm-associated antigen 4 as a potential biomarker of glioblastoma progression and prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
147,28978155,1,Submitted,0,extracellular vesicle; CSF; liquid biopsy,"1. Comparison of CSF miRNA profiles between glioblastoma patients and non-brain tumor patients yielded a tumor ""signature"" consisting of nine miRNAs; 2. MiRNA profiles from clinical CSF correlated with those found in glioblastoma tissues; 3. The ""signature"" correlated with glioblastoma tumor volume (p=0.008); 4. When prospectively applied to cisternal CSF, the sensitivity and specificity of the ""signature"" for glioblastoma detection were 67% and 80%, respectively; 5. For lumbar CSF, the sensitivity and specificity of the signature were 28% and 95%, respectively;",A cerebrospinal fluid microRNA signature as biomarker for  glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
148,28211798,1,Submitted,0,Glioma; microRNA-376 family;  diagnosis;  prognosis;  biomarker,"1. Serum miR-376a, miR-376b and miR-376c in glioma patients were significantly lower than those in healthy controls (all P < 0.05); 2. Their expression could efficiently distinguish the glioma patients from healthy controls according to the receiver operating characteristic (ROC) analysis [for miR-376a, the area under ROC curve (AUC) = 0.872, the optimal cut-off value = 1.95, the sensitivity = 81.0% and the specificity = 82.0%; for miR-376b, AUC = 0.890, the optimal cut-off value = 2.07, the sensitivity = 82.0% and the specificity = 78.0%; for miR-376c, AUC = 0.837, the optimal cut-off value = 2.12, the sensitivity = 90.0% and the specificity = 70.0%; all P < 0 .001]; 3. Decreased expression of miR-376a, miR-376b and miR-376c in patients' sera were significantly associated with advanced WHO grade (all P < 0.01) and low KPS (all P < 0.05); 4. Kaplan-Meier and Cox regression analyses showed that low miR-376a, miR-376b and miR-376c expression, and high grade were all independent factors predicting poor outcome of glioma patients; 5. Notably, subgroup analyses showed that serum miR 376a, miR-376b and miR-376c levels had more significant prognostic values in patients with high grade gliomas than those with low grade gliomas;",Serum microRNA-376 family as diagnostic and prognosticmarkers in human gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
149,28744130,1,Submitted,0,glioma; lncRNA; CASC2; biomarker; Wnt/β-catenin,"1. CASC2 expression was significantly downregulated in glioma tissues and cell lines (U87 and U251) compared to adjacent normal brain tissues or normal human astrocytes; 2. Low expression level of casc2 was significantly associated with poorer prognosis in glioma patients; 3. CASC2 overexpression remarkably suppressed glioma cell proliferation, migration, and invasion; 4. Casc2 functions as a tumor suppressor by suppressing Wnt/β-catenin signaling activity; 5. CASC2 may potentially serve as a valuable diagnostic and prognostic biomarker;",Long noncoding rNa casc2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
150,29363730,1,Submitted,0,TrioBP; cytoskeleton; glioma; biomarker,"1. TrioBP expression was indicated to be highly elevated in U87-MG and U343-MG cells; 2. The TrioBP mRNA expression level was markedly increased in U87-MG and U251-MG cells compared with that in cerebral cortex cells,as determined by deep sequencing; 3. Comprehensive analysis of a public TCGA dataset confirmed that TrioBP expression is elevated in patients with glioblastoma; 4. TrioBP expression is increased in glioblastoma cell lines and in patients with glioma, suggesting that TrioBP has potential as a diagnostic marker or therapeutic agent for glioma;",The roles of TRIO and F-actin-binding  protein in glioblastoma cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
151,20448330,1,Submitted,0,IL-13Ra2; promoter; NFAT; AP1; glioblasma multiforme,"1. IL-13Ra2 is overexpressed by gliomas but not by normal tissue; 2. Transcription factors NFAT and AP1 (C-fos and C-jun) can bind consensus sequences in the GBM related IL-13Ra2 promoter; 3. Transcription factors NFAT and AP1 are necessary and essential for the expression of this GBM related transcript, and are responsible for the high level of expression of IL-13Ra2 in GBM; 4. Expression of this transcript results in the production of a secreted form of IL-13Ra2 and thus may have the potential to be used as a diagnostic biomarker for GBM patients;",NFAT and AP1 are essential for the expression of a glioblastoma multiforme related IL-13Ra2 transcript,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
152,17431671,1,Submitted,0,OLIG2; ID2; Oligodendroglioma; CGH; 1p,"1. OLIG2 expression was predominant over ID2 expression in oligodendroglial tumors; 2. ID2 expression was predominant over OLIG2 expression in astrocytic tumors; 3. Gliomas with loss on chromosome 1p, which is closely associated with chemosensitivity, also showed the predominant expression of OLIG2 over ID2; 4. The relative expression level of OLIG2 to ID2 can be a useful screening for oligodendroglial tumors;",Predominant expression of OLIG2 over ID2 in oligodendroglial tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
153,11284014,1,Submitted,0,central nervous system; brain tumor; expression; malignancy; proliferative activity,"1. The Musashi1 expression in gliomas was significantly higher than in normal brain, testis, or other cancers; 2. The elevated expression of Musashi1 in gliomas compared to normal brain tissue was similar to the results described above obtained by RT-PCR; 3. Glioblastomas, the most malignant form of glioma, showed higher Musashi1 expression than less malignant gliomas by immunohistochemical analysis; 4. Tumors with strong Musashi1 expression tended to have high proliferative activity; 5. These results suggest that primary CNS tumors may share gene expression patterns with primitive, undifferentiated CNS cells and that Musashi1 may be a useful marker for the diagnosis of CNS tumors;",Expression of the neural RNA-binding protein Musashi1 in human gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
154,29108264,1,Submitted,0,PVT1; HAR1A; prognosis biomarker; therapy outcome; diffuse glioma,"1. Further analysis of TCGA and GEO data revealed that the expressions of PVT1 and CYTOR were up-regulated, while HAR1A and MIAT expressions were downregulated in gliomas; 2. Their expression patterns were validated in an independent cohort containing 98 glioma specimens and 12 non-tumor tissue controls; 3. High expression of PVT1 and CYTOR as well as low HAR1A and MIAT expression were associated with high Ki-67 level and more TP53 mutation; 4. Kaplan Meier survival curve and Cox regression analyses showed that glioma patients with high PVT1 expression or low HAR1A expression had poor survival outcome, aberrantly expressed PVT1 and HAR1A could be the independent prognosis biomarkers for glioma patients; 5. Down-regulation of PVT1 and up-regulation of HAR1A contributed to improve the survival of patients who received chemotherapy and radiotherapy; 6. PVT1 and HAR1A could be explored as promising biomarkers for diagnosis, prognosis and target therapy of diffuse gliomas;",lncRNAs PVT1 and HAR1A are prognosis biomarkers and indicate therapy outcome for diffuse glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
155,30808902,1,Submitted,0,S100A8/S100A9; Serum biomarkers;glioblastoma,1. Transcript levels of S100A8/S100A9 were found to be independent poor prognostic indicators in GBM; 2. Medium levels of pre-operative and three-month post-operative follow-up serum S100A8 levels predicted poor prognosis in GBM patients who lived beyond median survival; 3. In vitro experiments showed that recombinant S100A8/S100A9 proteins promoted integrin signalling dependent glioma cell migration and invasion up to a threshold level of concentrations;,Serum biomarkers identifcation  by iTRAQ and verifcation by MRM:  S100A8/S100A9 levels predict  tumor-stroma involvement and  prognosis in Glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
156,21950922,1,Submitted,0,protoporphyrin IX; aminolevulinic acid; glioblastoma; fluorescence-guided resection; magnetic resonance imaging,"1. Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy; 2. This study shows that both in vivo standard gadolinium contrast enhanced and absolute T2 MR images can positively predict the presence of diffuse gliomas, however, ex vivo PpIX fluorescence accomplishes the same feat with higher sensitivity and diagnostic accuracy;",Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
157,24652828,1,Submitted,0,18F-DOPA PET; pediatric; brain tumor; MRI,"1. The 18F-DOPA uptake pattern was heterogeneous in all positive scans (9/13), revealing metabolic heterogeneities within each tumor; 2. Significant differences in terms of 18F-DOPA uptake were found between low- and high-grade lesions (P < 0.05); 3. The diagnostic and therapeutic contribution of 18F-DOPA PET/MR image fusion was relevant in 9 of 13 patients (69%); 4. 18F-DOPA uptake correlated significantly with progression-free survival (P < 0.004);","Value of 18F-3,4-Dihydroxyphenylalanine PET/MR Image Fusion in Pediatric Supratentorial Inﬁltrative Astrocytomas: A Prospective Pilot Study",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
158,30985412,1,Submitted,0,"advanced neuroimaging, glioma, methionine PET,MR spectroscopy, PET/MRI","1. Maximum tumor-to-brain ratio was highest in glioblastoma patients (4.18) followed by patients with IDH wild-type grade II and III glioma (3.41); 2. The latter TBRmax values were higher compared with those in patients with IDH-mutant grade II/III glioma without 1p/19q codeletion (1.95) and in patients with IDH-mutant 1p/19q codeleted grade II and III glioma (2.79); 3. Magnetic resonance spectroscopy marker distribution showed no clear trend; 4. Receiver operating characteristic analysis revealed TBRmax to be the best performing parameter in identifying IDH status (area under the curve, 0.67) and all spectroscopy markers combined in identifying glioma subgroups (area under the curve, 0.68), respectively;",Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
159,31492588,1,Submitted,0,CPS1; Glioblastoma multiforme; TCGA; Diagnositic,"1. The transcriptome data from several public databases, such as Oncomine and GEPIA, revealed that CPS1 transcriptional level was significantly upregulated in GBM tissues and cells; 2. CPS1 was hypomethylated in GBM tissues; 3. The Wanderer database, linked to the Cancer Genome Atlas (TCGA), showed the association between CPS1 expression or its methylation values and the clinicopathological parameters in GBM patients; 4. CPS1 expression was upregulated in GBM and this gene could be used as a potential diagnostic and prognosis indicator for GBM;",Expression and clinical significance of CPS1 in glioblastoma multiforme,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
160,29620180,1,Submitted,0,STAT-1; p53; glioma; correlation; prognosis,"1. The mean expression of STAT-1 in glioma was significantly lower compared with normal brain tissue (P<0.05). However, there was no significant difference in the STAT-1 positive expression rate between the two groups (χ2=1.38, P>0.05); 2. The expression score (P<0.05) and positive expression rate (χ2=31.27, P<0.05) of mutant p53 in glioma was significantly higher compared with those in normal brain tissue; 3. Statistical analysis revealed a negative correlation between STAT-1 expression and the grade of glioma (r=-0.767, P<0.05); 4. In addition, mutant p53 expression was negatively correlated with STAT-1 expression in glioma (r=-0.876, P<0.05);",A study on the correlation between STAT-1  and mutant p53 expression in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
161,16619508,1,Submitted,0,Glioblastoma; MCM7; cell cycle; proliferation index,"1. MCM7 detected more cells in the cycle than Ki67 and PCNA and all cases of small cell (SC) glioblastoma, the most aggressive subset, displayed a significant increase of MCM7-stained nuclei versus those stained with Ki67; 2. Cell cycle-associated proteins MCM are not only useful markers of proliferation, but also valid aids for diagnosis in cerebral glioblastoma;",Minichromosome Maintenance Protein 7: A Reliable  Tool for Glioblastoma Proliferation Index,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
162,28938636,1,Submitted,0,glioma; glioma stem cells; PATZ1; tumor heterogeneity; biomarker,"1. PATZ1 is expressed in human gliomas and is enriched in the proneural subtype; 2. PATZ1 is preferentially expressed in glioma stem cells; 3. Survival analysis demonstrated that PATZ1 lower levels informed poor prognosis in GBM and, specifically, in the proneural subgroup, suggesting it may serve a role as diagnostic and prognostic biomarker for intra-subtype heterogeneity of proneural GBM; 4. PATZ1 suppresses the expression of the mesenchyme-inducer CXCR4, and that PATZ1 and CXCR4 are inversely correlated in GSC and proneural GBM;",PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
163,31807116,1,Submitted,0,Glioma; miR-346; NFIB; Proliferation,1. MiR-346 is downregulated in human glioma tissues and cell lines; 2. MiR-346 overexpression suppresses cell proliferation; 3. NFIB is a direct target of miR-346 in glioma cells; 4. MiR-346 inhibits the proliferation of glioma cells in an NFIB-dependent manner; 5. MiR-346 overexpression inhibits tumor growth in vivo;,MicroRNA-346 inhibits the growth of glioma by directly targeting NFIB,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
164,25311315,1,Submitted,0,18F-FET PET; low-grade glioma; prognosis; imaging;grading,"1. Homogeneous increasing, focal decreasing and homogeneous decreasing TAC were seen in 51, 19 and 28 patients; 2. The corresponding 1-year (2-years) PFS were 92% (85%), 89% (51%) and 50% (28%; p 5 0.002); 3. IDH1/2 mutations were more frequent in tumors with homogeneous increasing (90%) and focal decreasing (79%) TAC, but were rare in those exhibiting homogeneous decreasing TAC (25%; p < 0.001); 4. Overall, TAC patterns, IDH1/2 mutational and 1p/19q codeletion status were powerful and independent prognostic factors; 5. Dynamic 18F-FET PET might be an important and independent imaging biomarker for patients with suspected WHO grade II gliomas and offers perspectives for stratified diagnostic and therapeutic strategies;",Dynamic 18F-FET PET in suspected WHO grade II gliomas deﬁnes distinct biological subgroups with different clinical courses,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
165,28887715,1,Submitted,0,Biomarker; Epithelial membrane protein-2; Glioblastoma; Prognosis; Glioma,"1. The mean EMP2 expression was 1.68 in lower grade gliomas versus 2.20 in GBMs (P = 0.01); 2. The percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas (90.0 vs. 52.6%, P = 0.001); 3. No significant difference was found between median survival among patients with GBM tumors exhibiting high EMP2 expression and survival of those with low EMP2 expression (8.38 vs. 10.98 months, P = 0.39); 4. EMP2 expression ≥ 2 correlated with decreased survival (r = -0.39, P = 0.001); 5. The EMP2 expression level also correlated with Ki-67 positivity (r = 0.34, P = 0.008); 6. The mortality hazard ratio for GBM patients with EMP2 score of 3 or higher was 1.92 (CI 0.69-5.30);",Tissue microarray analysis for epithelial membrane protein-2as a novel biomarker for gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
166,30277536,1,Submitted,0,Glioblastoma; RANO; Macrophage; Ferumoxytol; Pseudo-progression,1. With the development of pseudo-progression we observed a significantly elevated mismatch ratio when compared to disease recurrence (P< 0.01) within IDH-1 wild type patients; 2. Patients with IDH-1 mutation demonstrated significantly reduced mismatch ratio with the development of pseudoprogression when compared to disease recurrence (P< 0.01); 3. Receiver operator curve analysis demonstrated 100% sensitivity and specificity for the use of mismatch ratios as a diagnostic biomarker of pseudo-progression;,Combined Iron Oxide Nanoparticle Ferumoxytoland Gadolinium Contrast Enhanced MRI Defines Glioblastoma Pseudo-progression,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
167,28425046,1,Submitted,0,Glioblastoma; Temozolomide resistance; miR-198; MGMT,"1. MiR-198 levels were greatly downregulated in glioblastoma specimens and decreased expression of miR-198 was associated with poor prognosis in patients with glioblastoma; 2. Overexpression of miR-198 increased chemosensitivity to temozolomide in  vitro and in  vivo; 3. O6-methylguanine-DNA methyltransferase (MGMT) was identified as a direct target of miR-198, and miR-198 overexpression prevented the protein translation of MGMT; 4. Overexpression of MGMT restored miR-198-induced chemosensitivity to temozolomide; 5. The protein levels of MGMT were upregulated in clinical glioblastoma specimens and inversely correlated with miR-198 levels;",MiR-198 enhances temozolomide sensitivity in glioblastoma  by targeting MGMT,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
168,29476310,1,Submitted,0,ANCR; Brain tumors; LncRNAs; Tumor marker,"1. Our qRT-PCR results revealed a significant upregulation of ANCR in more malignant and less differentiated types of brain tumors (P=0.03); 2. This data was in accordance with down regulation of ANCR during neural differentiation; 3. ANCR suppression caused an elevation in apoptosis rate, as well as a G1 cell cycle arrest in glioblastoma cell line;","Anti-differentiation non-coding RNA,ANCR, is differentially expressed in different types of brain tumor",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
169,27050560,1,Submitted,0,glioma; interleukin-33 (IL-33); prognosis,"1. IL-33 may be a promising biomarker for the detection of gliomas, and IL-33 expression is useful for predicting the prognosis of the disease; 2. IL-33 protein was highly expressed in 54.65% (47/86) of glioma tissues, while a small amount of IL-33 protein was detected in all normal brain tissues; 3. IL-33 up-regulation predicts poor prognosis in glioma patients; 4. A high IL-33 expression was significantly associated with a shorter PFS (P< 0.001) and OS (P< 0.001) in glioma patients, and IL-33 overexpression (OS: P< 0.0001; PFS: P< 0.0001) and the glioma grade (OS: P= 0.0003; PFS: P< 0.0001) were independent factors predicting a poor prognosis;",Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
170,29333924,1,Submitted,0,Magnetic Resonance Imaging; Glomeruloid Vascular Proliferations; Tissue Factor; Glioblastoma; Biomarker,"1. Inhibition of tissue factor (TF) decreased GVPs in Mouse GBM xenograft model; 2. TF shRNA reduced microvascular area and diameter, other than bevacizumab; 3. TF dominantly functions via PAR2/HB-EGF-dependent activation under hypoxia in endothelial cells (ECs), resulting in a reduction of GVPs and cancer cells invasion; 4. TF expression strongly correlated to GVPs and microvascular area (MVA) in GBM specimens from 56 patients, which could be quantitatively evaluated in an advanced MRI images system in 33 GBM patients;",Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
171,28534372,1,Submitted,0,brain metastasis; glioblastoma multiforme; miRs; non-small cell lung carcinoma; serum biomarkers,1. Serum expression level of miR-504 is a reliable biomarker to be used for differentiating primary GBM from solitary brain metastasis of NSCLC; 2. High sensitivity (100%) and specificity (88.89%) of using miR-504 serum expression as differential diagnostic test; 3. MiR-504 inhibits cell proliferation and promotes apoptosis in human glioma and its downregulation is associated poor prognosis in high grade glioma patients;,Serum expression level of miR-504 can differentiate betwee glioblastoma multiforme and solitary brain metastasis of   non-small cell lung carcinoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
172,27441955,1,Submitted,0,Biomarker; glioma; IDH1mutation; pyrosequencing; SOCS3 methylation,1. SOCS3 methylation is a potential biomarker for grading and prognosis in human glioma; 2. SOCS3 has been shown to function as a tumour suppressor by negatively regulating the Janus kinase  signal transducer and activator of transcription (IAK-STAT)  signalling pathway; 3. The IDH1 R132H mutation was significantly correlated with SOCS3 promoter methylation; 4. SOCS3 promoter hypcrmethylation was more frequent in WHO Grade III and  the (anaplastic) oligoastrocytomas group than in the groups that included other grades and glioma types;,Diagnostic significance of suppressor of cytokine signalling 3 (SOCS3) methylation and its correlation with IDH1 mutation in Chinese glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
173,22855183,1,Submitted,0,Matrix metalloproteinase-14; Matrix metalloproteinase-19; Glioma; Immunohistochemistry; Western blot; Co-expression; Prognosis,"1. Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma; 2. These findings indicated for the first time that the co-expression of MMP-14 and MMP-19 is significantly correlated with prognosis in glioma patients, suggesting that the co-expression of these proteins may be used as both an early diagnostic and independent prognostic marker;",Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
174,28423357,1,Submitted,0,glioma; miR-29b; MYCN,1. Expression of miR-29b was decreased in glioma; 2. MiR-29b inhibits the proliferation and promotes the apoptosis of glioma cells; 3. MYCN is a direct target of miR-29b in glioma cells; 4. MiR-29b inhibits the proliferation of glioma cells via MYCN dependent way; 5. MiR-29b can be a biomarker for the diagnosis of glioma;,MiR-29b inhibits the growth of glioma via MYCN dependent way,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
175,31710121,1,Submitted,0,adipokines; GBM; gliomas; GRN; LGG; NAMPT; prognosis; SERPINE1;TCGA,"1. The levels of mRNA of NAMPT, APLN, GRN, SERPINE1, and CCL2 were significantly upregulated in both LGG and GBM; 2. Out of 11 adipokines studied, five adipokines namely NAMPT, GRN, SERPINE1, IL6, and CCL2 showed reduced OS for patients having higher mRNA expression in LGG; 3. In the clinicopathological analysis, mRNA expression status of five adipokines, namely NAMPT, GRN, IL6, SERPINE1, and CCL2 was significantly associated with the neoplasm histological G2 and G3 grade in LGG patients; 4. NAMPT, GRN, and SERPINE1 were also found to be upregulated using immunohistochemistry in a lower grade and high grade gliomas as compared to normal cells; 5. NAMPT, GRN, and SERPINE1 as potential diagnostic and prognostic markers that might be instrumental in the development and progression of gliomas;","NAMPT, GRN, and SERPINE1 signatureas predictor of disease progression and survival in gliomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
176,27314542,1,Submitted,0,pilocytic astrocytoma; basic fibroblast growth factor; bFGF; tissue inhibitor of metalloproteinase 3; TIMP3; urinary biomarkers; oncology,"1. Using optimal urinary cutoff values of bFGF > 1.0 pg/μg and TIMP3 > 3.5 pg/μg, multiplexing bFGF and TIMP3 predicts juvenile pilocytic astrocytomas (JPAs) presence with 98% accuracy; 2. Multiplexing bFGF and MMP13 distinguishes JPA from other brain tumor subtypes with up to 98% accuracy; 3. Urinary biomarker expression correlated with both tumor immunohistochemistry and in vitro tumor levels; 4. Urinary bFGF and TIMP3 decrease following successful tumor treatment and correlate with changes in tumor size;",Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
177,18383878,1,Submitted,0,Glioma; cancer; protease; plasminogen activator inhibitor-1 (PAI-1); serum marker,"1. We found significantly higher serum levels in the patients with high-grade gliomas than in the healthy volunteers (p=0.0009, unpaired t-test) and those with low-grade tumors (p=0.0074); 2. Furthermore, high-grade glioma patients with a low serum level of PAI-1 survived significantly longer than those with high levels (p=0.0082); 3. Immunohistochemical analysis using anti-PAI-1 antibody revealed dense and spotty staining in the high-grade tumor tissues from the patients with high serum PAI-1 levels;",High Serum Level of Plasminogen Activator Inhibitor-1  Predicts Histological Grade of Intracerebral Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
178,25416442,1,Submitted,0,Human hedgehog interacting protein (HHIP); Glioma; Glioblastoma promoter methylation; Melting curve analysis-Meth (MCA-Meth); GLI1,"1. Low or no expression of hedgehog interacting protein (HHIP) in most of the cell lines and primary glioma tumor samples; 2. We further proceeded to promoter methylation study of this gene in the same cell lines and primary tumor samples and found 87 % (7/8) HHIP methylation in glioblastoma cell lines and 75 % (33/44) in primary tumor samples; 3. These methylation pattern correlates with low or unexpressed HHIP in both cell lines and primary tumor samples; 4. Our results suggest the possibility of epigenetic regulation of this gene in glioma, similarly to medulloblastoma, gastric, hepatic, and pancreatic cancers; 5. HHIP might be a diagnostic or prognostic marker in glioma and help to the detection of these tumors in early stages of disease;",Epigenetic regulation of human hedgehog interacting protein in glioma cell lines and primary tumor samples,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
179,27175595,1,Submitted,0,"population-based, serum metabolite, vitamin E, antioxidants, brain tumor","1. The study points out a latent biomarker for future glioblastoma consisting of nine metabolites (γ-tocopherol, α-tocopherol, erythritol, erythronic acid, myo-inositol, cystine, 2-keto-L-gluconic acid, hypoxanthine and xanthine) involved in antioxidant metabolism; 2. We detected significantly higher serum concentrations of α-tocopherol (p=0.0018) and γ-tocopherol (p=0.0009) in future glioblastoma cases; 3. Compared to their matched controls, the cases showed a significant average fold increase of α- and γ-tocopherol levels: 1.2 for α-T (p=0.018) and 1.6 for γ-T (p=0.003); 4. These tocopherol levels were associated with a glioblastoma odds ratio of 1.7 (α-T, 95% CI:1.0-3.0) and 2.1 (γ-T, 95% CI:1.2-3.8); 5. Our exploratory metabolomics study detected elevated serum levels of a panel of molecules with antioxidant properties as well as oxidative stress generated compounds;",Metabolomic screening of pre-diagnostic serum samples identifies association between α- and γ-tocopherols and glioblastoma risk,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
180,28534979,1,Submitted,0,glioma; PIWIL2; proliferation; migration; prognosis,"1. Through western blot and immunohistochemical analyses we found that PIWIL2 was overexpressed in glioma tissues; 2. The expression level of PIWIL2 was also significantly correlated with the WHO grades of human gliomas and Ki-67 expression; 3. Kaplan-Meier curves indicated that PIWIL2 was a prognostic factor for the survival of glioma patients and a high expression of PIWIL2 was correlated with a poor prognosis; 4. In vitro, knockdown of PIWIL2 in glioma cells was shown to induce cell cycle arrest and increase apoptosis; 5. Silencing of PIWIL2 expression also obviously suppressed the migration of glioma cells;","High expression of PIWIL2 promotes tumor cell proliferation, migration and predicts a poor prognosis in glioma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
181,31092421,1,Submitted,0,Glioblastoma; astrocytoma; death receptor 6; DR6; TNFRSF21,1. The expression of DR6 was significantly enhanced in gliomas (p<0.05); 2. It showed a trend towards rising expression with increasing malignancy of the tumor; 3. Chemotherapy treatment could have an influence on DR6 expression;,Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
182,11703362,1,Submitted,0,antigen; glioma; immune response,1. The gene encoding the GLEA2 antigen was mapped on chromosome 20; 2. There is circumstantial evidence that chromosome 20 bears specific genomic alterations associated with glioma development; 3. The frequency of GLEA2 antibodies in sera from glioblastoma patients is 43% and significantly higher than the frequency of the immune response against GLEA2 protein in the control sera (14%) from healthy persons; 4. We found GLEA2 gene expression in all tissues tested;,Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
183,17998256,1,Submitted,0,glioblastoma; GFAP; biomarker; serum,"1. Serum GFAP levels were determined using a commercially available ELISA test and were detectable in 40 out of the 50 GBM patients (median: 0.18 kg/l; range: 0-5.6 kg/l); 2. The levels were significantly elevated compared with those of the non-GBM tumour patients and healthy controls (median: 0 kg/l; range: 0-0.024 kg/l; P<0.0001, respectively); 3. Non-GBM tumour patients and all healthy subjects showed zero serum GFAP levels; 4. There was a significant correlation between tumour volume (Spearman Rho, CC = 0.47; 95% confidence interval, 0.2-0.67; P<0.001), tumour necrosis volume (CC = 0.49; 95% confidence interval, 0.2-0.72;P= 0.004), the amount of necrotic GFAP positive cells (CC = 0.61; 95% confidence interval, 0.29-0.81; P= 0.007)and serum GFAP level among the GBM patients; 5. A serum GFAP level of >0.05 kg/l was 76% sensitive and 100% specific for the diagnosis of GBM in patients with a single supratentorial mass lesion in this series;",Serum GFAP is a diagnostic marker for glioblastoma multiforme,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
184,25028501,1,Submitted,0,450k; 1p/19q; anaplastic glioma; G-CIMP; MGMT,"1. G-CIMP and 1p/19q codeletion are reliably detectable by HM450 analysis and are associated with prognosis in the NOA-04 trial; 2. For MGMT, HM450 suggests promoter methylation in the vast majority of G-CIMP tumors, which is supported by pyrosequencing;","Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
185,30426531,1,Submitted,0,CRIPTO‐1; dedifferentiation; epithelial to mesenchymal transition (EMT); proliferation; vasculature,"1. Upon overexpressing Cripto‐1 in U87 GBM cells, the stemness markers Nanog, Oct4, Sox2, and CD44 increased expression; 2. An increase in Ki67 was observed demonstrating Cripto‐1's potential to induce cellular proliferation; 3. Increased expression of the markers of migration and invasion, Vimentin and Twist, correlated with upregulation of Cripto‐1; 4. Cripto‐1 exposure led to VEGFR‐2 overexpression along with higher tube formation under conditions promoting endothelial growth;",Investigating the role of CRIPTO‐1 (TDGF‐1) in glioblastoma multiforme U87 cell line,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
186,24946857,1,Submitted,0,Glioma; Filamin C; FLNC; Biomarker; Early diagnosis,1. High-grade gliomas expressed higher level of filamin C mRNA than low-grade gliomas; 2. FLNC protein expression level was higher in high-grade glioma than in low-grade gliomas which expressed significantly higher level of FLNC than normal brain tissues; 3. The serum anti-FLNC autoantibody level was significantly higher in low-grade gliomas than in high-grade gliomas or healthy volunteers; 4. The filamin C mRNA expression level inversely correlated with the serum anti-FLNC autoantibody concentrations; 5. There was a discrepancy between the decreased level of anti-FLNC autoantibody and the increased tissue expression of FLNC in the patients with high-grade gliomas;,Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
187,27926502,1,Submitted,0,miR-433-3p; CREB; glioma; carcinogenesis; chemosensitivity,1. MiR-433-3p and miR-433-5p are down-regulated in malignant glioma; 2. MiR-433-3p suppresses malignant behavior of glioma cells; 3. CREB is a direct target of miR-433-3p; 4. CREB can rescue the phenotypes caused by miR-433-3p; 5. MiR-433-3p inhibits glioma growth in nude mice; 6. MiR-433-3p increases chemosensitivity of glioma  to temozolomide (TMZ) by targeting CREB;,MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
188,27753657,1,Submitted,0,ependymoma; EMA; EBP50; meningioma; glioblastoma,"1. Ring-like positivity was 100% specific for ependymomas, but showed a poor sensitivity (EMA, 29%; EBP50, 37%); 2. Dot EMA positivity was more sensitive in grade III ependymomas (100%), whereas dot EBP50 positivity was more sensitive in grade I subependymomas (80%) and myxopapillary ependymomas (40%); 3. Among grade II ependymomas, EBP50 labeled a significantly higher number of dots and rings, which may be of value in small biopsies; 4. Focal dot positivity for EMA and EBP50 in glioblastoma multiforme and meningioma contributed to the lowered specificity (EMA, 84%; EBP50, 80%); 5. Myxopapillary ependymomas (60%), choroid plexus papillomas (66%), and papillary tumors of pineal region (100%) showed membranous staining with EBP50;",A Comparative Immunohistochemical Study of Epithelial Membrane Antigen and NHERF1/EBP50 in the Diagnosis of Ependymomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
189,26381556,1,Submitted,0,NA,"1. Grade III gliomas showed significantly higher average tumor-to-normal tissue and maximum tumor-to-normal tissue than grade II gliomas in 11C-methionine (P=0.013, P=0.0017, respectively), but not in FDG-PET imaging; 2. 11C-methionine PET maximum tumor-to-normal tissue ratio of 2.0 was most suitable for detecting grade III gliomas among nonenhancing gliomas (sensitivity, 83.3%; specificity, 73.9%); 3. Among patients not receiving any adjuvant therapy, median progression-free survival was 64.2 ± 7.2 months in patients with maximum tumor-to-normal tissue ratio of 2.0 for 11C-methionine PET and 18.6 ±  6.9 months in patients with maximum tumor-to-normal tissue ratio of 2.0 (P=0.0044);",Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
190,31321952,1,Submitted,0,Glioma; mammalian sterile 20-like 1; Sirtuin 6; viability; apoptosis; molecular mechanisms; immunohistochemistry,1. MST1 and SIRT6 were down-regulated in glioma tissues; 2. Over-expression of MST1 inhibited cell viability and colony formation and induced cell apoptosis of glioma cells; 3. MST1 positively regulated SIRT6 expression via FOXO3a; 4. MST1 inhibited cell viability and induced cell apoptosis of glioma cells through regulating SIRT6 expression;,MST1 suppresses viability and promotes apoptosis of glioma cells via upregulating SIRT6 expression,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
191,25862748,1,Submitted,0,"Isocitrate dehydrogenase , 2-Hydroxyglutarate , Biomarker , Plasma , Urine , Glioma","1. In all patients, we analyzed the mean 2HG concentration in the plasma, urine, and plasma/urine ratio (Ratio_2HG). We found a significant difference in the Ratio_2HG between patients with and without an IDH1 mutation (22.268.7 vs. 15.666.8; p < .0001); 2. The optimal cutoff value for Ratio_2HG to identify IDH1 mutation was 19 (sensitivity, 63%; specificity, 76%; accuracy, 70%); 3. In the patients with high-grade glioma only, the optimal cutoff value was 20 (sensitivity, 76%; specificity, 89%; accuracy, 84%; positive predictive value, 80%; negative predictive value, 86%); 4. In 7 of 7 patients with high-grade glioma, we found a correlation between the Ratio_2HG value and the response to treatment 5. Ratio_2HG might be a predictor of the presence of IDH1 mutation;",Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
192,23595627,1,Submitted,0,biomarker; brain tumor; prognosis; survival; zinc transporter; ZIP4,"1. The expression of ZIP3, 4, 8, 14, ZnT5, 6, and 7 were increased, and the expression of ZnT10 was decreased in grade IV gliomas, compared with grade II gliomas; 2. Among all 24 zinc transporters, ZIP4 is most significantly associated with tumor grade and overall survival; 3. High ZIP4 expression was significantly associated with higher grade of gliomas and shorter overall survival (hazard ratio = 1.61, 95% confidence interval = 1.02-2.53, P= 0.040 in CGCA cohort; hazard ratio = 1.32, 95% confidence interval = 1.08-1.61, P = 0.007 in REMBRANDT cohort);",ZIP4 is a novel molecular marker for glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
193,27385098,1,Submitted,0,glioblastoma; exosomes; neurotrophin receptors; TrkB; undifferentiated cells,"1. Characterization of YKL-40-inactivated  glioblastoma cells: differentiated state and  functional properties; 2. YKL-40 glioma cell-inactivation decreased TrkB, p75NTR and sortilin cell expressions; 3. Neurotrophin receptors, TrkB, p75NTR and  sortilin are decreased in sh YKL-40-derived  exosomes; 4. Functional properties of exosomes were  depending on the transfer of TrkB; 5. Tumor growth was diminished by exosomes from YKL-40-inactivated cells; 6. TrkB is detected in plasma exosomes from GBM  patients;",TrkB-containing exosomes promote the transfer of glioblastoma  aggressiveness to YKL-40-inactivated glioblastoma cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
194,25786084,1,Submitted,0,TTF-1; chordoid glioma of the third ventricle; lamina terminalis; circumventricular organs; RENOP,"1. TTF-1 was constantly expressed in chordoid glioma of the third ventricle (CG3V), as in developing and adult lamina terminalis; 2. No mutation of IDH1 R132, IDH2 R172, or BRAF V600 codons was found; 3. We showed TTF-1 as a useful marker for the diagnosis of CG3V and the understanding of its oncogenesis;",Chordoid Gliomas of the Third Ventricle Share TTF-1 Expression With Organum Vasculosum of the Lamina Terminalis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
195,26622819,1,Submitted,0,"B7-H3, monoclonal antibody, expression, glioma","1. The expression of B7-H3 isoforms in human glioma tissues was also examined and the expression of 2IgB7-H3 was found in the majority of the glioma tissues, but not in the normal tissues; 2. One novel mAb recognizing 2IgB7-H3 was successfully generated in the present study; 3. Using the mAb obtained, it was shown that 2IgB7-H3 is not the major isoform in a number of carcinoma cells; 4. Its overexpression in glioma suggests that 2IgB7-H3 mAb may be a useful tool for the diagnosis and therapy of glioma;",Differential expression of 2IgB7 H3 and 4IgB7 H3 in cancer cell lines and glioma tissues,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
196,20714943,1,Submitted,0,p14ARF; Methylation; Glioma; P53; Immunohistochemistry,"1. The average percentage of methylation in the promoter region of p14ARF gene in brain samples from glioma patients is 39.4%, while 0 from autopsy donors; 2. No difference in the methylation level between low-grade and high-grade gliomas was detected; 3. The methylation status has no correlation with the prognosis in glioma patients; 4. A significant correlation between the expression of mutant form of TP53 and the grade of the glioma was established; 5. There was a negative correlation between methylation of the p14ARF promoter and the expression of the mutant form of TP53; 6. Methylation in the promoter region of the p14ARF gene may be used as a biomarker for the diagnosis of glioma;",p14ARF promoter region methylation as a marker for gliomas diagnosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
197,20096670,1,Submitted,0,FRAT1; β-catenin; Glioma; Immunohistochemistry; Western blot; RT-PCR,"1. FRAT1 was found to be specifically expressed in the majority of glioma samples, and their expression levels increased markedly with the increase of WHO grades; 2. There was a positive correlation between FRAT1 immunoreactivity score (IRS) and β catenin IRS; 3. FRAT1 may be an important factor in the tumorigenesis and progression of gliomas, and could be used as a potential molecular marker for pathological diagnosis and a target for biological therapy;",The expression profile of FRAT1 in human gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
198,15146346,1,Submitted,0,Microtubule-associated protein-2; Neuropathology; Gliomas; Astrocytomas; Precursor cells,"1. Specific pattern of MAP2-positive tumor cells can be identified in 95% of glial neoplasms; 2. Ependymal tumors do not express MAP2 in their rosette-forming cell component; 3. Tumors of the pineal gland as well as malignant embryonic tumors are also characterized by abundant MAP2 immunoreactivity; 4. Virtually no MAP2 expression can be observed in the neoplastic glial component of glio-neuronal tumors, i.e. gangliogliomas; 5. Malignant glial tumor variants (WHO grade III or IV) exhibit different and less specific MAP2 staining patterns compared to their benign counterparts (WHO grade I or II); 6. With the exception of melanomas and small cell lung cancers, MAP2 expression is very rare in metastatic and non-neuroepithelial tumors; 7. Glial MAP2 expression was not detected in 56 nonneoplastic lesions;",Microtubule-associated protein-2 immunoreactivity:  a useful tool in the differential diagnosis  of low-grade neuroepithelial tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
199,15663956,1,Submitted,0,Glioblastoma multiforme; Astrocytoma; Liver-type glutaminase; Kidney-type glutaminase; RT-PCR,"1. RT-PCR analysis of RNA derived from postoperative tissue samples revealed the absence or only traces of LGA mRNA in all (9) cases of malignant gliomas (astrocytoma anaplasticum, AA, WHO grade III; glioblastoma multiforme, WHO grade IV) examined; 2. The RNA was strongly expressed in the non-neoplastic tissue derived from the same patients (6 cases), and in most of the brain metastases from different organs (5 out of 7 cases); 3. The mRNAs coding for the kidney-type glutaminase (KGA) and its less ubiquitous isoform GAC, which catalyze degradation of the cytoplasmic pool of Gln, were expressed in all the tissues examined; 4. The lack of LGA may be thus considered as a useful negative diagnostic marker of highly malignant gliomas in situ;",Lack of expression of the liver-type glutaminase (LGA) mRNA in human malignant gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
200,32081419,1,Submitted,0,Glioma; Endothelial cells; Extracellular vesicles; Migration; MYO1C,"1. EV-mediated transfer of MYO1C induced glioma cell LN229 migration. Knockdown of MYO1C in GhEC or GhEC-EV suppressed this effect; 2. Overexpression of MYO1C promoted migration on the contrary; 3. MYO1C was also detected in glioma cerebrospinal fluid (CSF), which is more suitable as a liquid biopsy biomarker and contributes to early diagnosis and monitoring in glioma;",Glioma-derived endothelial cells promote glioma cells migration via extracellular vesicles-mediated transfer of MYO1C,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
201,20501753,1,Submitted,0,NA,"1. The mean transcript levels of IGFBP-2 and -3 were significantly higher in glioblastomas (GBM) relative to anaplastic astrocytoma (AA), diffuse astrocytoma (DA), and controls whereas IGFBP-5 mRNA was higher in GBM relative to AA and controls (P < 0.05); 2. By immunohistochemistry, the mean labeling index of all isoforms was significantly higher in GBM compared with AA, DA, and control (P < 0.05); 3. A strong positive correlation was observed between their respective mRNA and protein expressions (P < 0.01); 4. Multivariate analysis revealed IGFBP-3 expression (hazard ratio, 1.021; P = 0.030) and patient age (hazard ratio, 1.027; P = 0.007) to be associated with shorter survival in glioblastoma;","Grade-Specific Expression of Insulin-like Growth Factor-Binding Proteins-2, -3, and -5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
202,24308561,1,Submitted,0,A2B5; GBM; SEREX; URGCP,1. URGCP was expressed highly in most of glioma cell lines; 2. The mRNA lever of URGCP was high expressed in human glioma cells compared with normal brain; 3. URGCP was high expressed in both low- and high-grade gliomas;,Serological Identification of URGCP as a Potential Biomarker for Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
203,24483339,1,Submitted,0,AJAP1; Cytoskeleton; Glioma; Invasion; Proliferation,"1. AJAP1 expression was significantly decreased in gliomas compared with normal brain in REMBRANDT and CGCA cohorts; 2. Low AJAP1 expression was associated with worse survival in GBMs in REMBRANDT and TCGA U133A cohorts and was significantly associated with classical and mesenchymal subtypes of GBMs among four cohorts; 3. Confocal imaging indicated AJAP1 localized in cell membranes in low-grade gliomas and AJAP1-overexpressing GBM cells, but difficult to assess in high-grade gliomas due to its absence; 4. AJAP1 overexpression altered the cytoskeleton and cellular polarity in vitro and inhibited the tumor growth in vivo;",AJAP1 is Dysregulated at an Early Stage of Gliomagenesis and Suppresses Invasion Through Cytoskeleton Reorganization,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
204,19594548,1,Submitted,0,NA,"1. Circulating filamin-A was detected in the plasma of 109 of 143 patients with breast cancer and primary brain tumors; 2. Filamin-A levels were increased in malignant breast or brain tissues, but not in normal control tissues; 3. Filamin-A localized to lysosomes in MDA.MB.231 breast cancer cells, but not in normal human mammary epithelial cells, suggesting that filamin-A may undergo cancer-specific processing; 4. Plasma filamin-A appears to be a specific and sensitive marker for patients with high-grade astrocytoma or metastatic breast cancer;",Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
205,18821037,1,Submitted,0,Astroglial brain tumors; p53 and CD31 immunostaining; Image analyzer system CAS-200,"1. Both p53 and CD31 expressions were correlated well with the histopathological grades of different subtypes of astrogliomas with good discrimination between low and high grades; 2. Overall, a highly significant statistical correlation was observed between the grades of astrocytomas and the p53 and CD31 labeling indices; 3. The expressions of p53 and CD31 were markedly increased in glioblastoma multiforme (GBM) with mean values (59.7 ± 13.5) (P = 0.0001) and (40.7 ± 8.9) (P = 0.001), respectively; 4. The co-expression and increased levels of p53 and CD31 in astrogliomas are increasing as the tumor grade is increasing;",Significance of p53 and CD31 in astrogliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
206,24435880,1,Submitted,0,Biomarkers; diagnosis; exosomes; GBM; sncRNAs,1. The expression levels of 1 small noncoding RNA (RNU6-1) and 2 microRNAs (miR-320 and miR-574-3p) were significantly associated with a GBM diagnosis; 2. RNU6-1 was consistently an independent predictor of a GBM diagnosis;,A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
207,23851827,1,Submitted,0,PomGnT1; receiver operating characteristic (ROC) curve; pseudopodia; c-myc; glioma,"1. PomGnT1 expression was correlated with glioma grade, and it could be used as a marker to distinguish low- and high-grade gliomas; 2. Stably transfected U87 cells were constructed to overexpress short hairpin RNA of PomGnT1; 3. Immunofluorescence test detected that this protein also could restrain the generation of U87 cells' pseudopodia; 4. Western blotting further showed that the PomGnT1 protein had an impact on the c-myc protein level;","O-Linked Mannose A-1,2-N-acetylglucosaminyltransferase 1 Correlated With the Malignancy in Glioma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
208,26317248,1,Submitted,0,Serum 25-Hydroxyvitamin D Concentration; Glioma,"1. Among men diagnosed with high grade glioma >56, we found a negative trend (P = 0.04); 2. Men diagnosed ≤ 56 showed a borderline positive trend (P = 0.08); 3. High levels (>66 nmol/L) of 25(OH)D in men >56 were inversely related to high grade glioma from 2 yr before diagnosis (OR = 0.59; 95% CI = 0.38, 0.91) to 15 yr before diagnosis (OR = 0.61; 95% CI = 0.38,0.96);",Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
209,26978735,1,Submitted,0,Early Diagnosis; Glioma; MicroRNAs; Plasma; Prognosis,"1. The level of circulating miR-182 in glioma patients was higher than that in healthy controls (P<0.001), which was significantly associated with KPS score (P=0.025) and WHO grade (P<0.001); 2. The area under the receiver operating characteristic (ROC) curve (AUC) was 0.778. The optimal cut-off value was 1.56, and the sensitivity and specificity were 58.5% and 85.2%, respectively; 3. A high predictive value of circulating miR-182 was observed in high-grade glioma (AUC=0.815); 4. Kaplan-Meier analysis demonstrated that the cumulative 5-year overall survival rate in the high miR-182 group was significantly lower than that in the low miR-182 group in both overall survival (OS) (P=0.003) and disease-free survival (DFS) (P=0.006); 5. Multivariate Cox analysis revealed that circulating miR-182 was an independent prognostic indicator for OS (P=0.034) and DFS (P=0.013);",Potential Diagnostic and Prognostic Value of  Plasma Circulating MicroRNA-182 in Human  Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
210,23824536,1,Submitted,0,Galectin-1; Serum; High-grade glioma; Glioblastoma,1. Galectin-1 serum levels in healthy individuals depend on age and sex; 2. Galectin-1 serum levels are signiﬁcantly elevated in patients with newly diagnosed GBM; 3. Galectin-1 serum levels are signiﬁcantly elevated in patients with relapsed HGG; 4. The discriminative ability of the galectin-1 serum levels increases with age;,Altered galectin-1 serum levels in patients diagnosed with high-grade glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
211,27910945,1,Submitted,0,thyroid transcription factor-1; subependymal giant cell astrocytoma; subependymal giant cell astrocytoma,"1. Immunohistochemical stain for TTF-1 was positive in all 24 subependymal giant cell astrocytomas, whereas negative in all astrocytomas, gangliogliomas, ependymomas, and subependymomas; 2. Neurocytomas were positive for TTF-1 in 4/19 (21%) of cases using clone 8G7G3/1 and in 9/19 (47%) of cases using clone SPT24; 3. In the three fetal brains that we examined, TTF-1 expression was seen in the medial ganglionic eminence, a transient fetal structure between the caudate nucleus and the thalami; 4. There was no BRAFV600E mutation identified by direct sequencing in the 20 subependymal giant cell astrocytomas that we studied; 5. TTF-1 is a useful marker in distinguishing subependymal giant cell astrocytoma from its histologic mimics, in particular gemistocytic astrocytoma and ganglioglioma;",Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells in the medial ganglionic eminence,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
212,28534976,1,Submitted,0,Glioma; miR-130b; cylindromatosis; proliferation; inva-sion; apoptosis; prognosis,1. miR-130b upregulation is associated with unfavorable clinicopathological parameters in human glioma; 2. CYLD is a potential downstream target of miR-130b; 3. MiR-130b regulates the proliferation of U87 and U251 cells; 4. MiR-130b regulates apoptosis in U87 and U251 cells; 5. miR-130b regulates the invasiveness and metastasis of U87 and U251 cells; 6. miR-130b affects glioma growth in nude mice; 7. MiR-130b regulates CYLD protein expression in U87 and U251 cells;,"miR-130b regulates the proliferation, invasion and apoptosis of glioma cells via targeting of CYLD",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
213,31410112,1,Submitted,0,glioma; LINK-A lncRNA; survivin; apoptosis,"1. Serum levels of LINK-A lncRNA and survivin were significantly higher in patients with glioma compared with healthy controls; 2. Increased levels of LINK-A lncRNA distinguished glioma patients from healthy controls, based on ROC curve analysis; 3. Serum levels of LINK-A lncRNA and survivin were positively correlated in glioma patients, but not in healthy controls; 4. Overexpression of LINK-A lncRNA led to increased survivin protein expression, while survivin overexpression had no effect on LINK-A lncRNA expression; 5. LINK-A lncRNA and survivin overexpression each reduced glioma cell apoptosis, but LINK-A lncRNA siRNA-mediated knockdown increased apoptosis; 6. Survivin overexpression attenuated the inducing effects of LINK-A lncRNA knockdown on apoptosis; 7. LINK-A lncRNA inhibited glioma cell apoptosis potentially by the upregulation of survivin;",LINK-A lncRNA participates in the pathogenesis  of glioma by interacting with survivin,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
214,11895042,1,Submitted,0,Apolipoprotein D; Astrocytoma; Brain tumor; Microarray analysis; Pilocytic astrocytoma,"1. Apolipoprotein D (apoD), which expressed 8.5-fold higher in pilocytic astrocytomas, showed the greatest level of differential expression and emerged as a potential marker for pilocytic tumors; 2. By immunohistochemistry, 10 of 13 pilocytic astrocytomas stained positively for apoD, while none of 21 infiltrating astrocytomas showed similar staining. ApoD immunostaining was also seen in 9 of 14 of gangliogliomas, 4 of 5 subependymal giant cell astrocytomas (SEGAs), and a single pleomorphic xanthoastrocytomas (PXAs); 3. By in situ hybridization, pilocytic astrocytomas, in contrast with infiltrating astrocytomas, showed widespread increased apoD expression; 4. SAGE analysis using the NCBI database showed a higher level of expression of apoD RNA in pilocytic astrocytoma than in any of the other 94 neoplastic and non-neoplastic tissues in the database; 5. ApoD is associated with decreased proliferation in some cell lines, and is the protein found in highest concentration in cyst fluid from benign cystic disease of the breast; 6. ApoD might play a role in either decreased proliferation or cyst formation in pilocytic astrocytomas, gangliogliomas, SEGAs, and PXAs;","Differential Expression between Pilocytic and Anaplastic Astrocytomas: Identification of Apolipoprotein D as a Marker for Low-Grade, Non-Infiltrating Primary CNS Neoplasms",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
215,24497408,1,Submitted,0,glioma; laminin-8; LAMB1; miR-124-5p,1. LAMB1 expression is upregulated in high-grade gliomas; 2. MiR-124-5p is downregulated in high-grade gliomas; 3. MiR-124-5p regulates LAMB1 expression at the posttranscriptional level; 4. Restoration of miR-124-5p expression in glioma cells inhibits tumor growth; 5. Microvessel density in glioma xenografts is reduced by restoration of miR-124-5p expression; 6. LAMB1 knockdown suppresses growth inhibition and reduces microvessel density in glioma xenografts;,MiR-124-5p inhibits the growth of high-grade gliomas through posttranscriptional regulation of LAMB1,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
216,24274717,1,Submitted,0,differentiation; FABP7; glioblastoma; stem cells,"1. FABP7 expression was significantly downregulated in differentiated GSCs induced by the addition of serum; 2. In the glioma surgical specimens, FABP7 was highly expressed in the majority of glioblastoma; 3. Double immunostaining for FABP7 and Sox2 showed that FABP7+ Sox2+ tumor cells were significantly increased in glioblastoma (grade IV) compared with diffuse astrocytoma (grade II) and anaplastic astrocytoma (grade III);",Fatty acid binding protein 7 as a marker of glioma stem cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
217,32038986,1,Submitted,0,glioma; soluble programmed cell death-ligand 1; biomarker; cerebrospinal fluid; inflammatory markers,"1. Serum and CSF levels of sPD-L1 were significantly elevated in patients with gliomas compared to those with meningiomas and  healthy controls (HCs); 2. Additionally, increased levels of sPD-L1 were observed in relatively advanced tumors; 3. sPD-L1 overexpression in the CSF appears to be more representative of aggressive tumor features than overexpression in the serum; 4. For glioma diagnosis, both serum and CSF sPD-L1 showed significant value in the diagnosis and stratification of glioma, and the best diagnostic performance was obtained with serum sPD-L1 rather than blood-based inflammatory markers; 5. A descending trend in the level of serum sPD-L1 was observed in postoperative patients;",The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
218,18666437,1,Submitted,0,UbcHIO; astrocytic tumors; gliosis; immunohislochemistry; proteasome inhibitors,1. UbcH10 expression was observed in low-grade astrocytoma and in glioblastoma; 2. Our data indicate a clear correlation between UbcH10 expression and the histological grade of the astrocytic tumors; 3. The analysis of UbcH10 expression allows the differentiation between gliotic and malignant tissues;,Analysis of UbcHIO expression represents a useful tool for the diagnosis and therapy of astrocytic tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
219,19737649,1,Submitted,0,NA,"1. The frequency of the presence of 1p/19q in oligodendrogliomas grade II and grade III was significantly different than for the other tumor subtypes (oligoastrocytomas and astrocytic tumors) (P = 0.006); 2. The FISH techniques were performed successfully on 37 available specimens, identifying 24 cases with 1p/19q, one case with only 1p, and two cases with only 19q. Ten cases had neither deletion; 3. Deletion status was more predictive of survival than histology in the mixed tumors: the low grade tumor did worse (median survival, 203 days) than the anaplastic tumors (median survival, 853 days);",Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
220,29679199,1,Submitted,0,18F-FDOPA PET; biomarker; glioma; MRI,"1. The volume of contrast enhancement and 18F-FDOPA T/N SUVmax were significantly higher in glioblastoma (WHO IV) compared with lower grade gliomas (WHO I-III), as well as for high-grade gliomas (WHO III-IV) compared with low-grade gliomas (WHO I-II)' 2. Receiver-operator characteristic (ROC) analyses confirmed the volume of contrast enhancement and 18F-FDOPA T/N SUVmax could each differentiate patient groups; 3. Multivariable Cox regression suggested continuous measures of 18F-FDOPA PET T/N SUVmax (HR = 4.43, P = 0.016) were significant prognostic factors for OS in WHO I-IV gliomas;",18F-FDOPA PET and MRI characteristics correlate with degree of  malignancy and predict survival in treatment-naïve gliomas: a  cross-sectional study,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
221,10653879,1,Submitted,0,NA,"1. 1p and 19q common deletion regions were each highly associated with the oligodendroglial phenotype; 2. Primary tumors with apparent loss of an entire copy of chromosome 1 or 19 were classified as having loss of 1p or loss of 19q, respectively, for comparisons of genotype with survival; 3. Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade;","Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
222,22772608,1,Submitted,0,Karyopherin a2; Infiltrative astrocytomas; NBS1 protein; IDH1 mutation; Prognosis; Biomarker,"1. Karyopherin a2 expression correlated significantly with histological grade (p<0.001), with proliferative activity as assessed by the MIB1 index (p<0.001), with IDH1 mutation status (p = 0.032), and with Nijmegen breakage syndrome 1 protein expression (p = 0.001); 2. Recurrent tumors expressed significantly higher levels of karyopherin a2 (p = 0.045) than primary growths; 3. Multivariate analysis of the overall series identified low karyopherin a2 expression (defined as less than 5 %) as an independent prognostic predictor of overall (p = 0.041) and progression-free survival (p = 0.004); 4. Survival of glioblastoma patients > 5 years was seen only in those with KPNA2 expression levels ≤1 % (p = 0.014); 5. KPNA2 expression may have potential as a novel diagnostic and prognostic biomarker for astrocytic gliomas;",Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
223,12482624,1,Submitted,0,Human cerebral tumor; Serum lipid peroxidation; Glial tumor; Malondialdehyde; Neurooncology,1. Patients with CNS tumors showed higher serum MDA concentration compared to control groups (epilepsy patients and healthy subjects); 2. These patients had a higher tumor tissue MDA concentration compared to lobectomy tissue from epilepsy patients; 3. Serum and tissue MDA concentrations were also higher in the malignant glial tumor group compared to the low grade glial tumor group;,Lipid peroxidation in cerebral tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
224,32257943,1,Submitted,0,TNFRSF1A; subtype; prognosis; mesenchymal; proliferation; glioma,1. TNFRSF1A was enriched in MAPK signaling pathway and TNF signaling pathway; 2. Overexpressed TNFRSF1A was strongly related to clinical features such as WHO grade; 3. TNFRSF1A was functioned as an independent poor prognostic predictor of glioma patients; 4. TNFRSF1A was preferentially upregulated in the Mesenchymal subtype gliomas (Mesenchymal-associated); 5. Knockdown of TNFRSF1A inhibited proliferation and migration of glioma cell lines in vitro;,Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
225,23564324,1,Submitted,0,miR-383; Glioma; Invasion; IGF1R,1. miR-383 is downregulated in human glioma tissues and cell lines; 2. Upregulation of miR-383 inhibits glioma cell invasion; 3. Inhibition of miR-383 promotes glioma cell invasion; 4. MiR-383 regulates IGF1R/AKT signaling and MMP2 expression; 5. MiR-383 directly targets IGF1R; 6. IGF1R expression is critical for miR-383 downregulation-induced cell invasion;,Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
226,24344030,1,Submitted,0,Astrocytoma; CDC25B; cellular proliferation; cyclin dependent kinases; Ki-67; p53,"1. The average CDC2B staining index (CSI) was  0.6% in pilocytic astrocytoma (PA), 0.4% in diffuse astrocytoma (DA), 7.7% in anaplastic astrocytoma (AA) and 25.5% in glioblastoma multiforme (GBM); 2. The increase of CSI in parallel with the increase of WHO grade was significant (p=0.001); 3. No expressions were identified in  reactive gliosis (RG) and normal brain; 4. There was also significant relationship between the tumor size and CSI (p=0.027) and also between Ki-67 PI and CSI (p=0.001); 5. Among the groups with low and high CSI in astrocytoma cases, the disease free survival (DFS) was significantly higher in the low CSI group (p=0.0001);","CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
227,26451167,1,Submitted,0,Subtelomeric DNA methylation; Telomere length; Glioma; Epigenetic biomarker,"1. DNA methylation level dramatically increased at the subtelomere of Chr.8q, 21q, and XpYp in malignant glioma, which could be used as an early epigenetic diagnostic biomarker of the disease; 2. Subtelomeric methylation levels were consistently higher in glioma patients at all age groups, addressed in this study, and the change in methylation level can be detected even at the early stage of glioma (grade-II); 3. Significant changes in the percentage of methylation were observed in two out of six CpGs in Chr.7q, five out of six CpGs in Chr.8q, and two out of six CpG sites in Chr.18p;",Selective increase in subtelomeric DNA  methylation: an epigenetic biomarker for  malignant glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
228,25346165,1,Submitted,0,BRAF; dysembyoplastic neuroepithelial tumor; glioblastoma with neuronal marker expression; pleomorphic xanthoastrocytoma; subependymal giant cell astrocytoma,"1. We found frequent BRAF V600E in dysembryoplastic neuroepithelial tumors (DNTs) (26/51, 51%), subependymal giant cell astrocytomas (SEGAs) (6/14, 42.9%), and pleomorphic xanthoastrocytomas (PXAs) (14/28, 50%); 2. In DNTs, BRAF V600E was more commonly detected in tumors with extra‐temporal location (68.2% vs. 37.9%; P = 0.032); 3. The diagnostic subgroups of tuberous sclerosis complex were not correlated with BRAFV600E in patients with SEGA (P = 0.533); 4. One PXA case revealed a unique duplication mutation (p.Thr599dup) of codon 599; 5. All neuronal marker expression (GBM‐N) cases did not carry BRAF mutation;",BRAF V600E Mutations are Frequent in Dysembryoplastic Neuroepithelial Tumors and Subependymal Giant Cell Astrocytomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
229,26828272,1,Submitted,0,GGCT; Glioma; Notch; Akt,"1. GGCT is a tumor supporter protein in human glioma; 2. GGCT expression was up-regulated in human glioma tissues and cell lines, and knockdown of GGCT repressed glioma cells proliferation and colony formation in T87G and U251 glioma cells; 3. GGCT is a tumor promoter in human glioma by regulating the Notch-Akt signaling; 4. We propose that GGCT-dependent Notch receptor recovery could be a key event in subsets of glioma and that pharmacologic inhibition of GGCT could represent a promising therapeutic approach combined with Notch inhibitors; 5. Notch inhibition blocked the effects of GGCT on Akt activation and glioma cell proliferation and colony formation; 6. Notch-Akt signaling is an important mechanism by which GGCT regulates cell cycle and proliferation, which may also exist in other type of cancer;",Gamma-glutamylcyclotransferase promotes the growth of human glioma cells by activating Notch-Akt signaling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
230,29115595,1,Submitted,0,microRNA 181 family; glioma; early stage; alteration; cancer stem cells,"1. The current  study demonstrated that all subtypes of the miRNA 181 family were downregulated at stages of human glioma, including miR181a1, a2, b1, b2, c and d; 2. miR181c declined the most in the samples from patients with World Health Organization (WHO) grade I glioma; 3. As glioma  development progressed from grade I to IV, the expression  of miRN181 family members continued to decline, with miR181b1 exhibiting the fastest decline rate; 4. A lentivirus was used to overexpress miR181c in primary glioma cells, the result indicated that miR181c overexpression was  able to significantly inhibit glioma cell proliferation; 5. MiR181 may be a useful biomarker for human glioma at early stages; 6. Detection of the level of miR181 family members may  be a potential method for glioma diagnosis, determining the  tumor WHO grade and guiding clinical treatment;",Role of the microRNA 181 family in glioma development,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
231,11958371,1,Submitted,0,NA,"1. We report a minisatellite polymorphism in the untranslated region of exon 1, with allelic variants that have one, two or three 27-bp repeats; 2. The polymorphism is informative in 55.7% of a reference population, and accurately detects allelic loss of 19q in human gliomas; 3. This novel marker offers distinct advantages for assessing 19q status in malignant gliomas; 4. The relatively large size of the repeats allows detection of allelic variants with standard ethidium bromide-stained agarose gels and the PLA2G4C marker is the closest polymorphism to the smallest common deletion area in the putative glioma tumor suppressor gene region;",Novel PLA2G4C Polymorphism as a Molecular Diagnostic Assay for 19q Loss in Human Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
232,31785437,1,Submitted,0,Glioma; Periostin (POSTN); Prognosis; TCGA; CGGA,"1. Periostin (POSTN) as a mesenchymal subtype biomarker with prognostic value across histological grades, and confirmed the reliability of POSTN by gene-expression meta-analysis combining TCGA, Chinese Glioma Genome Atlas (CGGA) and REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) GBM cohorts (HR = 1.71 (1.47-2.07), n =693) and LGG cohorts (HR = 2.55 (1.61-4.05), n=1226); 2. By using available online glioma databases, our study provided an insight into the expression of POSTN as an independent predictor for glioma patients (GBM and LGG) and could be useful for diagnostic simplification to identify high-risk groups; 3. The Cancer Genome Atlas-Glioblastoma (TCGA-GBM) and The Cancer Genome Atlas-Low Grade Glioma (TCGA-LGG) Ribonucleic Acid sequencing (RNAseq) cohorts have been analyzed and confirmed that the mesenchymal subtype was associated with the worst prognosis;",Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
233,28979807,1,Submitted,0,Glioma; miR-625; AKT2; proliferation,1. MiR-625 is downregulated in human glioma  tissues and cell lines; 2. MiR-625 overexpression suppresses cell proliferation and colony formation and induces G0/ G1 arrest in glioma cell lines; 3. AKT2 is a direct target of miR-625 in glioma  cells; 4. MiR-625 suppresses tumor growth and angiogenesis in vivo; 5. AKT2 overexpression reverses the inhibitory effects of miR-625 in glioma cell lines; 6. MiR-625 overexpression increases the chemosensitivity of glioma cells to TMZ by targeting AKT2;,MicroRNA-625 inhibits the proliferation and  increases the chemosensitivity of glioma  by directly targeting AKT2,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
234,26834160,1,Submitted,0,2-Hydroxyglutarate; dehydrogenase 1 (IDH1) and IDH2 genes; serum and urine,"1. Urine 2-HG levels are elevated among patients with IDH-mutant glioma when compared with that of patients with IDH-WT disease; 2. A noninvasive method for detecting and quantifying 2-HG levels would have clinical impact in patients with IDH-mutant glioma; 3. Urinary 2-HG is increased among patients with IDH-mutant gliomas, andmay representa future surrogate, noninvasive biomarker to aid in diagnosis, prognosis, and management;",Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
235,21138738,1,Submitted,0,Hiwi; Glioma; Prognosis,"1. Hiwi was found to be specifically expressed in the majority of glioma tissues, and the expression was greatly increased with the ascending of tumor grades; 2. The Hiwi high positive cases showed a marked worse outcome than the low positive cases;",Clinical significance of Hiwi gene expression in gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
236,28453784,1,Submitted,0,Glioma; CSF; Vesicle; Biomarker; EGFRvIII,"1. EGFRvIII positive tumors had significantly greater wtEGFR DNA amplification (p=0.02) and RNA expression (p=0.03), and EGFRvIII positive CSF-derived EVs had significantly more wtEGFR RNA expression (p=0.004); 2. EGFRvIII was detected in CSF-derived EVs for 14 of the 23 EGFRvIII tissue-positive GBM patients. Conversely, only one of the 48 EGFRvIII tissuenegative patients had the EGFRvIII mutation detected in their CSF-derived EVs; 3. These results yield a sensitivity of 61% and a specificity of 98% for the utility of CSF-derived EVs to detect an EGFRvIII-positive GBM;",Detection of wtEGFR Amplification and EGFRvIII Mutation in CSF-Derived  Extracellular Vesicles of Glioblastoma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
237,28440425,1,Submitted,0,TFAM; mitochondria; glioma; biomarker,1. Immunohistochemical analysis of glioma tissue specimens indicated that TFAM is highly upregulated; 2. Bioinformatical analysis with Rembrandt knowledgebase also supported that TFAM mRNA is upregu lated in glioma patients; 3. The differential mRNA expression and prognostic value of TFAM was further validated in the REMBRANDT cohort; 4. Positive relationship between high TFAM expression and glioblastoma tissue specimens; 5. Therefore TFAM may be a novel diagnostic marker and thera peutic target for glioma and other cancer;,Mitochondrial transcription factor A (TFAM) is upregulated in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
238,29033691,1,Submitted,0,PHF20; Glioblastoma; U87 cell; Gene expression profle; Bioinformatics,"1. Expression of 540 genes, including FEN1 and CCL3, were signifcantly altered upon PHF20 gene silencing; 2. GO analysis results showed that DEGs were signifcantly enriched in small molecule metabolic and apoptotic processes; 3. Pathway analysis indicated that DEGs were mainly involved in cancer and metabolic pathways; 4. The MAPK, apoptosis and p53 signaling pathways were identifed as the hub pathways in the pathway network, while PLCB1, NRAS and PIK3 s were hub genes in the signaling network;",Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
239,24607494,1,Submitted,0,NA,1. WT1 increases with malignancy in diffuse astrocytomas; 2. Distribution of WT1 scores significantly differs between astrocytic and oligodendroglial tumors; 3. Absence of WT1 expression in high-grade gliomas is associated with younger age and presence of IDH1 mutation; 4. WT1 expression is reduced in recurrent tumors; 5. WT1 gene expression and immunohistochemistry data indicates a prognostic role for diffuse astrocytoma;,WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
240,15153841,1,Submitted,0,NA,"1. In the VEGF arm, 89% of samples with malignant astrocytoma and 27% of nonastrocytoma samples had detectable levels of VEGF; 2. VEGF was not detectable in normal CSF samples; 3. The levels of VEGF were significantly higher in high-grade astrocytomas than in nonastrocytic tumors; 4. Recoverin levels were 10-fold higher in patients with  recurrent GBM relative to controls; 5. In patients with low-grade glioma, anaplastic glioma, and GBM with no evidence of recurrence, a 3- to 5-fold increase was observed;",Cerebrospinal Fluid (Vascular Endothelial Growth Factor) and Serologic (Recoverin) Tumor Markers for Malignant Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
241,24858071,1,Submitted,0,glioma; microRNA; microarray; pathway; blood,"1. MiR-576-5p, miR-340 and miR-626 were significantly overexpressed, but miR-320, let-7g-5p and miR-7-5P showed significantly low expression in GBM patients;",miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
242,23483195,1,Submitted,0,glioma; HAUSP/USP7; deubiquitinating enzyme; prognosis,1. HAUSP expression levels were increased from grade I to grade IV in the tumors of the glioma patients; 2. The survival rate of patients with HAUSP-positive tumors was lower when compared to that of patients with HAUSP-negative tumors; 3. High expression of HAUSP was a significant and independent prognostic indicator in glioma by multivariate analysis;,Expression of HAUSP in gliomas correlates with disease progression and survival of patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
243,23982875,1,Submitted,0,MACC1; Glioma; Biomarker; Prognosis,1. MACC1 mRNA and protein expression were both significantly higher in glioma tissues than in corresponding noncancerous brain tissues; 2. High MACC1 expression was significantly correlated with advanced pathological grade; 3. Patients with high expression of MACC1 protein exhibited a poorer prognosis than those with low MACC1 expression;,Overexpression of MACC1 protein and its clinical implications in patients with glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
244,17230535,1,Submitted,0,glioma; tumor antigen; SOX5; SEREX; IgG response,"1. SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex; 2. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and 1 of the 37 healthy individuals (2.7%); 3. Patients with glioblastoma (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies;","Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
245,19513897,1,Submitted,0,Smad1; BMPR-IB; Glioma development,1. Decreased phosphorylation of Smad1/5/8 was directly correlated with the malignant stage of glioma and poor prognosis; 2. Expression of BMPR-IB was downregulated in AAST(anaplastic astrocytoma) and GBM; 3. Overexpression of BMPR-IB activates Smad1/5/8 and promotes differentiation and apoptosis of glioblastoma cells;,Expression and Functional Roles of Smad1 and BMPR-IB in Glioma Development,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
246,17020973,1,Submitted,0,NA,"1. High-grade glioma patients who underwent a surgical resection of their tumor had transient increase of bothYKL-40 and MMP-9 serum levels in the postoperative period; 2. Glioblastoma multiforme (GBM) patients with no radiographic evidence of disease (n = 10 patients, 50 samples) had a significantly lower level of YKL-40 and MMP-9 than patients with active tumor (n = 66 patients, 209 samples; P = 0.0003 and 0.0002, respectively); 3. Anaplastic glioma patients with no radiographic evidence of disease (n = 32 patients, 107 samples) also had a significantly lower level of YKL-40 compared with those patients with active tumor (n = 48 patients, 199 samples; P = 0.04); 4. There was a significant inverse association between YKL-40 and survival in GBM, hazard ratio (hazard ratio, 1.4; P = 0.02), and anaplastic astrocytoma patients (hazard ratio, 2.2; P = 0.05);",YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
247,26356815,1,Submitted,0,Homeobox (HOX) gene; HOXA13; glioma; SMAD; epithelial-to-mesenchymal transition (EMT),1. Protein and mRNA expression of 5' HOXA  genes are associated with tumor grade in human  glioma specimens; 2. HOXA13 is up-regulated in high-grade gliomas; 3. HOXA13 is an independent prognostic factor in  HGG patients; 4. HOXA13-associated genes are mainly enriched  in cancer pathways; 5. Lenti-si HOXA13 suppresses the expression of  HOXA13 in the nucleus and affects glioma cells  in vitro; 6. The down-regulation of HOXA13 expression  inhibits glioma cell invasion by regulating the  TGF-β signaling pathway in vitro; 7. HOXA13 knockdown in U87-EGFRvIII cells impedes orthotopic tumor growth in vivo;,HOXA13 is a potential GBM diagnostic marker and promotes  glioma invasion by activating the Wnt and TGF-β pathways,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
248,31133717,1,Submitted,0,NLRC4 infammasome; gliomas remains;  astrocytomas ,"1. The level of NLRC4 protein was increased in brain tissues, specifcally, in astrocytes, from glioma patients; 2. NLRC4 expression was associated with a poor prognosis in glioma patients, and the upregulation of NLRC4 in astrocytomas was associated with poor survival; 3. Hierarchical clustering of data from the Cancer Genome Atlas dataset showed that NLRC4 was highly expressed in gliomas relative to that in a normal healthy group; 4. The upregulation of the NLRC4 infammasome contributes to a poor prognosis for gliomas and presents a potential therapeutic target and diagnostic marker;",Upregulation of the NLRC4 infammasome contributes to poor prognosis in glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
249,31286678,1,Submitted,0,chromatin architectural interaction; GATAD1; gene amplification; glioma; prognosis biomarker,1. Our results indicated that GATAD1 gene amplification and GATAD1 gene expression are novel independent diagnosis biomarkers to indicate poor outcome of glioma patients; 2. GATAD1 knockdown can remarkably suppress GBM cell proliferation both in vitro and in vivo; 3. GATAD1 could promote CCND1 gene transcription by inducing long range chromatin architectural interaction on the CCND1 promoter; 4. Then GATAD1 sequentially accelerates GBM cell cycle transition and proliferation via regulating CCND1;,GATAD1 gene amplification promotes glioma malignancy by  directly regulating CCND1 transcription,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
250,16211217,1,Submitted,0,A2G2F; apoptosis; glioblastoma; LCA lectin; N-linked  oligosaccharide,"1. The amount of a biantennary  big alactosylated structure with one core fucosylation (A2G2F) was present in increased levels in glioblastoma tissue (mean = 2.90%) and glioma cell lines (mean = 5.60%), while  being less than 0.1% in normal brain tissue; 2. The present study is the first to reveal that A2G2F is abundantly present in glioblastoma tissue and cell lines; 3. Caspase cascade is critical for LCA lectin-induced cytotoxicity; 4. Incubation of WI-38 and NB1RGB, which do  not express A2G2F, with LCA lectin at 25 ug/ml or more for 20h resulted in no apoptosis; 5. LCA lectin binds glioma cells specifically indicates the application of LCA lectin for in vivo imaging and molecular targeted therapy with lectin-conjugated drugs, using A2G2F as a molecular probe;",Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
251,26101711,1,Submitted,0,ALDH1A1; glioma; invasion; matrix metalloproteinase; prognosis,"1. ADLH1A1 was frequently overexpressed in the high-grade glioma (WHO grade III-IV) as compared to the low-grade glioma (WHO grade I-II) patients; 2. The tumor cells with ALDH1A1 expression were more abundant in the region between tumor and the borderline of adjacent tissue as compared to the central part of the tumor; 3. ALDH1A1 overexpression was associated with poor differentiation and dismal prognosis; 4. The overall and disease-free survivals of the patients who had ALDH1A1+ tumor cells sparsely located in the adjacent tissue were much worse; 5. ALDH1A1 expression was correlated with the ""classical-like"" (CL) subtype as we examined GBM specimens from 72 patients; 6. Multivariate Cox regression analysis revealed that ALDH1A1 was an independent marker for glioma patients' outcome; 7. Mechanistically, both in vitro and in vivo studies revealed that ALDH1A1+ cells isolated from either a glioblastoma cell line U251 or primary glioblastoma cells displayed significant invasiveness, clonogenicity, and proliferation as compared to ALDH1A1-cells, due to increased levels of mRNA and protein for matrix metalloproteinase 2, 7 and 9 (MMP2, MMP7 and MMP9);",Aldehyde dehydrogenase 1A1 circumscribes high   invasive glioma cells and predicts poor prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
252,25298751,1,Submitted,0,SELD-ToF MS; LC-MS/MS; Glioblastoma; Biomarkers; S100A8; S100A9; CXCL4,"1. S100A8, 5100A9 and CXCL4 were selected as putative biomarkers and confirmed by ELISA; 2. CXCL4, S100A8 and S100A9, with increased serum level tissue overexpression in glioblastoma versus control;",Potential serum biomarkers for glioblastoma  diagnostic assessed by proteomic approaches,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
253,31896490,1,Submitted,0,Circulating Micro RNAs; GBM; Biomarkers; Plasma exosomal-micro RNAs; Prognosis; EGFR and MET signaling pathways,"1. Circulating microRNA can be potentially used as novel biomarkers for glioma that might be beneficial in clinical management of glioma patients; 2. MiR-5194 as an oncomiR that induces tumor invasion, apoptosis resistance, and EMT in mesenchymal subtype of GBM; 3. The upregulation of miR-210 and downregulation of miR-5194 and miR-449 are a promising diagnostic and prognostic biomarker positively correlated with histopathological grade and invasiveness of GBM; 4. MiR-185, miR-5194, and miR-449 were significantly downregulated (P<0.05) in GBM and LGA compared to trauma patients;",Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
254,25710480,1,Submitted,0,NA,"1. CD150 expression in CNS tumors can  be considered a new diagnostic marker and potential target for novel  therapeutic approaches; 2. CD150 is expressed I the cytoplasm but not on the surface of human glioma cell lines; 3. In glioma cells, CD150 I colocalized with th endoplasmic reticulum and Golgi complex; 4. CD150 protein remains in the cytoplasm of glioma cells, although both splice isoforms, mCD150 and nCD150, contain a leader sequence and a transmembrane domain that are essential for the receptor's surface expression;",Expression of CD150 in Tumors of the Central Nervous System: Identification of a Novel Isoform,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
255,26284486,1,Submitted,0,extracellular vesicles; cerebrospinal fluid; hsa-mir-21; glioma; cancer prognosis,"1. Exosomal miR-21 levels in the CSF of glioma patients were found significantly higher than in the controls, whereas no difference was detected in serum-derived exosomal miR-21 expression; 2. The CSF derived exosomal miR-21 levels correlated with tumor spinal/ventricle metastasis and the recurrence with anatomical site preference; 3. MiR-21 levels associated with tumor grade of diagnosis and negatively correlated with the median values of patient overall survival time; 4. The levels of miR-21 target genes of PTEN, RECK and PDCD4 were up-regulated at protein levels; 5. The exosomal miR-21 levels could be demonstrated as a promising indicator for glioma diagnosis and prognosis, particularly with values to predict tumor recurrence or metastasis;",Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
256,24913449,1,Submitted,0,glial inflammation; differentially expressed gene;  pathway analysis; feature gene; small molecules,"1. It is hypothesized that candoxin stimulation can cause glial inflammation through mutations in cell adhesion activity; 2. EPS8L1 may be a marker for glial inflammation, and its overexpression at 24 h could direct a diagnosis of glial inflammation;",Screening and functional analysis of glioma-related  genes induced by candoxin,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
257,28282372,1,Submitted,0,glioma; PTBP1; automated fluorescent miscroscopic image,1. Our data demonstrated that recurrent glioblastoma showed more DAPIPTBP1 positive cells and a higher mean intensity value of PTBP1 signal compared to resections from second surgeries that showed only reactive gliosis;,Automated fluorescent miscroscopic image analysis of PTBP1 expression in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
258,22939532,1,Submitted,0,Plexin-B1; Glioma; Natural killer cell,"1. Plexin-B1 was highly expressed in the cytoplasm and on the membrane of glioma tissues, while only trace levels of Plexin-B1 were present in normal brain tissue; 2. The expression level of Plexin-B1 in glioma tissue was associated with the pathological grade of the glioma; 3. Cytotoxicity assays showed cytolysis of the U251 glioma cell line by the NK cell line, NK92, and this was markedly downregulated when the neutralizing antibody to Plexin-B1 was added; 4. Plexin-B1 could be used as a diagnostic biomarker, and also suggests that it may be involved in the cytotoxicity of NK cells to glioma cells; 5. Plexin-B1 could be a useful future target for glioma immunotherapy;",Plexin-B1: A potential diagnostic biomarker for glioma and a future target for  glioma immunotherapy ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
259,27185265,1,Submitted,0,Glioma; MicroRNA; Proliferation; Invasion; Cellcycle; Temozolomide,1. MiR-93 may  become a  promising diagnostic marker and therapeutic target for glioma; 2. MiR-93 is upregulated in glioma tissues compared to normal brain tissues; 3. High miR-93 level is associated with the advanced malignancy and poor prognosis of glioma patients; 4. MiR-93 promotes the malignant phenotypes of glioma cells; 5. Knockdown of miR-93 enhances the chemosensitivity of U87 cells to TMZ;,MicroRNA-93 promotes the malignant phenotypes of human  glioma cells and induces their chemoresistance to temozolomide ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
260,26171163,1,Submitted,0,O6-methylguanine-DNA methyltransferase; glioma; circulating DNA; cerebrospinal fluid; tumor-specific molecular marker,"1. Assessment of MGMT promoter methylation may be more sensitive for CSF than for blood serum; 2. Using the CSF of patients with tumors of the nervous system may be advantageous over using serum for free DNA detection; 3. The occurrence of MGMT promoter methylation is greater for patients with residual tumors, but that CSF is more sensitive than blood for detecting the MGMT promoter methylation for either patient population (P<0.05);",MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
261,31930024,1,Submitted,0,Glioma; oligodendroglial; neutrophil-lymphocyte ratio (NLR); albumin-to-gamma-glutamyl transferase ratio (AGR); systemic inflammatory index,"1. Gliomas of oligodendroglial origin tended to have a lower NLR (P=0.018) and a higher AGR than those with tumors of astrocytic origin; 2.	 Both NLR and AGR had predictive value for oligodendroglial tumors, when compared with astrocytic tumors; 3. Multivariate analysis further demonstrated NLR + AGR as an independent predictor for overall survival; 4. NLR + AGR satisfactorily predicted the presence of oligodendroglial tumors and co-deletion of 1p/19q;",Pretreatment neutrophil-to-lymphocyte ratio plus albumin-to-gamma-glutamyl transferase ratio predict the diagnosis of grade III glioma ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
262,2531122,1,Submitted,0,NA,"1. We detected cALLa on 10 out of 13 glioma cell lines using 2 different anti cALLa MAbs (AI2-G4 and FAH99); 2. NEP antigen, as detected by immunostaining with an anti-NEP MAb (135A3), was expressed on the same 10 lines; 3. cALLa-positive, but not cALLa negative cell lines displayed an endopeptidase activity; 4. This activity could be blocked by phosphoramidon, a specific inhibitor of NEP; 5. MRNAs hybridizing to an NEP specific probe were present in cALLa-positive glioma cells but not in cALLa-negative cells;",Human glioma cell lines expression the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
263,17094475,1,Submitted,0,Astrocytoma; MCM7; Ki67; proliferation markers; grading,"1. The expressions of MCM7 and Ki67 were estimated in 66 primary human astrocytomas in relation to tumor grade (Grade I-IV, WHO); 2. MCM7 significantly stained more nuclei compared to Ki67 in all the histopathological grades investigated; 3. A stronger increase of the MCM7 labelling index, in relation to the tumor aggressiveness, was observed;",Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 in Astrocytoma Grading,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
264,15115103,1,Submitted,0,NA,"1. Telomerase activity was detected in 30% of the samples analysed, included glioblastoma multiforme, meduloblastoma, paraganglioma and oligodendroglioma; 2. The result of Fisher's exact test indicated that there was a significant association between telomerase activity status with tumor grade (p=0.003); 3. These results suggest that telomerase activity may be an important marker for tumor malignancy;",Telomerase activity in Malaysian patients with central nervous system tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
265,31311947,1,Submitted,0,NA,1. Brain tumor cells release EVs containing GFAP and Tau  and suggest that EV GFAP and Tau have potential as brain tumor biomarkers; 2. Sixty-fve percent (11/17) of brain tumor patients showed higher EV-GFAP than the maximum observed in controls; 3. Ninety-four percent (16/17) of tumor patients showed higher EV-Tau than the maximum observed in controls; 4. We found a good correlation between Western blot-detected Tau and DEP-detected Tau IF; 5. EV-GFAP and Tau serve as biomarkers of redundant or related pathophysiologic processes;,A Pilot Proof-Of-Principle Analysis  Demonstrating Dielectrophoresis  (DEP) as a Glioblastoma Biomarker  Platform,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
266,31865249,1,Submitted,0,Glioma; Radiotherapy; Exosomal miRNAs; Potential biomarker,"1. MicroRNA (miRNA) sequencing was performed on miRNAs isolated from serum exosomes in a cohort of glioma patients before and after radiotherapy; 2. A total of 18 up-regulated differentially expressed (DE) miRNAs and 16 down-regulated DE miRNAs were identified; 3. qPCR confirmed the overexpression of hsa-miR-6731-5p and hsa-miR-208b-3p, and the lower-expression of hsa-miR-2116-3p after radiotherapy; 4. The target genes of DE miRNAs were primarily involved in metabolic process, p53 signaling pathway and cancer pathways;",Identification of miRNA signatures in serum exosomes as a potential  biomarker after radiotherapy treatment in glioma patients ,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
267,25950799,1,Submitted,0,NA,"1. We identified 19 miRNAs with significantly different plasma levels in GBM patients, compared to the healthy individuals group. The most strongly downregulated miRNA in GPs was the hsa-miR-383 (logFC=1.85), whereas the most strongly up-regulated one was the hsa-miR-603(logFC=2.68); 2. Ten miRNAs overlapped in this respect and were therefore considered to be both diagnostic and prognostic, which makes them particularly appealing. These were hsa-miR-302c-3p, hsa-miR-592, hsa-miR-484, hsa-miR-1260a, hsa-miR-493-3p, hsa-miR-514a-3p, hsa-miR-145-5p, hsa-miR-30a-5p, hsa-miR-124-3p and hsa-miR-483-5p; 3. To expose the most significant, we propose hsa-miR-592 and hsa-miR-514a-3p as potential novel GBM biomarkers with both diagnostic and prognostic clinical potential; 4. Validated target genes of hsa-miR-592 are DICER (dicer 1,  ribonuclease type III), an endonuclease with a role in the biogenesis of the active small RNA component and CCNDI that interacts  with the Rb tumor suppressor protein;",Analysis of Glioblastoma Patients Plasma Revealed the Presence of MicroRNAs with a  Prognostic Impact on Survival and Those of Viral Origin,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
268,22318658,1,Submitted,0,Astrocytic tumor; Astrocyte; Glial fibrillary acidic protein-S; Spinal cord,"1. In normal control tissues, GFAP immunoreactivity was detected in astrocytes whereas GFAP-d immunoreactivity was observed in very few astrocytes adjacent to the subpial layer of the spinal cord; 2. GFAP-d immunoreactivity was significantly correlated with spinal cord astrocytoma grade in astrocytomas compared to that in normal control tissues; 3. The optical density of GFAP-d increased significantly with astrocytoma grade (correlation coefficient, R2 = 0.680); 4. BRAF and IDH1 immunoreactivity were detected in astrocytoma. We suggest that GFAP-d may be an additional, reliable histopathological diagnostic marker for spinal cord astrocytomas;",A histopathological diagnostic marker for human spinal astrocytoma: expression of glial fibrillary acidic protein-d,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
269,21937590,1,Submitted,0,Cerebrospinal fluid(CSF); glioma; microRNA(miRNA); primary central nervous system lymphoma,"1. MiR-15b and miR-21 were differentially expressed in CSF samples from patients with gliomas, compared to control subjects with various neurologic disorders, including patients with primary CNS lymphoma and carcinomatous brain metastases; 2. Receiveroperating characteristic analysis of miR-15b level revealed an area under the curve of 0.96 in discriminating patients with glioma from patients without glioma; 3. Inclusion of miR-15b and miR-21 in combined expression analyses resulted in an increased diagnostic accuracy with 90% sensitivity and 100% specificity to distinguish patients with glioma from control subjects and patients with primary CNS lymphoma;",ldentification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
270,16150117,1,Submitted,0,astrocytoma; cell cycle; glioblastoma; Mcm-2; prognosis,"1. There was a significant increase in Mcm-2 (P < 0.0001), Ki67 (P < 0.0001), cyclin A (P < 0.0001) and cyclin B1 (P = 0.002) expression with increasing grade from diffuse astrocytoma through anaplastic astrocytoma to glioblastoma, suggesting that any of these four markers has potential as a marker of tumour grade; 2. In a subset of glioblastomas (n = 16) for which accurate clinical follow-up data were available, there was a suggestion that the cyclin A: Mcm-2 labelling fraction might predict a relatively favourable response to radical radiotherapy;",Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in  diagnostic neuropathology,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
271,24913705,1,Submitted,0,TPM3; MMP-9; SNAI1; Invasion; Migration; EMT; Survival; Glioma,"1. TPM3 overexpression was significantly associated with high-grade gliomas and higher mortality; 2. Using microarray combined with Pearson correlation analysis, we found that TPM3 was positively correlated with the expression of MMP family members and EMT-like activators; 3. Reduction of TPM3 (via TPM3-siRNA) inhibited cellular invasion and migration and decreased MMP-9 and SNAI1 levels in glioma cells;","TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
272,16132504,1,Submitted,0,brain tumor; c-kit; CD11; immunohistochemical staining,"1. Specimens from 52 glial tumors of various histologic types and grades were assayed for CD117 immunoreactivity, and about 75% of the tumors were positive for CD117 expression; 2. The proportion of high grade tumors of all tumor types with detectable CD117 immunoreactivity was statistically significantly greater than low grade tumors, and glioblastoma and anaplastic oligodendroglioma showed the highest staining grade;",CD117 expression in glial tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
273,22843679,1,Submitted,0,NA,1. Migfilin expression significantly correlated with pathological grades of Gliomas; 2. High Migfilin expression is associated with poor prognosis; 3. Migfilin promotes Cell Migration and invasion in Vitro; 4. C-terminal region is essential for Migfilin Up-regulated EGFR expression and Mifflin mediated Migration and Invasion in Glioma Cells; 5. Migfilin-mediated Migration and Invasion is through EGFR- mediated PLC- and STAT3 signaling Pathways;,Migfilin Protein Promotes Migration and Invasion in Human Glioma through Epidermal Growth Factor Receptor-mediated Phospholipase C-  and STAT3 Protein Signaling Pathways,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
274,16444993,1,Submitted,0,11C-methionine-PET; Ki-67LI; glioma,"1. Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031); 2. The prognosis differed significantly between the highgrade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032); 3. The accuracy thus calculated was highest (85.7%) when T/N was 1.5 as determined by ROC analysis; 4. The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6; 5. For the astrocytic tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV;",Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
275,2754455,1,Submitted,0,Polyamines; brain tumours; glioma; metastasis; meningioma,"1. For spermine the test had a specificity of 97% and a sensitivity of 30% in preoperative patients, increasing to 40% in glioma patients; 2. Tumour recurrence in postoperative patients gave a sensitivity of 48% increasing to 60% in glioma groups;",Red blood cell polyamines as a diagnostic indicator of glioma presence and recurrence,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
276,22307528,1,Submitted,0,malignant glioma; proteomics; biomarkers; serum; plasma; prognosis,"1. MIP-1α, was found to correlate with WHO grade among invasive gliomas; 2. MIP-1α promotes human glioblastoma cell proliferation and migration;",Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
277,29901110,1,Submitted,0,glioma; microRNA-141; Ephrin type-A receptor 2; vasculogenic mimicry; migration; invasion,"1. miR-141 expression was downregulated, and Ephrin type-A receptor 2 (EphA2) was upregulated in the primary human gliomas and human glioma-derived cell lines tested; 2. A negative correlation existed between miR-141 and EphA2 expression levels in glioma grades II, III and IV; 3. Exogenous miR-141 expression resulted in decreased proliferation, migration and invasion, as well as in apoptosis and cell cycle arrest in vitro; 4. Exogenous miR-141 expression resulted in in vivo inhibition of tumor growth and inhibition of the development of vasculogenic mimicry (VM); 5. EphA2 was a direct target of miR-141;",miR-141 inhibits glioma vasculogenic mimicry  by controlling EphA2 expression,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
278,21075857,1,Submitted,0,NA,"1. The molecular classification on the basis of IDH1/2 mutation, TP53 mutation, and 1p/19q loss has power similar to histological classification and avoids the ambiguity inherent to the diagnosis of oligoastrocytoma; 2. There was no significant difference in distribution and type of TP53 mutations between different histological types; 3. The majority of tumors with TP53 mutation IDH1/2 mutation (74%) and those with IDH1/2 mutation only (66%) were histologically diagnosed as diffuse astrocytomas, whereas most tumors with 1p/19q loss IDH1/2 mutation (65%) were histologically diagnosed as oligodendrogliomas; 4. The molecular profile of low-grade diffuse gliomas based on IDH1/2 mutations, TP53 mutations and 1p/19q loss provides a more objective classification and correlates well with clinical outcome;",Molecular Classification of Low-Grade Diffuse Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
279,23096411,1,Submitted,0,ELTD1; gliomas; glioblastoma multiforme (GBM); immunohistochemistry (IHC); rat F98 glioma model; molecular MRI,"1. ELTD1 was found to be significantly higher (P=0.03) in high-grade gliomas (50 patients) compared to low-grade gliomas (21 patients), and compared well to traditional IHC  markers including VEGF, GLUT-1, CAIX, and HIF-1α; 2. ELTD1 gene expression indicates an association with grade, survival across grade, and an increase in the mesenchymal subtype; 3. Significantly high (P<0.001) in vivo levels of ELTD1 were additionally found in F98 tumors, compared to normal brain tissue;","ELTD1, A Potential New Biomarker for Gliomas",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
280,21530612,1,Submitted,0,Brain tumor; Tumor suppressor; Tumor microenvironment; ECM degradation; Cell proliferation; MMPs,"1. TFPI-2 expression was absent in five of nine investigated high-grade glioma cell lines; 2. TFPI-2 knockdown impedes glioma cell proliferation, migration and invasion; 3. Glioma cell migration and invasion is limited by TFPI-2; 4. The anti-invasive properties of TFPI-2 are associated with inhibition of MMP-1 and MMP-2, while inhibition of MMP-9 seems to play a minor role in this context;",Knockdown of TFPI-2 promotes migration and invasion of glioma cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
281,18976507,1,Submitted,0,NA,"1. The sequence spanning positions -835 to -293 relative to the translation start site was identified as the LRRC4 promoter, this sequence is a TATA- and CAAT- less, high GC content region; 2. LRRC4 promoter activity is strongly suppressed after treatment with SssI methylase in vitro; 3. LRRC4 promoter methylation was observed by methylationspecific PCR in two glioma cell lines and all 30 primary glioma specimens, but not in normal brain tissue; 4. Bisulfite DNA sequencing showed that most of the CpG sites were located around the LRRC4 promoter methylated in glioma cells and tissues, but not in normal brain tissue; 5. The methylase inhibitor 5-Aza-2'-deoxycytidine could induce LRRC4 mRNA expression and LRRC4 promoter partial demethylation in SF126 and SF767 glioma cells;",Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
282,29366782,1,Submitted,0,glioblastoma; temozolomide resistance; MSH6; DNA mismatch repair; O6 -methylguanine-DNA methyltransferase,"1. Increased expression of MSH6, one of key components of MMR, in recurrent GBM patients' samples who underwent TMZ chemotherapy, comparing with those matched samples collected at the time of diagnosis; 2. Using the cellular models of acquired resistance to TMZ, we further confirmed the up-regulation of MSH6 in TMZ resistant cells; 3. A TCGA dataset contains a large cohort of GBM clinical samples with or without TMZ treatment reinforced the increased expression of MSH6 and other MMR genes after long-term TMZ chemotherapy, which may resulted in MMR dysfunction and acquired TMZ resistance;",Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
283,23504125,1,Submitted,0,Actinin-4; Immunohistochemistry; Infiltrating glioma; WHO grade; Differentiation,"1. All seven World Health Organization (WHO) grade II tumors were negative for actinin-4, whereas 20 of 22 tumors with strong actinin-4 expression were WHO grade IV; 2. Actinin-4 expression was significantly associated with histological grade (P<0.0001) and proliferative activity measured by Ki-67 staining (P = 0.0045); 3. Actinin-4 expression was more pronounced in high-grade astrocytic tumors than oligodendroglial tumors (P<0.0001); 4. Pseudopalisading cells in glioblastoma exhibited stronger actinin-4 expression than the rest, likely reflecting enhanced cellular motility in pseudopalisades;",Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
284,29574566,1,Submitted,0,Diffusion magnetic resonance imaging; Apparent diffusion coefficient; Brain neoplasms; Biopsy,"1. Significant differences in minimum ADC values were found in the quantitative analysis between the grade III and II glioma groups; 2. The sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), accuracy and AUC for identifying grade III and II gliomas at the optimum cut-off value of 0.895×10−3 mm2/s of minimum ADC were 81.0, 89.1, 77.3, 91.1, 86.6 and 0.87, respectively; 3. The predictive diagnostic equation was superior to the single minimum ADC indicator with a sensitivity of 90.5%, a specificity of 84.8%, a PPV of 73.1%, an NPV of 95.1%, and an accuracy of 86.6%, respectively;",Diagnostic performance of apparent diffusion coefficient parameters  for glioma grading,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
285,32484805,1,Submitted,0,Astrocytoma; Cell Death; Lipid Peroxidation; Prognosis,"1. Eight genes panel (ALOX5, CISD1, FTL, CD44, FANCD2, NFE2L2, SLC1A5, and GOT1) were highly related to OS (P<0.001) and PFS (P<0.001) of low-grade glioma (LGG) patients; 2. 6 genes (ALOX5, CD44, FANCD2, NFE2L2, SLC1A5, and GOT1) had significantly different expression in healthy brain tissue vs. glioma (P<0.001);",Ferroptosis in Low-Grade Glioma: A New Marker for Diagnosis and Prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
286,32639004,1,Submitted,0,NA,"1. Plasma miR-720 in the glioma group was significantly higher than that in the healthy control group; 2. Plasma miR-720 level was associated with tumor grade (t = 104.418, P<0.001); 3. The advanced tumor tended to have higher miR-720 expression level; 4. The high expression of miR-720 (HR = 1.48, 95%CI: 1.12-2.97, P=0.023) was independently predictors of adverse prognosis in patients with glioma;",Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
287,32539851,1,Submitted,0,Glioma; Multi-omics; PRKCG; Biomarker; Cerebrospinal fluid,"1. PRKCG is a brain-specific gene and detectable in cerebrospinal fluid; 2. PRKCG is significantly differentially expressed among normal, LGG and GBM samples; 3. PRKCG expression is highly sensitive to survival; 4. PRKCG is significantly differentially methylated among normal, LGG and GBM samples; 5. Combined methylation signatures of PRKCG and MGMT are more effective in treatment prediction; 6. PRKCG-like genes may present heterogeneous roles in glioma tumorigenesis;",Computational identification and characterization of glioma candidate biomarkers through multi-omics integrative profiling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
288,32589128,1,Submitted,0,NA,"1. A total of 14 (51.9%) cases were positive for MYB; 2. MYB-QKI rearrangement was revealed by FISH examination in 95.8% (23/24) of the AGs, including 3 cases with atypical histological appearance;",MYB-QKI rearrangement in angiocentric glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
289,32658431,1,Submitted,0,mir-9; glioma; prognosis,"1. There were 16, 20, 21 cases which showed high expression of mir-9 in grade II and III gliomas and glioblastoma, 16/22 (72.7%), 20/24 (83.3%), 21/25 (84.0%), respectively; 2. The expression of mir-9 was correlated with the grade of glioma; 3. The mir-9 RNA expression in glioblastoma were higher than grade II and III gliomas (p < 0.05); 4. High expression of mir-9, grade, chemotherapy, radiation therapy, and patient onset age were associated with glioma patient prognosis (p < 0.05);",Identification of Mir-9 in Glioma Diagnosis and Prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
290,33287933,1,Submitted,0,Glioma; ATRX; Immunohistochemistry,"1. Positive ATRX immunoexpression was demonstrated in 27 (27.8%) cases; 2. The highest rates of ATRX expression (55.6%) were among 30-39 years' age group, supratentorial (34.2%), and among grade II and III tumors (40.7% and 30% respectively); 3. A significant association was observed between ATRX expression and patient's age, tumor location, tumor type and grade (p-values 0.010, 0.004, 0.004, and 0.037 respectively);",Immunohistochemical expression of ATRX in gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
291,33173989,1,Submitted,0,"transmembrane phosphatase with tensin homology pseudogene 1, microrna-106a-5p, MaPK14, stemness, radioresistance, glioma","1. TPTEP1 is downregulated in glioma and is associated with good patient survival; 2. TPTEP1 suppresses glioma cell stemness and radioresistance both in vitro and in vivo; 3. TPTEP1 interacts with miR-106a-5p in glioma cells; 4. TPTEP1 promotes MAPK14 expression by antagonizing miR-106a-5p binding and activates the P38 MAPK signaling pathway; 5. Associations of TPTEP1, miR-106a-5p and MAPK14 in glioma tissues;",lncRNA TPTEP1 inhibits stemness and radioresistance of glioma through miR-106a-5p-mediated P38 MAPK signaling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
292,33014189,1,Submitted,0,NA,1. The ELF3-AS1 expression level was signiﬁcantly higher in glioma specimens compared with adjacent nontumor specimens; 2. A high expression of ELF3-AS1 was shown to be associated with the WHO grade and KPS score; 3. ROC assays revealed that high ELF3-AS1 expression had an AUC value of 0.8073 for glioma; 4. A high ELF3-AS1 expression had signiﬁcantly poor OS (p = 0.006) and DFS (p = 0.0002); 5. ELF3-AS1 expression was an independent poor prognostic factor for glioma patients; 6. Knockdown of ELF3-AS1 suppressed the proliferation and invasion of glioma cells;,Diagnostic and Prognostic Potentials of Long Noncoding RNA ELF3-AS1 in Glioma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
293,32894165,1,Submitted,0,"Glioma stem cells; Angiogenesis; ISL2, circRNA ARF1; U2AF2; miR-342-3p","1. ISL2 is overexpressed in gliomas and correlates with poor patient survival; 2. ISL2 transcriptionally regulates VEGFA expression in GSCs; 3. ISL2-mediated GCM regulates the proliferation, invasion, and angiogenesis of hBMECs via VEGFA-mediated ERK signaling; 4. MiR-342-3p negatively regulates ISL2 expression through binding its 3'-UTR; 5. MiR-342-3p suppresses the proliferation, invasion, and angiogenesis of hBMECs by inhibiting ISL2 expression in GSCs; 6. The cARF1 acts as a sponge of miR-342-3p; 7. The cARF1 is overexpressed in glioma and correlates with poor patient survival; 8. The cARF1 promotes the proliferation, invasion, and angiogenesis of hBMECs, while miR-342-3p reverses its function in GSCs; 9. The cARF1 promotes gliomas angiogenesis via upregulating ISL2 expression in GSCs; 10. U2AF2 binds to and promotes the expression of cARF1 in GSCs; 11. U2AF2 is expressed at higher levels in glioma and is correlated with poor patient survival; 12. U2AF2 promotes glioma angiogenesis by upregulating cARF1 expression in GSCs; 13. ISL2 transcriptionally regulates U2AF2 expression in GSCs to form a feedback loop; 14. The U2AF2/cARF1/miR-342-3p/ISL2 axis regulates glioma tumorigenesis and angiogenesis in vivo;",The U2AF2 /circRNA ARF1/miR-342-3p/ISL2 feedback loop regulates angiogenesis in glioma stem cells,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
294,32724447,1,Submitted,0,glioma; microRNA-9-3p; forkhead proliferation; apoptosis; U87 cells; TG-905 cells,1. miR-9-3p is downregulated in glioma tissues; 2. Overexpression of miR-9-3p inhibits cell proliferation and increases cell apoptosis; 3. FOXG1 is a direct target of miR-9-3p in glioma cells; 4. FOXG1 gene silencing enhances the effect of miR-9-3p mimic on cell proliferation inhibition and apoptosis;,miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
295,33341429,1,Submitted,0,NA,"1. DKI (mean kurtosis [MK], axial kurtosis [Ka], and radial kurtosis [Kr]) and DTI (mean diffusivity [MD] and fractional anisotropy [FA]) parameters in the enhancing lesions and in the perilesional edema were measured; 2. Relative MK (rMK) was significantly higher and relative MD (rMD) was significantly lower in the enhancing lesions of high-grade glioma recurrence compared to PsP (P < 0.001, P = 0.006, respectively); 3. The AUC was 0.914 for rMK and 0.760 for rMD, and this difference was significant (P = 0.030); 4. In the perilesional edema, rMK values were significantly higher and rMD values were significantly lower in high-grade glioma recurrence compared to PsP (P < 0.001, P = 0.005);",Differentiating high-grade glioma recurrence from pseudoprogression: Comparing diffusion kurtosis imaging and diffusion tensor imaging,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
296,32647893,1,Submitted,0,Biomarker; Glioblastoma; Glioma; Molecular biology,"1. LRG1 high expression rate was 41.2% in glioblastoma, 3.7% in astrocytoma, and 21.4% in oligodendroglioma; 2. Glioblastoma showed a significantly higher LRG1 expression than lower grade glioma (p = 0.0003); 3. High expression of LRG1 was an independent favorable prognostic factor (p = 0.019) in IDH-wildtype glioblastoma and correlated with gross total resection (p = 0.002) and the tumor location on nonsubventricular zone (p = 0.00007);",The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
297,33154941,1,Submitted,0,alpha-methylacyl-CoA racemase; glioblastoma; brain; cancer; biomarker,1. The protein and mRNA levels of AMACR were highly elevated in glioblastoma; 2. Downregulation of AMACR inhibited cell proliferation; 3. Comprehensive analysis of the public REMBRANDT GBM dataset also conﬁrmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients;,"Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
298,32744694,1,Submitted,0,MiR-186; Smad6; Glioma; Apoptosis.,1. MiR-186 was downregulated in glioma tissue samples and glioma U87 Cells; 2. MiR-186 promoted glioma U87 cells apoptosis; 3. Suppression of miR-186 inhibited glioma U87 cells apoptosis; 4. Smad6 was negatively regulated by miR-186 in gliomas; 5. Smad6 overexpression rescued glioma U87 cells apoptosis induced by miR-186; 6. Smad6 suppression promoted glioma U87 Cells apoptosis induced by miR-186;,MiR-186 promotes the apoptosis of glioma U87 cells by down-regulating the expression of Smad6,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
299,32678519,1,Submitted,0,biomarker; glioma; immunotherapeutic targets; PARP9; prognosis,"1. PARP9 is highly expressed in glioma, and high expression of PARP9 is associated with poor prognosis and advanced clinicopathological features; 2. Some immune-related pathways were closely associated with high expression of PARP9; 3. PARP9 was closely related to inflammatory and immune responses, high immune cell infiltration, and immune checkpoint molecules;",Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
300,32425605,1,Submitted,0,glioma; circRNA; plasma; biomarker; serum,"1. circFOXO3, circ_0029426, and circ-SHPRH might be the ﬁngerprints for GBM compared with controls; 2. The risk score analysis revealed that the combination of three circRNAs could distinguish the GBM from healthy control with the area under curve value of 0.980 and 0.906, respectively; 3. circFOXO3, circ_0029426, and circ-SHPRH weres stably expressed and detectable in human plasma;",Plasmatic circRNA Predicting the Occurrence of Human Glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
301,32725378,1,Submitted,0,Glioblastoma; Pituitary tumor-transforming gene 1; Angiogenesis; Invasion,"1. PTTG1 was overexpressed in human GBM tissues; 2. PTTG1 silencing suppressed the proliferation ability of U251 cells; 3. Correlations between PTTG1 levels and the mRNA levels of HIF-α, PDGFβ, VEGF, MMP2, MMP9, MMP14, p53, p21 and cyclin D1; 4. Effects of PTTG1 on angiogenesis, apoptosis, invasion and migration in U251 GBM cells; 5. PTTG1 knockdown represses U251 cell angiogenesis; 6. Knockdown of PTTG1 induced U251 cell apoptosis; 7. PTTG1 knockdown represses U251 cell invasion and migration in vitro; 8. PTTG1 exerts an oncogene function through the TGF-β1/PI3K/AKT/mTOR-signaling pathway;","Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
302,32506303,1,Submitted,0,miRNA-351; NAIF1; Glioma; Proliferation; Invasion,"1. The miR-351 expression was significantly decreased in U87 and U251 cell lines compared with the NHA cell line (P < 0.05); 2. NAIF1 expression was significantly higher in glioma cell lines compared with the NHA cell line (P < 0.05); 3. The NAIF1 expression showed a negative correlation with miR-351 (P = 0.005, r = −0.522); 4. Apoptosis was significantly decreased in both cell lines transfected with miR-351 mimics compared with the NC group at 72 and 96 h after transfection (P < 0.05) and significantly increased in the transfected group with miR-351 inhibitors compared with the NC group at 72 and 96 h after transfection (P < 0.05); 5. According to our results, after 24 and 48 h, migration was increased in the mimic group compared with the miR-351 NC group and decreased in the inhibitory group compared with the miR-351 NC group in the U251 cell line;",MicroRNA-351 Promotes the Proliferation and Invasion of Glioma Cells through Downregulation of NAIF1,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
303,32626942,1,Submitted,0,glioblastoma; Feline leukemia Virus Subgroup C cellular receptor 1 antisense RNA 1; mir-30b-3p; invasion,"1. FLVCR1-AS1 expression was significantly upregulated in GBM tissues compared with adjacent normal brain samples, and was higher in GBM cell lines compared with normal human astrocyte cells; 2. miR-30b-3p was revealed to be a putative target of FLVCR1-AS1, and the suppressive effects of miR-30b-3p on cellular proliferation and invasion were reversed following FLVCR1-AS1-knockdown; 3. FLVCR1-AS1-knockdown inhibited GBM cell proliferation and invasion ability; 4. FLVCR1-AS1 was found to directly interact with miR-30b-3p, and a rescue experiment further established that FLVCR1-AS1 contributed to glioma progression by inhibiting miR-30b-3p; 5. FLVCR1-AS1 may serve an oncogenic role in GBM and promote disease progression by interacting with miR-30b-3p;",Long non-coding RNA FLVCR1-AS1 promotes glioma cell proliferation and invasion by negatively regulating miR-30b-3p,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
304,32724343,1,Submitted,0,glioma; Rab5; cyclin E; tumorigenesis; metastasis,"1. The upregulation of Rab5 in glioma tissues and cells was observed; 2. The expression of Rab5 was positively associated with proliferation, migration and invasion of glioma cells; 3. Rab5 was involved in the cell cycle of glioma cells via the regulation of cyclin E;","Rab5 regulates the proliferation, migration and invasion of glioma cells via cyclin E",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
305,33083454,1,Submitted,0,NA,"1. miR-766-5p and miR-376b-5p were signiﬁcantly downregulated in high-grade glioma and intracranial lymphoma patients compared with the healthy controls (all p < 0.001), and the expression of serum exosomal miR-766-5p in the intracranial lymphoma group was lower compared with the high-grade glioma group (p < 0.05); 2. The expressions of miR-766-5p and miR-376b-5p in serum exosomes could be used for auxiliary diagnosis of high-grade glioma and intracranial lymphoma, while miR-766-5p had a higher diagnostic eﬃcacy;",High-Throughput Sequencing-Based Identification of Serum Exosomal Differential miRNAs in High-Grade Glioma and Intracranial Lymphoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
306,32918539,1,Submitted,0,circMMP1; exosome; glioma; HMGB3; miR-433,1. CircMMP1 is up-regulated in glioma tissues and serum exosomes derived from glioma patients; 2. CircMMP1 depletion suppresses the proliferation and metastasis abilities of glioma cells; 3. CircMMP1 interference induces the apoptosis of glioma cells; 4. MiR-433 is a direct target of circMMP1 in glioma cells; 5. CircMMP1 accelerates glioma progression through its miR-433 sponge activity; 6. MiR-433 reduces the level of HMGB3 through direct interaction; 7. HMGB3 overexpression partly overturns miR-433 accumulation-mediated influences on glioma cells; 8. HMGB3 is regulated by circMMP1/ miR-433 axis in glioma cells; 9. CircMMP1 promotes glioma progression in vivo;,CircMMP1 promotes the progression of glioma through miR-433/HMGB3 axis in vitro and in vivo,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
307,33282010,1,Submitted,0,NA,1. ZNF667-AS1 was signiﬁcantly upregulated in glioma tissues compared to normal tissue samples (p < 0.01); 2. Higher levels of ZNF667-AS1 were positively associated with the WHO grade (p = 0.018) and KPS score (p = 0.008); 3. ROC assays revealed that the high ZNF667-AS1 expression had an AUC value of 0.8541 (95% CI: 0.8148 to 0.8934) for glioma; 4. Survival data revealed that glioma patients in the high ZNF667-AS1 expression group had signiﬁcantly shorter 5-year overall survival (p = 0.0026) and disease-free survival (p = 0.0005) time than those in the low ZNF667-AS1 expression group; 5. ZNF667-AS1 expression was an independent predictor of the overall survival and disease-free survival for glioma patients; 6. Knockdown of ZNF667-AS1 suppressed the proliferation of glioma cells;,Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
308,32434559,1,Submitted,0,Astrocytoma; Oligodendroglioma; Biomarkers; Decision making; prognosis,"1. The sensitivity and specificity of the mismatch sign for IDH-mut detection were 26.4 and 97.6%, respectively; 2. There were no differences between patients with an IDH-mut astrocytoma with or without mismatch sign when grouped according to T2-FLAIR mismatch sign with respect to baseline characteristics, clinical outcomes and methylation profiles; 3. The overall interrater agreement between neuroradiologist and clinical neurosurgeons for the T2-FLAIR mismatch sign was significant when all 215 MRI examination assessed (κ = 0.77, p < 0.001, N = 215);",The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
309,32301283,1,Submitted,0,glioma; prognostic signature; protein disulphide isomerase,"1. DNAJC10, TMX1, PDIA4, PDIA5, PDIA6, P4HB and TXNDC5 was significantly up-regulated in brain and CNS cancers when compared with normal tissue; 2. Immunohistochemistry staining data suggested that the expression of P4HB, PDIA5, TMX1, PDIA4, PDIA6, DNAJC10, TMX3, ERP44, ERP29, ERP27 and TXNDC5 was positively correlated with glioma grade; 3. Four subgroups of gliomas (cluster 1/2/3/4) were identified based on consensus clustering of the PDI gene family;",Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
310,32822001,1,Submitted,0,Rhoj; GBM; Actin cytoskeleton; Invasion; Moesin,1. Rhoj Is Significantly Overexpressed in Glioblastoma and Correlates with Poor Patients' Survival; 2. Silencing Rhoj Inhibits Proliferation and Tumorigenesis of GBM Cells and Induces Cell Cycle Arrest; 3. The Deficit of Rhoj Restrained Cell Migration and Invasion of GBM Cells In Vitro and Was Related to EMT-Like Phenotype; 4. The Transcription Factor c-Jun Directly Regulated Rhoj Expression;,Rhoj Is a Novel Target for Progression and Invasion of Glioblastoma by Impairing Cytoskeleton Dynamics,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
311,33369441,1,Submitted,0,Glioblastoma; cell cycle; miR-4731; miRNAs,"1. Down-regulation of miR-4731 expression occurred in GBM cell; 2. MiR-4731 behaved as a tumor suppressor by inhibiting GBM cell proliferation; 3. MiR-4731 affected cell proliferation, migration, and invasion of U87 and U251 cells; 4. miR-4731 targeted the 3'-untranslated region (3′-UTR) of EGFR;","Involvement of EGFR, ERK-1,2 and AKT-1,2 Activity on Human Glioma Cell Growth",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
312,32462908,1,Submitted,0,Diagnosis; Glioma; Invasion; miR-33b;  Migrationprognosis; Proliferation,"1. Expression of miR-33b in glioma patients and cells was decreased; 2. Expression of miR-33b had high diagnostic accuracy and could predict a poor prognosis; 3. Overexpression of miR-33b led to suppressed glioma cell proliferation, migration and invasion;","Clinical significance of miR-33b in glioma and its regulatory role in tumor cell proliferation, invasion and migration",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
313,32888253,1,Submitted,0,Glioma; Proteomics; Epidermal growth factor receptor; EGF-like domain multiple 7; Targeted therapy; Selumetinib,1. The expression of EGF-like domain multiple 7 (EGFL7) was higher in EGFR-positive tumor tissues than in EGFR-negative tumor tissues; 2. EGFL7 could act as an activator in vitro and in vivo to promote glioma cell proliferation; 3. EGFL7 was associated strongly with EGFR and prognosis; 4. EGFL7 knockdown effectively suppressed glioma cell proliferation; 5. Selumetinib treatment showed tumor reduction effect in EGFR-positive glioblastoma xenograft mouse model;,Proteomics identifies EGF-like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor-positive glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
314,33235502,1,Submitted,0,"solitary brain metastasis; β2-microglobulin; neutrophil/lymphocyte ratio; monocyte/lymphocyte ratio, routine blood test; high-grade glioma","1. The patients with sBM had significantly higher values of preoperative age, β2-m, NLR and MLR as well as lower lymphocytes count than patients with HGG; 2. The combination of Age+β2-m+NLR+MLR showed the best diagnostic performance with AUC of 0.731 (0.675-0.788) and 0.048*Age+0.001*β2-m+0.201*NLR+0.594*MLR>5.813 could indicate sBM rather than HGG;",Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
315,32642707,1,Submitted,0,NA,1. PTPRZ mRNA and protein were elevated in glioma tissue compared with a normal brain; 2. sPTPRZ in CSF from glioma patients was elevated 10-fold compared with control CSF; 3. sPTPRZ in CSF is a potential diagnostic marker for glioma;,Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
316,32628487,1,Submitted,0,"glioblastoma; biomarker, secretome; cerebrospinal ﬂuid; laminin subunit alpha-4; osteopontin","1. Laminin subunit alpha-4 (LAMA4) and osteopontin (OPN) had increased expression levels in the CSF from GBM patients compared to those from non-brain tumor patients; 2. The areas under the curves in a receiver operating characteristic analysis of LAMA4 and OPN were greater than 0.9, allowing for discrimination of GBM patients from non-brain tumor patients; 3. The CSF levels of LAMA4 and OPN were also signiﬁcantly correlated with the GBM tumor volume;",Laminin Subunit Alpha-4 and Osteopontin Are Glioblastoma-Selective Secreted Proteins That Are Increased in the Cerebrospinal Fluid of Glioblastoma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
317,33397920,1,Submitted,0,NA,1. TERT expression and the ALT pathway induce unique 1 H-MRSdetectable metabolic signatures in genetically-engineered glioma models; 2. Hyperpolarized [1-13C]-alanine can non-invasively monitor TMM status in genetically-engineered glioma models; 3. H-MRS and hyperpolarized [1-13C]-alanine can track modulation of TERT expression or the ALT pathway in patientderived LGOG and LGA models; 4. TERT expression and the ALT pathway lead to alterations in steady-state metabolite levels in orthotopic tumor xenografts that can be detected by 1 H-MRS; 5. Hyperpolarized [1-13C]-alanine non-invasively monitors TERT expression and the ALT pathway in genetically-engineered and patient-derived LGOG and LGA models in vivo; 6. TERT expression and the ALT pathway are linked to MRSdetectable metabolic reprogramming in LGOG and LGA patient biopsies;,Non-invasive assessment of telomere maintenance mechanisms in brain tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
318,32783304,1,Submitted,0,biomarker; DNA methylation; gliomas; MS-HRM,"1. RASSF1A was the most frequently methylated gene, with statistically significant differences depending on the tumor WHO grade; 2. Higher MGMT methylation levels were observed in females, whereas the levels of SFRP1 and INA promoter methylation significantly increased with patients' age; 3. A positive correlation of promoter methylation levels was observed between pairs of genes, for example, CBLN4 and INA or MGMT and RASSF1A;",DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
319,32436804,1,Submitted,0,Glioma; HOXA2; biomarker; oncogene,"1. High HOXA2 expression was found to be positively correlated with clinical grade, histological type, age, and tumor recurrence, but negatively correlated with 1p19 codeletion and isocitrate dehydrogenase mutation status; 2. RT-PCR results showed that HOXA2 expression levels were significantly higher in tumor tissues than in non-tumor brain tissues; 3. HOXA2 promoted the activation of the activation of the JAK-STAT-signaling pathway, focal adhesion, cell-adhesion-molecules-CAMS pathway, cytosolic DNA sensing pathway, and natural killer cell-mediated cytotoxicity;",Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
320,32879995,1,Submitted,0,Amides; Chemoradiotherapy; Glioma; Magnetic resonance imaging,"1. APT imaging was compatible with other advanced MRI parameters in differentiating recurrent diffuse glioma from treatment-induced changes; 2. The diagnostic performance of the predictive model improved upon inclusion of APT signal, as confirmed by NRI and IDI values greater than zero;",Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
321,33228171,1,Submitted,0,T2-FLAIR mismatch sign; glioma; diagnosis; prediction,"1. The T2-FLAIR mismatch sign when co-registered with the degree of tumor homogeneity were significant predictors of the IDH status (OR 29.642; 95% CI 1.73-509.15, p = 0.019); 2. The probability of being IDH mutant in the presence of T2-FLAIR mismatch sign was as high as 92.9% (95% CI 63-99%); 3. The sensitivity and specificity of T2-FLAIR mismatch sign in the detection of the IDH mutation was 88.9% and 86.7%, respectively;",The Role of the T2-FLAIR Mismatch Sign as an Imaging Marker of IDH Status in a Mixed Population of Low- and High-Grade Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
322,33085976,1,Submitted,0,BRAFV600E mutation; Chordoid glioma of the third ventricle; Histiocyte-like cells; PRKCA D463H mutation,"1. Fourteen of our 16 cases (87.5%) were found to harbor PRKCA D463H mutations, including case 5 and case 9 harboring BRAF V600E mutation;","PRKCA D463H Mutation in Chordoid Glioma of the Third Ventricle: A Cohort of 16 Cases, Including Two Cases Harboring BRAFV600E Mutation",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
323,34006227,1,Submitted,0,Soluble cytotoxic T-lymphocyte antigen 4(sCTLA-4); Glioma; Biomarker; Prognosis,"1. Serum sCTLA-4 levels were significantly increased in patients with glioma compared to that of healthy individuals, and which was also positively correlated with the tumor grade; 2. ROC curve analysis showed that the best cutoff value for sCTLA-4 for glioma is 112.1 pg/ml, as well as the sensitivity and specificity with 82.0 and 78.0%, respectively, and a cut-off value of 220.43 pg/ml was best distinguished in patients between low-grade glioma group and high-grade glioma group with sensitivity 73.1% and specificity 79.2%; 3. Patients with high sCTLA-4 levels (> 189.64 pg/ml) had shorter progression-free survival (PFS) compared to those with low sCTLA-4 levels (≤189.64 pg/ml); 4. High-grade tumor, high sCTLA-4 levels and high Ki-67 index were significantly associated with shorter PFS; 5. sCTLA-4 levels and tumor grade remained an independent prognostic factor;",Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
324,33483477,1,Submitted,0,NA,1. ADO acts as an oncogene in glioma and its expression associates with tumor malignancy; 2. ADO promotes the endogenous synthesis of hypotaurine; 3. ADO is upregulated in glioblastoma stem-like cells; 4. ADO promotes glioma stemness via augmenting a NF-κBCCL20 axis; 5. Inhibiting ADO attenuates glioblastoma growth in vivo;,ADO/hypotaurine: a novel metabolic pathway contributing to glioblastoma development,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
325,33098284,1,Submitted,0,apparent diffusion coefficient; diffusion-weighted imaging; magnetic resonance imaging; brain tumors.,1. There was a statistically significant difference LGG and HGG in terms of mean ADC t and mean ADC tch values and ratios; 2. ADC tch values and ratios showed a statistically significant difference in the differentiation of HGG and metastasis and in the differentiation of HGG and lymphoma;,Diagnostic efficacy of apparent diffusion coefficient measurements in differentiation of malignant intra-axial brain tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
326,33579299,1,Submitted,0,"Gliomas; Immunotherapy; T cell; FCER1G, biomarker",1. FCER1G was significantly higher in glioma with greater malignancy and predicted poor prognosis; 2. FCER1G is associated with immune infiltration and immune activation in gliomas; 3. Gene FCER1G stratified glioma cases into high and low FCER1G expression subgroups that demonstrated with distinct clinical outcomes and T cell activation; 4. High FCER1G levels presented great immunotherapeutic response in glioma patients;,Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
327,34022185,1,Submitted,0,NA,"1. Roughly half of gangliogliomas have ganglion cells stained by cyclin D1, two thirds of PXA have pleormophic cells stained by cyclin D1 and 15% of giant cell glioblastoma have pleomorphic cells stained by cyclin D1 (p < 0.001); 2. Cyclin D1 never stained normal neu rons either in the adjacent cortex of circumscribed tumor, or in entrapped neurons in IDH wild type glioblastomas; 3. The expression of cyclin D1 is correlated to the presence of BRAF V600E mutation in ganglioglioma and PXA; 4. cyclin D1 positivity might be used to confirm the neoplastic nature of ganglion cells;","Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
328,33391514,1,Submitted,0,EDB-Fibronectin; Glioma; Big Data; Biomarkers; Micelles,"1. In brain tumor tissues, EDB-FN expression was universally increased regardless of grade or molecular status compared to normal tissues, with a p value of < 0.0001; 2. Grade IV brain tumors showed the highest EDB-FN expression levels; 3. EDB-FN expression levels increased as grades progressed from I to IV; 4. EDB-FN can be a useful target for brain tumors, especially MG, regardless of the molecular status; 5. EDB-FN as a prognostic biomarker for GBM;",Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
329,33551616,1,Submitted,0,inflammatory markers; glioma; IDH status; oncology,1. dNLR has the maximum diagnostic value in diagnosing glioma from other tumors; 2. NLR (AUC = 0.83926) showed the highest accuracy for GBM diagnosis and may be a parameter in predicting the grade of glioma; 3. NLR has maximum diagnostic value in differentiating IDH wild GBM from IDH mutant GBM;,Peripheral Inflammatory Blood Markers in Diagnosis of Glioma and IDH Status,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
330,34064637,1,Submitted,0,glioblastoma; circulating miRNA; blood plasma; NanoString; network analysis; biomarker,"1. Expression of hsa-miR-433-3p, hsa-miR-195-5p, and hsa-miR-29a-3p was significantly upregulated compared with those in the control samples; 2. Hsa-miR-433-3p, hsa-miR-195-5p, and hsa-miR-29a-3p could discriminate patients with malignant tumors from patients with non malignant masses with a power AUC of 0.98214, 0.9704, and 0.98214, respectively;",Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
331,33925821,1,Submitted,0,SRSF1; diagnosis; glioma; neuropathology; immunohistochemistry,"1. Most glioblastoma (81%), oligodendroglioma (71%), sub-ependymal giant cell astrocytoma (80%) and pleomorphic xanthoastrocytoma (75%) cases showed strong SRSF1 immunoexpression, while no detectable staining was found in the majority of ependymomas (87% of cases) and pilocytic astrocytomas (67% of cases);",Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
332,34094916,1,Submitted,0,glioblastoma; lncRNA; ceRNA; miR-137; LSD1,"1. HAS2-AS1 expression was upregulated in GBM cell lines, and HAS2-AS1 was localized mainly in the cytoplasm; 2. In vitro, high HAS2-AS1 expression promoted proliferation, and knockdown of HAS2-AS1 signiﬁcantly inhibited proliferation; 3. HAS2-AS1 functioned as a ceRNA (competing endogenous RNA) of miR-137, leading to the disinhibition of its downstream target LSD1; 4. The miR-137 level was downregulated by HAS2-AS1 overexpression and upregulated by HAS2-AS1 knockdown; 5. LSD1 expression was negatively regulated by miR137, while miR-137 reversed the LSD1 expression levels caused by HAS2-AS1;",LncRNA HAS2-AS1 Promotes Glioblastoma Proliferation by Sponging miR-137,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
333,33791000,1,Submitted,0,small ubiquitin-like modifier 1 pseudogene 3; glioma; proliferation; cell cycle; migration,"1. SUMO1P3 expression was upregulated in glioma tissues and cell lines; 2. SUMO1P3 was associated with a poor overall survival of patients with glioma; 3. SUMO1P3-knockdown suppressed cell proliferation and cell cycle; 4. SUMO1P3-knockdown significantly repressed cell migration and invasion; 5. SUMO1P3 promoted glioma by regulating the expression levels of β-catenin, cyclin-D1, N-cadherin and E-cadherin;",Long non-coding RNA SUMO1P3 promotes tumour progression by regulating cell proliferation and invasion in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
334,34098960,1,Submitted,0,Glioma; Oncogene; Biomarker; GNG5,"1. GNG5 is highly expressed in gliomas; 2. High expression of GNG5 is a predictor of poor prognosis; 3. Relationship between GNG5 and the underlying molecular and clinical characteristics in glioma patients; 4. GNG5 regulates signaling pathways, including cell adhesion molecules in glioma; 5. GNG5 is related to the immune microenvironment;","GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
335,33552592,1,Submitted,0,prognostic; glioblastoma; GPX2; expression; database,1. No signiﬁcant differences in GPX2 expression between normal and GBM from GEPIA data (P > 0.05) and UALCAN (P = 0.257); 2. Patients with higher GPX2 intended to have a poorer prognosis (P = 0.0089); 3. The KEGG pathways found that chemokine-signaling pathway were the more preferred;,The clinical significance of glutathione peroxidase 2 in glioblastoma multiforme,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
336,33975615,1,Submitted,0,Glioma; Exosome; Temozolomide; Hsa_circ_0072083; miR-1252-5p; NANOG,"1. circ_0072083 abundance is enhanced in TMZ-resistant glioma tissues and cells; 2. circ_0072083 silence inhibits NANOG level via regulating ALKBH5-mediated demethylation in TMZ-resistant glioma cells; 3. circ_0072083 interacts with miR-1252-5p to modulate ALKBH5/NANOG axis and TMZ resistance in TMZ-resistant glioma cells; 4. The secretion of exosomal circ_0072083 is dependent on Warburg effect in TMZ-resistant glioma cells; 5. Exosomal circ_0072083 from resistant cells promotes TMZ resistance in sensitive glioma cells; 6. Exosomal circ_0072083 is related to TMZ resistance, diagnosis and survival of glioma patients;",Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
337,33603467,1,Submitted,0,GBM; SLC16A1-AS1; miR-149; methylation; proliferation,"1. SLC16A1-AS1 expression was upregulated in GBM tissues, and the upregulated expression of SLC16A1-AS1 predicted poor survival of GBM patients; 2. MiR-149 was downregulated in GBM tissues and inversely correlated with the expression of SLC16A1-AS1; 3. In GBM cells, overexpression of SLC16A1-AS1 downregulated the expression of miR-149 and increased the methylation of miR-149 gene; 4. In cell proliferation and colony formation assay, overexpression of SLC16A1-AS1 reduced the inhibitory effects of miR-149 on GBM cell proliferation;",LncRNA SLC16A1-AS1 is Upregulated in Glioblastoma and Promotes Cancer Cell Proliferation by Regulating miR-149 Methylation,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
338,33732379,1,Submitted,0,glioblastoma; proliferation; Hes5; Notch intracellular domain; Notch1,1. NICD is upregulated in human GBM tissues compared with normal brain tissues; 2. The Notch1 signaling pathway is activated in GBM tissues; 3. NICD promotes the proliferation of U87 cells; 4. Downregulation of NICD suppresses the proliferation of U87 cells;,Notch intracellular domain regulates glioblastoma proliferation through the Notch1 signaling pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
339,33583081,1,Submitted,0,GFAP; glioma; alternative splicing; GFAP isoforms; intermediate filaments,"1. The analysis of RNA sequencing data of glioma patient material has revealed the expression of another and new GFAP isoform in glioma, GFAPµ; 2. The GFAPµ transcript was detected in different glioma subtypes by RNA sequencing and was significantly decreased in grade IV glioma; 3. The expression of GFAPµ mRNA, a product of GFAP exon 2 skipping which results in a PTC in exon 3, was confirmed by qPCR analysis in healthy brain tissue, spinal cord tissue, glioma cell lines, and primary glioma cells; 4. We here provide evidence for a new GFAP alternative splicing event observed in glioma and in the healthy brain that results in the expression of GFAPµ; 5. GFAP alternative splicing could form an interesting therapeutic target for glioma treatment;",New GFAP splice isoform (GFAPµ) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
340,34051735,1,Submitted,0,Glioma; XRCC2; Oncogene; Prognosis; Biomarker,"1. We found the overexpression of XRCC2 in glioma; 2. The overexpressed XRCC2 was associated with a variety of clinical features related to prognosis; 3. Cox and meta-analyses showed that XRCC2 is an independent risk factor for the poor prognosis of glioma; 4. Overexpressed XRCC2 could promote malignant progression through involved signaling pathways, such as in the cell cycle; 5. Doxazosin, quinostatin, canavanine, and chrysin were identified to exert anti-glioma effects by targeting XRCC2;",Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
341,33868481,1,Submitted,0,glioblastoma multiforme; temozolomide; X-ray repair cross-complementing protein; drug resistance,1. XRCC5 expression is upregulated in GBM tissues and is associated with poor prognosis; 2. XRCC5 is involved in TMZ-induced apoptosis in U-87MG cells; 3. High expression level of XRCC5 in GBM cells can promote TMZ resistance; 4. TMZ induces XRCC5 expression level in TMZ-resistant U-87 MG cells to promote resistance to TMZ both in vivo and in vitro;,Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
342,34115146,1,Submitted,0,Humans; Glioma; Magnetic resonance imaging; Oxygen metabolism; Neoplasm recurrence; Treatment failure; Neovascularization,"1. Quantitative analysis of MRI biomarkers demonstrated microvascular but no macrovascular hyperperfusion in early recurrence; 2. Neovascularization activity (AUC=0.833), microvascular perfusion (0.682), and oxygen metabolism (0.661) showed higher diagnostic performance for early recurrence detection of WHO grade 3 glioma compared to conventional MRI including cerebral blood volume (0.649);","Physiological MRI of microvascular architecture, neovascularization activity, and oxygen metabolism facilitate early recurrence detection in patients with IDH-mutant WHO grade 3 glioma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
343,34017077,1,Submitted,0,NA,1. CircCHAF1A is overexpressed in TP53-wild type gliomas and associated with low survival rate; 2. Effect of circCHAF1A on the TP53wt GBM cells' growth; 3. Effect of HOXC8 on the growth of TP53wt GBM cells; 4. Transcription regulation of MDM2 expression in GSCs by HOXC8; 5. CircCHAF1A serves as a miRNA sponge of miR-2115p to regulate HOXC8 expression; 6. MiR-211-5p suppresses TP53wt GSCs proliferation through inhibiting HOXC8 expression; 7. CircCHAF1A facilitates the proliferation of TP53wt GSCs through miR-211-5p-mediated HOXC8 expression; 8. FMR1 bound to and upregulate circCHAF1A expression in GSCs; 9. HOXC8 transcriptionally regulates FMR1 expression; 10. CircCHAF1A and HOXC8 promoted GSCs tumorigenesis in vivo;,FMR1/circCHAF1A/miR-211-5p/HOXC8 feedback loop regulates proliferation and tumorigenesis via MDM2-dependent p53 signaling in GSCs,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
344,33858489,1,Submitted,0,"Glioma stem cells; CircATP5B; MiR-185-5P, HOXB5; SRSF1; IL6; JAK2/STAT3 signaling",1. CircATP5B upregulation in glioma correlates with poor patient survival; 2. HOXB5 is overexpressed in glioma and correlates with poor patient survival; 3. HOXB5 regulates the proliferation of GSCs; 4. MiR-185-5p negatively regulates HOXB5 expression; 5. MiR-185-5p suppresses the proliferation of GSCs via HOXB5 inhibition; 6. CircATP5B acts as a miRNA sponge of miR-185-5p; 7. CircATP5B promotes the proliferation of GSCs through miRNA sponging of miR-185-5p; 8. CircATP5B can upregulate the expression of HOXB5 through miRNA sponging of miR-185-5p; 9. CircATP5B promotes the proliferation of GSCs by upregulating the expression of HOXB5; 10. HOXB5 transcriptionally regulates IL6 expression and activates JAK2/STAT3 signaling; 11. HOXB5 regulates the proliferation of GSCs via IL6/JAK2/ STAT3 signaling; 12. SRSF1 can bind to and upregulate circATP5B expression; 13. SRSF1 regulates the proliferation of GSCs by upregulating circATP5B expression; 14. HOXB5 transcriptionally regulates SRSF1 expression in GSCs; 15. The SRSF1/circATP5B/miR-185-5p/HOXB5 feedback loop regulates glioma tumorigenesis in vivo;,The SRSF1/circATP5B/miR-185-5p/HOXB5 feedback loop regulates the proliferation of glioma stem cells via the IL6-mediated JAK2/STAT3 signaling pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
345,32359929,1,Submitted,0,Conventional MRI features; Gliomas; Molecular pathology; Noninvasive predictor.,"1. Patients with calcification and T1 nonenhancement are more likely to be IDH-mutant; 2. Patients with noncalcification, homogenous signal, sharp lesion margins, subventricularzone involvement on T2 and T2/fluid attenuated inversion recovery mismatch signs are more likely to be 1p/19q non-codeletion;",The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
346,35585639,1,Submitted,0,Low-grade gliomas; HLA-DRA; Glioma; Immune; TEM; Biomarker,"1. Our analysis revealed that a high expression of HLA-DRA was associated with a poor prognosis of LGG; 2. Correlation analysis of immune cells showed that HLA-DRA expression level was related to immune infiltration, positively related to macrophage M1 phenotype, and negatively related to activation of NK cells;",New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
347,35547391,1,Submitted,0,H2BC12; TCGA; diagnosis; gliomas; prognosis,"1.Based on the sample data from multiple databases and RT-qPCR, higher expression of H2BC12 mRNA was found in GII and GIII glioma tissue compared to normal tissue, which was consistent with a trend with our clinical specimen; 2. High H2BC12 levels were associated with IDH status, 1p/19q codeletion, primary therapy outcome, and the histological type of gliomas; 3.The overall survival (OS), disease-specific survival (DSS), and progress-free interval (PFI) of GII glioma patients with higher levels of H2BC12 were shorter than those of patients with lower levels as well as GIII patients; 4. A high H2BC12 level was an independent predictor for poor survival outcomes of gliomas; 5.H2BC12 DNA methylation was high in TP53 nonmutant patients, and no H2BC12 mutation was observed in gliomas patients;",The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
348,34173716,1,Submitted,0,"glioma, grade, migration, PAICS, proliferation, weighted gene co‐expression network analysis",1. Expression of PAICS is up-regulated in glioblastoma tissues; 2. Inhibition of PAICS suppresses proliferation and migration in glioma cell lines; 3. Inhibition of PAICS suppresses cell cycle and apoptosis in glioma cell lines; 4. PAICS regulates the genes expression through NER pathway; 5. L-aspartic acid inhibits proliferation of glioma cells by regulating the expression of PAICS;,PAICS is related to glioma grade and can promote glioma growth and migration,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
349,35490433,1,Submitted,0, ITGA9; Integrin subunits; biomarkers; cancer; mechanisms; targets.,"1. The abnormal expression of ITGA9 in a variety of tumors, including glioblastoma, rhabdomyosarcoma, melanoma, hepatocellular carcinoma, nasopharyngeal carcinoma, multiple myeloma, non-small cell lung cancer, and prostate cancer, was closely related to the proliferation, metastasis, adhesion, and angiogenesis of tumor cells；",ITGA9: Potential Biomarkers and Therapeutic Targets in Different Tumors,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
350,35490305,1,Submitted,0,Biomarker; Brain tissue; Diagnosis; Glioblastoma; miRNA,"1. We showed the downregulation of hsa-let-7c-5pand hsa-miR-206-5p, and upregulation of hsa-miR-1909-5p in glioblastoma tumor compared to healthy samples; 2. ROC curve analysis showed that the signature of candidate miRNAsis a potential biomarker distinguishing between glioblastoma and healthy samples; 3. Only hsa-miR-206-5p showed the association with poor prognosis in glioblastoma patients;",A signature of three microRNAs is a potential diagnostic biomarker for glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
351,35488516,1,Submitted,0,IDH status; advanced diffusion models; amide proton transfer imaging; glioma grading; magnetic resonance imaging,"1. Compared with IDH-mutant gliomas, IDH-wildtype gliomas showed a significantly higher mean, 5th-percentile (APT5 ), and 95th-percentile from APTw, the 95th-percentile value of axial, mean, and radial diffusivity from DKI, and 95th-percentile value of isotropic volume fraction from NODDI, and no significantly different parameters from DTI and MAP (P = 0.075-0.998); 2. The combined APT model showed a significantly wider area under the curve (AUC 0.870) for IDH status, when compared with DKI and NODDI; 3. APT5 was significantly different between two of the three groups (glioma II vs. glioma III vs. glioma IV: 1.35 ± 0.75 vs. 2.09 ± 0.93 vs. 2.71 ± 0.81).",Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
352,35454889,1,Submitted,0,EVs; SRPX; glioblastoma; proteomics,"1. SRPX mRNA and protein expression were associated with tumor grade; 2. Temozolomide (TMZ)-resistant tumor tissues showed highly positive SRPX staining, compared to all other tumor grades; 3. Glioblastoma cells displayed enhanced SRPX gene expression when exposed to TMZ; 4. Knockdown of SRPX gene expression via siRNA inhibited cell viability;",SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
353,35419275,1,Submitted,0,Biomarker; Cancer; Endocytosis; Glioblastoma; SCARF2,"1. Higher expression of SCARF2 has been found in glioblastoma (GBM) than normal brain tissue; 2. Through analysis of The Cancer Genome Atlas database, it was confirmed that SCARF2 is widely expressed in GBM, and increased SCARF2 expression correlated with a poor prognosis in patients with glioma;",Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
354,34250760,1,Submitted,0,biomarker; c-Kit; diagnosis; glioblastoma multiforme; prognosis; stem cell factor.,"1. Mean preoperative SCF plasma level of the GBM patients was significantly higher than the healthy controls and patients with nonglial tumor; 2. Receiver operating characteristic analysis revealed that the preoperative SCF plasma level could distinguish the GBM patients from healthy controls and patients with nonglial tumors with the area under curve values of 0.915 and 0.790, respectively; ",Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
355,35347632,1,Submitted,0,Biomarker; Brain tumor; Childhood; Pilocytic astrocytoma (PA); Tumor microenvironment (TME),"1. The ROC analysis revealed that the five hub genes had good diagnostic value for patients with PA (AUC > 0.99); 2. The expression of NCKAP1L was negatively correlated with immune, stromal, and estimated scores, and positively correlated with immune gene sets;",Clinical and Epidemiological Study of Intracranial Tumors in Children and Identification of Diagnostic Biomarkers for the Most Common Tumor Subtype and Their Relationship with the Immune Microenvironment Through Bioinformatics Analysis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
356,34288811,1,Submitted,0,CHST12; Glioblastoma; β-catenin pathway.,"1. The expression of CHST12 increased in GBM tissues than in adjacent tissues and had an important diagnostic value in distinguishing tumor tissues from adjacent tissues; 2. The high expression of CHST12 indicated a lower overall survival rate, was negatively associated with the Karnofsky Performance Scale score, was positively associated with the KI67 expression rate, and was an independent risk factor for GBM; 3. Knockdown of CHST12 significantly decreased the GBM cell proliferation; 4. Suppression of CHST12 expression inhibited GBM cell mobility; 5. Inhibition of CHST12 significantly decreased the WNT/β-catenin pathway in GBM cells; 6. Restoration of the β-catenin expression reversed the effects of CHST12 knockdown;",Knockdown of carbohydrate sulfotransferase 12 decreases the proliferation and mobility of glioblastoma cells via the WNT/β-catenin pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
357,34311746,1,Submitted,0,Autophagy; Biomarker; Glioma; Prognosis; VMP1.,1. VMP1 is overexpressed in glioma and is associated with an advanced stage; 2. VMP1 overexpression predicts a poor prognosis in glioma; 3. VMP1 knockout (KO) by the CRISPR-Cas9 gene editing system significantly inhibits cell proliferation; 4. VMP1 depletion blocked the progression of autophagic flux; 5. VMP1 depletion sensitizes glioma to radiotherapy and chemotherapy; 6. Nomogram model based on VMP1 expression shows highprognostic value in glioma;,"VMP1, a novel prognostic biomarker, contributes to glioma development by regulating autophagy",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
358,35364762,1,Submitted,0,IDH-wild-type astrocytoma; Imaging marker; Molecular glioblastoma; T2-FLAIR; TERT,"1. A gyriform infiltration was observed in 16/31 (52%) molecular glioblastoma, 40/294 (14%) IDH-wild-type glioblastoma, and none of the IDH-mutant glioma; 2. All the 56 gyriform-infiltration-positive tumors were IDH-wild-type and all but two had a TERT promoter mutation;",Gyriform infiltration as imaging biomarker for molecular glioblastomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
359,34367317,1,Submitted,0,NA,"1. The AP1S3 level was dramatically upregulated in glioblastoma (GBM) samples, but greatly reduced in low-grade glioma (LGG) samples when compared to that in normal tissues; 2. The KaplanMeier curve data showed that AP1S3 was closely related to the disease-free survival (DFS) of glioma; 3. The reduction of AP1S3 in glioma cells could result in the inhibition of cell proliferation, invasion, and migration;",Adaptor Protein Complex 1 Sigma 3 Is Highly Expressed in Glioma and Could Enhance Its Progression,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
360,35361282,1,Submitted,0,Glioma; PAICS; SPI1; migration; proliferation,1. Increasing SPI1 levels correlate with glioma progression; 2. SPI1 promotes glioma cell lines proliferation and migration in vitro; Inhibition of SPI1 suppresses cell cycle and apoptosis in glioma cell lines; 3. SPI1 is a transcriptional regulator of PAICS; 4. SPI1 promotes glioma cell proliferation and migration through PAICS;,Study on the role of transcription factor SPI1 in the development of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
361,35194922,1,Submitted,0,Cox-Lasso regression; biomarker; cross-talk signalling; epigenetic regulation; integrative analysis; malignant glioma; noncoding RNA,"1. The model is very suitable for LGG and is also suitable for GBM (AUC of approximately 0.90 and C-index of approximately 0.86 in LGG and AUC of approximately 0.75 and C-index of approximately 0.69 in GBM), which highlights the partial similarities and differences between LGG and GBM; 2. The ncRNAs AC020907.1, Y_RNA, TMEM72-AS1, KRT16P2, DLX6-AS1 and AP002414.1 would competitively interact with hsa-miR-424, which would bind to TBPL1 mRNA, indirectly promoting TBPL1 expression; 3. TBPL1 would bind to the NPAS2 promoter to promote its expression, and NPAS2 would interact with BMAL1 to promote CRY2 and PER2 expression and suppress C-MYC expression;",Top-down stepwise refinement identifies coding and noncoding RNA-associated epigenetic regulatory maps in malignant glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
362,35198024,1,Submitted,0,NA,"1. MiR-526b-3p levels were decreased within glioma cells and further decreased within ADR-resistant glioma cells; 2. MiR-526b-3p overexpression repressed glioma cell proliferation and invasion while inducing cell apoptosis; 3. Overexpression of miR-526b-3p within ADR-resistant glioma cells obtained similar results, which suggested miR-526b-3p suppressed glioma cell resistance to ADR; 4. MiR-526b-3p targeted MAPKE1 and negatively regulated MAPKE1 expressions; 5. Restoration of MAPKE1 levels reversed miR-526b-3p effects on the glioma process and resistance to ADR;",MiR-526b-3p Inhibits the Resistance of Glioma Cells to Adriamycin by Targeting MAPRE1,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
363,35269968,1,Submitted,0,glioma; HOXD-AS2; TFE3; miR-661,"1. TFE3 and miR-661 maintain the high expression level of HOXD-AS2 by regulating its production and degradation; 2. TFE3 acted as a transcription factor binding to the HOXD-AS2 promoter region and raised H3K27ac to activate HOXD-AS2; 3. As the cytoplasmic-located lncRNA, HOXD-AS2 could be degraded by miR-661; 4. This process was inhibited in gliomas due to the low expression of miR-661;","Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
364,35275520,1,Submitted,0,3’UTR; OPN; SPP1; alternative polyadenylation (APA); glioblastoma,"1. In this study we show that SPP1 gene undergoes Alternative cleavage and Polyadenylation (APA) mechanism, by which it generates two 3 termini, longer isoform and shorter isoform, in glioblastoma derived cell line, U87-MG; 2. Further bioinformatic analysis reveals that SPP1 alternative 3UTR (aUTR), which is absent in shorter isoform, is targeted by two families of microRNAs-miR-181abcd/4262 and miR-154/872; 3. These miRNAs also target and perhaps negatively regulate NAP1L1 and ENAH genes that are involved in cell proliferation and cell polarity, respectively; 4.Relative expression difference (RED), obtained from RNA-seq data of diverse normal tissues, representing APA usage appears to be negatively correlated with expression of NAP1L1 and ENAH, emphasizing co-expression of SPP1 longer isoform with these two genes, indicating miRNA sponge function of aUTR (longer 3UTR); 5. Bioinformatic analysis also shows that in normal brain tissue longer APA isoform of SPP1 is expressed; however shorter isoform appears to be expressed in cancer condition;",Alternative polyadenylation mechanism links secreted phosphoprotein 1 gene to glioblastoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
365,35293659,1,Submitted,0,HJURP; KLF11; biomarker; glioma; prognosis,"1.  In this study, we found that KLF11 was highly expressed in glioma cancer tissues and cells, and KLF11 high expression of glioblastoma (GBM) and lower-grade glioma (LGG) were correlated with poorer overall survival and disease-free survival percentages; 2. KLF11 knockdown inhibited glioma cell proliferation and migration, while KLF11 overexpression enhanced cell proliferation and migration; 3. In vivo, knockdown of KLF11 reduced the tumor size of glioma. With regard to the molecular regulatory mechanism, we clarified that the Holliday junction recognition protein (HJURP) was positively regulated by KLF11; 4. Meanwhile, we demonstrated that HJURP knockdown also inhibited glioma carcinoma progression; 5. Overexpression of HJURP rescued the suppressed proliferation and migration function of glioma cells with depletion of KLF11;",KLF11 promotes the progression of glioma via regulating Holliday junction recognition protein,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
366,35328072,1,Submitted,0,VEGF signaling pathway; biomarker; co-expression; differentially expressed genes; gene ontology pathway enrichment; glioblastoma multiforme.,1. We further observed these five most significant hub genes also up-regulated in another GBM gene expression dataset; 2. The protein-protein interaction (PPI) network of the turquoise module genes was constructed and a KEGG pathway enrichments study of the turquoise module genes was performed; 3. The VEGF signaling pathway was emphasized because of the strong link with GBM;,"Screening the Significant Hub Genes by Comparing Tumor Cells, Normoxic and Hypoxic Glioblastoma Stem-like Cell Lines Using Co-Expression Analysis in Glioblastoma",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
367,34439271,1,Submitted,0,FREM2; algorithmically deduced molecular pathway; glioblastoma; glioma; survival prognosis; transcriptomics.,"1. FREM2 molecular pathway was a better biomarker than FREM2 gene expression; 2. High FREM2 pathway activation level was associated with poor overall survival (OS) in LGG, and low progression-free survival in LGG and GBM; 3. FREM2 pathway activation level was also a poor prognosis biomarker for OS and PFS in LGG with IDH mutation, for PFS in LGG with wild type IDH and mutant IDH with 1p/19q codeletion, in GBM with unmethylated MGMT, and in GBM with wild type IDH.",Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
368,35064290,1,Submitted,0,Diagnosis; High-grade glioma; Low-grade glioma; Metastases; Prognosis; miR,"1. MiR-10b could reliably differentiate brain metastases from high-grade gliomas, while miR-491 could distinguish low-grade from high-grade gliomas and brain metastases from low-grade gliomas; 2. MiR-21 and miR-7 correlated with disease recurrence, survival status and the Karnofsky Performance Status; 3. The selected signature of miR-7, miR-21, miR-10b and miR-491 could be used as a highly accurate diagnostic, grading and prognostic biomarker in differentiating various types of brain tumours;","Diagnostic, grading and prognostic role of a restricted miRNAs signature in primary and metastatic brain tumours. Discussion on their therapeutic perspectives",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
369,35086552,1,Submitted,0,Antitumor therapy; BCL2L1 splicing variants; Glioblastoma; Glioma mouse models; Splicing factor SF3B1,"1. The splicing-factor-3B-subunit-1 (SF3B1, an essential and druggable spliceosome component) is low-frequency mutated in human gliomas (~ 1 %) but widely overexpressed in glioblastoma compared with control samples from the different human cohorts and mouse models included in the present study, wherein SF3B1 levels are associated with key molecular and clinical features; 2. Remarkably, in vitro and in vivo blockade of SF3B1 activity with pladienolide B drastically altered multiple glioblastoma pathophysiological processes likely by suppressing AKT/mTOR/ß-catenin pathways, and an imbalance of BCL2L1 splicing; ",SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
370,34485142,1,Submitted,0,"glioblastoma, PIWI-interacting RNA, piRNA, diagnosis, prognosis","1. Deregulation of piR1849, piR-9491, piR-12487, and piR-12488 was successfully conﬁrmed in the independent groups of patients and controls (all p < 0.0001), and piR-9491 and piR-12488 reduced GBM cells’ ability to form colonies in vitro; 2. In addition, piR-23231 was signiﬁcantly associated with the overall survival of the GBM patients treated withStuppregimen (p = 0.007);",Small RNA Sequencing Identifies PIWI-Interacting RNAs Deregulated in Glioblastoma—piR-9491 and piR-12488 Reduce Tumor Cell Colonies In Vitro,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
371,34539820,1,Submitted,0,Chinese Glioma Genome Atlas; collagen α-1 (IV) chain; glioma; intracranial malignancies; prognosis.,"1. COL4A1 expression was not only increased at the mRNA level but also at the protein level as compared with that in normal brain tissue; 2. COL4A1 expression was associated with reduced overall survival of patients, particularly those with World Health Organization grade III glioma; 3. Receiver operating characteristic analysis suggested that COL4A1 had a moderate diagnostic value for glioma; 4.The expression levels of COL4A1 were positively associated with the histological type and historical grade of the tumor, patient age, 'Primary, Recurrent, Secondary' type and the chemotherapy status, and negatively associated with isocitrate dehydrogenase mutation and 1p19q co-deletion (P<0.001); 5. Overexpression of COL4A1 promoted cancer-associated pathways, such as the JAK/STAT signaling pathway and cell cycle regulation; 6. Knockdown of COL4A1 inhibited the proliferation and migration ability of glioma cells;",COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
372,34539892,1,Submitted,0,RPL34-AS1; VEGFA; angiogenesis; glioma; lncRNA; proliferation.,"1. RPL34-AS1 is upregulated in glioma tissues and cell lines, and its expression is correlated with tumor grade; 2. Knockdown of RPL34-AS1 suppresses proliferation in GBM cell lines; 3. RPL34-AS1 promotes endothelial cell angiogenesis by regulating VEGFA; 4. Knockdown of RPL34-AS1 suppresses VEGFA production via regulation of ERK/AKT signaling;","A novel lncRNA, RPL34-AS1, promotes proliferation and angiogenesis in glioma by regulating VEGFA",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
373,34540893,1,Submitted,0,CD74; diagnosis; glioma; immune microenvironment; prognosis.,"1. CD74 was highly expressed in glioma tissue compared to normal brain tissue and its expression was significantly higher in the high-grade glioma compared to the lower grade glioma at transcriptional and translational levels; 2. CD74 was positively associated with immune checkpoints and inflammatory cytokines as well as immune processes including cytokine secretion and leukocyte activation; 3. The high expression of CD74 indicated a high infiltration of immune cells such as macrophages, dendritic cells, and neutrophils; 4. Patients with high expression of CD74 had poor prognoses;",CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
374,34556138,1,Submitted,0,Differentially expressed genes; GBM; Glioblastoma; Invasion; MDK; Midkine; Migration; PI3K-Akt signaling.,1. MDK RNA expression was higher in GBM brain tissue than in healthy controls; 2. MDK promotes the proliferation of GBM cells; 3. Overexpression of MDK enhances the migration and invasion of GBM cells; 4. MDK activates PI3K-Akt signaling pathway in human GBM cells;,Midkine promotes glioblastoma progression via PI3K-Akt signaling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
375,34627193,1,Submitted,0,CSF-1; Glioblastoma; circCDC45; miR-485-5p.,"1. CircCDC45 was aberrantly highly expressed in GBM tissues and cells; 2. CircCDC45 downregulation blocked GBM cell proliferation, migration and invasion; 3. CircCDC45 functioned as the molecular sponge of miR-485-5p; 4. CircCDC45 regulated GBM cell proliferation, migration and invasion by targeting miR-485-5p; 5. CSF-1 was a target of miR-485-5p; 6. CSF-1 knockdown blocked GBM cell proliferation, migration and invasion; 7. CircCDC45 downregulation repressed tumor growth in vivo by targeting the miR-485-5p/CSF-1 axis;",CircCDC45 promotes the malignant progression of glioblastoma by modulating the miR-485-5p/CSF-1 axis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
376,35109832,1,Submitted,0,"Biomarker; Cysteine cathepsin C; Gene set enrichment; Glioma; Piperlongumine, scopoletin; Prognosis","1. The expression of CTSC in glioma was higher than that in non-cancerous cells; 2. CTSC expression may regulate the malignant development of glioma through Toll-like receptor signaling pathways, pathways in cancer, and extracellular matrix receptor interaction signaling pathways; 3. Piperlongumine and scopoletin could inhibit CTSC expression in glioma cells;",Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
377,35163043,1,Submitted,0,Engrailed; Hedgehog; ROS; glioblastoma; irradiation sensitivity,"1. Engrailed 1 (EN1) is highly expressed in serum-free cultured glioma cells as well as glioma tissues, and increased expression level predicts a worse prognosis; 2. EN1 controls glioma cell proliferation, colony formation, migration, and tumorigenic capacity in vivo; 3. It also influences sensitivity of glioma cells to γ-ray irradiation by regulating intracellular ROS levels; 4. EN1 influences Hedgehog signaling by regulating the level of Gli1 as well as primary cilia length and the primary cilia transport-related protein TULP3;",EN1 Regulates Cell Growth and Proliferation in Human Glioma Cells via Hedgehog Signaling,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
378,35163067,1,Submitted,0,glioblastoma; somatostatin analogs; somatostatin receptor; splicing variant; sst5TMD4.,"1. sst5TMD4 was significantly overexpressed (at mRNA and protein levels) in human GBM tissue compared to non-tumor (control) brain tissue; 2. sst5TMD4 expression was significantly associated with poor overall survival and recurrent tumors in GBM patients; 3. In vitro sst5TMD4 overexpression (by specific plasmid) increased, whereas sst5TMD4 silencing (by specific siRNA) decreased, key malignant features (i.e., proliferation and migration capacity) of GBM cells (U-87 MG/U-118 MG models); 4. sst5TMD4 overexpression in GBM cells altered the activity of multiple key signaling pathways associated with tumor aggressiveness/progression (AKT/JAK-STAT/NF-κB/TGF-β), and its silencing sensitized GBM cells to the antitumor effect of pasireotide (a somatostatin analog); ","Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
379,35183683,1,Submitted,0,CDK2; GBM; Glioma; Immune cells; LGG; Survival,"1. CDK2 was overexpressed in glioma compared to normal brain tissues; 2. CDK2 was overexpressed in higher grade glioma compared to lower grade glioma; 3. CDK2 expression was higher in groups related to poor prognostic factors in low-grade glioma but had no difference in high-grade glioma; 4. CDK2 was associated with worse overall survival in overall glioma and within low-grade glioma; 5. The low expression of CDK2 was associated with genes regulating normal brain functions while the high expression of CDK2 was associated with genes regulating immune cells and cancer; 6. CDK2 was negatively correlated with B cells, T cells CD4+, and T cells CD8+; 7. CDK2 was positively correlated with endothelial cells, macrophage, and NK cells; 8.  CDK2 high group had higher expression of the immune checkpoint genes, and the calculation suggested that patients with a lower CDK2 expression were much more likely to respond to immunotherapy;",A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
380,34641541,1,Submitted,0,CSF; biomarkers; extracellular vesicles; glioblastoma; longitudinal; proteomics; serum.,"1. Forty-four proteins displayed signiﬁcant differences in signal intensities during GBM progression; 2. Dysregulated proteins are involved in cell motility, cell growth, and angiogenesis;","Longitudinal Bottom-Up Proteomics of Serum, Serum Extracellular Vesicles, and Cerebrospinal Fluid Reveals Candidate Biomarkers for Early Detection of Glioblastoma in a Murine Model",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
381,35186945,1,Submitted,0,PD-L1; glioma; immune suppression; lyn; microenvironment; prognostic marker,"1. High expression level of LYN was observed in advanced gliomas and other cancer types, which predicted a worse prognosis; 2.  LYN stratified patients survival in the Xiangya cohort and was also significantly associated with infiltrating immune cell types and inflammatory activities in the tumor microenvironment; 3. LYN was involved in tumor mutation, correlated with the regulation of oncogenic genes, and also showed a significant positive correlation with PD-L1;",Immune Characteristics of LYN in Tumor Microenvironment of Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
382,34646412,1,Submitted,0,Glioma; TIMELESS; biomarker; oncology; small molecule compound.,1. Abnormally high expression of TIMELESS in glioma; 2. High expression of TIMELESS is an unfavorable factor for prognosis of glioma;,Expression and clinical significance of TIMELESS in glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
383,34953037,1,Submitted,0,ITGB3BP; biomarker; clinical features; glioma; prognosis,"1. The expression level of ITGB3BP in glioma tissues was significantly higher than that in normal brain tissues; 2. ITGB3BP contributes to the poor prognosis of glioma by activating tumour-related signalling pathways; 3. Some small-molecule drugs were identified, such as hexestrol, which may specifically inhibit ITGB3BP and be useful in the treatment of glioma; 5. A correlation between the expression of ITGB3BP and the infiltration of various immune cells in glioma; ",ITGB3BP is a potential biomarker associated with poor prognosis of glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
384,34712225,1,Submitted,0,TNFSF13; gliomas; immune infiltration; inflammation; prognostic marker.,"1. TNFSF13 expression was upregulated in the increase of tumor grades based on Xiangya cohort; 2. In high TNFSF13 gliomas, somatic mutation was proved to correlate with amplification of EGFR and deletion of CDKN2A; while mutation of IDH1 was more frequently observed in low TNFSF13 group; 3. We also confirmed the positive correlation between TNFSF13 and infiltrating immune and stromal cells in glioma microenvironment; 4. TNFSF13 was found to be involved in immunosuppression via diverse immunoregulation pathways and was associated with other immune checkpoints and inflammation; 5. Single-cell sequencing revealed an abundant expression of TNFSF13 in neoplastic cells and M2 macrophages, which TNFSF13 might potentially regulate the cell communication via IL-8, C3, and CD44; 6. TNFSF13 mediated the activities of transcription factors including FOXO3, MEIS2, and IRF8;",TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
385,34970298,1,Submitted,0,FAM20C; LGG; bioinformatics; biomarker; lower-grade gliomas; prognosis,"1. Fam20C was drastically overexpressed in LGG and was positively associated with its clinical progression; 2. Fam20C was found as an independent risk factor in LGG patients; 3. The potential signaling pathways associated with Fam20C gene expression in LGG, these pathways were mainly enriched in extracellular matrix receptor interactions, cell adhesion, cell apoptosis, NOTCH signaling, cell cycle, etc; ",Fam20C Overexpression Predicts Poor Outcomes and is a Diagnostic Biomarker in Lower-Grade Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
386,34722888,1,Submitted,0,STOX1; bioinformatics; biomarker; glioma; overall survival.,"1. Low STOX1 expression was significantly associated with older age at initial diagnosis (P < 0.001), less IDH1 mutation (P < 0.001), and advanced WHO grade (P < 0.001); 2. STOX1 expression may serve as a novel independent prognostic biomarker in glioma patients; 3.  STOX1 was related to many key cancer pathways including P53 signaling pathway (P < 0.01), DNA replication (P < 0.05), homologous recombination (P < 0.05), and Wnt signaling pathway (P < 0.05);",Downregulation of STOX1 is a novel prognostic biomarker for glioma patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
387,34729101,1,Submitted,0,EMT; Glioma; LBX2-AS1; LIF; miR-491-5p.,"1,LBX2-AS1 was upregulated in glioma samples and cell lines, and its transcription was promoted by binding to the transcription factor SP1; 2. As a lncRNA mainly distributed in the cytoplasm, LBX2-AS1 sponge miR-491-5p to further upregulate LIF; 3. The subsequent activated LIF/STAT3 signaling was responsible for promoting proliferation and EMT in glioma;",SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
388,34976781,1,Submitted,0,ELK3; biomarker; glioma; oncology; prognosis,"1. The abnormally high expression of ELK3 in gliomas was confirmed; 2. A high ELK3 expression was markedly associated with low patient survival and served as an independent biomarker of gliomas; 3. ELK3 was positively correlated with several clinical characteristics of patients with gliomas, such as age, WHO classification, and recurrence; 4. ELK3 overexpression markedly promoted the proliferation and migration of glioma cells; 5. Overexpression of ELK3 regulated the JAK-STAT signaling pathway and upregulate the expression of signal transducer and activator of transcription 3 (STAT3) and phosphorylated STAT3 (P-STAT3) to promote the malignant transition of gliomas;",ELK3: A New Molecular Marker for the Diagnosis and Prognosis of Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
389,34760705,1,Submitted,0,IGHG1; cancer-derived immunoglobulin G; glioma; microenvironment; progression.,"1. The expression of IGHG1 was higher in glioma and molecular subtypes with poor prognosis; 2. The overall survival of patients with a high expression of IGHG1 was worse in the stratified analysis; 3. The expression level of IGHG1 was positively correlated with the stromal score, ESTIMATE score, and immune score and negatively correlated with tumor purity; 4. IGHG1 may function in phagosome, antigen processing and presentation, extracellular matrix structural constituent, antigen binding, and collagen-containing extracellular matrix; 5. Patients with a high expression of cancer-IgG had poor OS and disease-free survival (DFS):",Upregulated Expression of Cancer-Derived Immunoglobulin G Is Associated With Progression in Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
390,35044082,1,Submitted,0,CRISPR-Cas9; co-functional network; glioma; prognostic biomarkers; scRNA-seq,"1. We demonstrated the network significantly enriched various biological pathways and may play roles in glioma tumorigenesis; 2. From densely connected glioma functional modules, we further predicted 12 potential Wnt/β-catenin signalling pathway targeted genes, including AARSD1, HOXB5, ITGA6, LRRC71, MED19, MED24, METTL11B, SMARCB1, SMARCE1, TAF6L, TENT5A and ZNF281; 3. Cox regression modelling with these targets was significantly associated with glioma overall survival prognosis; 4. TRIB2 was identified as a glioma neoplastic cell marker in single-cell RNA-seq of GBM samples;",Identification of a glioma functional network from gene fitness data using machine learning,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
391,34765972,1,Submitted,0,XGBoost; classification; gene signature; glioblastoma subtypes; statistical learning.,"1. NKAIN1 has the highest expression in proneural subtype as compared to both classical and mesenchymal subtype with no difference in survival; 2. Proneural subtype has the highest expression of UBE2E2 as well, with mesenchymal subtype have a medium expression and classical subtype having the lowest expression; 3. F13A1 has the highest expression in mesenchymal subtype of GBM, a subtype that is also associated with high infiltration of tumor-associated macrophages in the tumor microenvironment; 4. RNF149 is highly expressed in mesenchymal subtype of GBM as compared to classical and pro-neural subtypes; 5. The expression of PLAUR is the highest in the mesenchymal subtype of GBM and high expression also trends towards predicting poor survival in GBM patients (log HR = 0.7[0.49–1], log-rank P-value = .0515); 5. On average, this approach achieved 80.12% accuracy in predicting these three subtypes of GBM; 6. Five-gene classifier successfully predict the subtype of GBM samples at our centre;",Identification of five important genes to predict glioblastoma subtypes,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
392,34812552,1,Submitted,0,Extracellular regulated protein kinase; Glioblastoma multiforme; P53 and DNA damage-regulated gene1; migration; proliferation.,1. PDRG1 was aberrantly overexpressed in GBM and correlated with poor clinicopathologic features of glioma; 2. PDRG1 is an independent prognostic indicator and significantly correlates with disease progression of glioma; 3. Knockdown of PDRG1 inhibits proliferation and migration of GBM cells; 4. PDRG1 silencing obviously inhibited the growth of primary glioma; 5. Expression of adhesion molecule CD44 was regulated by PDRG1 in GBM cells; 6. PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway;,PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
393,34863158,1,Submitted,0,Cell type; Glioma; Single-cell gene expression profile; Tumor gene biomarkers.,"1. The results showed that these candidate tumor gene biomarkers were closely related to glioma and could provide clues for the diagnosis and prognosis of patients with glioma; 2. In addition, we found that four of the candidate tumor gene biomarkers (NDUFS5, NDUFA1, NDUFA13, and NDUFB8) belong to the NADH ubiquinone oxidoreductase subunit gene family, so we inferred that this gene family may be strongly related to glioma;",Gene biomarker prediction in glioma by integrating scRNA-seq data and gene regulatory network,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
394,34900729,1,Submitted,0,blood-based biomarker; early detection; galectin-3 binding protein; plasma-derived extracellular vesicles; proteomics.,"1. LGALS3BP was seen to be upregulated across the different grades, and ELISA analysis from individual blood plasma and plasma-derived extracellular vesicles confirmed the increased expression of LGALS3BP in glioma patients (p<0.001);",Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
395,34908101,1,Submitted,0,CCNB2; Low-grade glioma; bioinformatics; diagnosis and prognosis biomarkers; immune infiltrates.,"1. The expression of CCNB2 differed across different tumor tissues, but was higher in LGG than in normal tissues; 2. LGG patients with high expression of CCNB2 have poorer prognosis; 3. The expression of CCNB2 was correlated with age, WHO grade, IDH mutational status, 1p/19q codeletion status, and other clinicopathological features;",CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
396,35052804,1,Submitted,0,extracellular vesicles; glioblastoma; liquid biopsy,"1. Data indicate the presence of an inflammatory biomarker signature comprising members of the complement and regulators of inflammation and coagulation including VWF, FCGBP, C3, PROS1, and SERPINA1; 2. This study is a step forward in the development of a non-invasive liquid biopsy approach for the identification of valuable biomarkers that could significantly improve GB diagnosis and, consequently, patients prognosis and quality of life; ",Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
397,34970477,1,Submitted,0,ADD3; deletion mapping; glioblastoma; loss of heterozygosity; tumor suppressor,"1. We found that allelic loss in both D10S173 (ADD3/MXI1 locus) and D10S1137 (MGMT locus) were positively associated with tumor grading and proliferative index (MIB-1); 2. LOH events at only the ADD3/MXI1 locus provided prognostic significance with a marked reduction in patient survival and appeared to have diagnostic potential in differentiating high-grade gliomas from low-grade ones; 3. Progressive loss of ADD3 in six out of seven patient-paired gliomas with malignant progression, as well as in recurrent GBMs; 4. The role of ADD3 as a novel tumor suppressor, whereby the loss of ADD3 is indicative of a progressive disease that may at least partially account for rapid disease progression in GBM;",ADD3 Deletion in Glioblastoma Predicts Disease Status and Survival,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
398,34953010,1,Submitted,0,SOX B1 family members; bioinformatics analysis; glioblastoma; overall survival,1. Exogenous inhibition of SOX2 appeared to reduce the migration and invasion of U251 cells in vitro; 2.  Overexpressed SOX2 could serve as a biomarker to identify high risk GBM patients; 3. SOX2 may enhance the migratory and invasive capacity of glioma cells; 4. SOX3 may serve as a prognostic biomarker set for GBM patients;,Expression and significance of SOX B1 genes in glioblastoma multiforme patients,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
399,34917513,1,Submitted,0,glioma; pancreatic adenocarcinoma; phospholipid phosphatase 4; proliferation; tumorigenesis.,"1. PLPP4 expression was primarily detected in the cytoplasm, and the staining intensity of PLPP4 was increased in glioma tissues compared with normal tissues; 2. High expression of PLPP4 was positively associated with advanced clinicopathological features in glioma patients; 3. Overexpression of PLPP4 promoted the invasiveness of glioma LN229 cells, while the number of cells in the shRNA-PLPP4 group was reduced, and the invasiveness was reduced by 55.2% through the transwell assay;",Phospholipid Phosphatase 4 as a Driver of Malignant Glioma and Pancreatic Adenocarcinoma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
400,34942001,1,Submitted,0,circular RNA; diagnosis; exosome; high-grade astrocytoma; liquid biopsy.,"1. By investigating the characteristics of HGA cell-derived exosome circRNAs and HGA cell circRNAs, we observed that exosomes were more likely to enrich short-exon and suppressor circRNAs than HGA cells; 2. A serum exosome circRNA panel including hsa_circ_0075828, hsa_circ_0003828, and hsa_circ_0002976 could be used to screen for HGA, whereas a good prognosis panel comprised high concentrations of hsa_circ_0005019, hsa_circ_0000880, hsa_ circ_0051680, and hsa_circ_0006365;",Circular RNA Sequencing Reveals Serum Exosome Circular RNA Panel for High-Grade Astrocytoma Diagnosis,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
401,34338912,1,Submitted,0,Astrocytoma; Diagnosis; Genetics; Oligodendroglioma; Vimentin.,"1. Vimentin was diffusely positive in astrocytic tumors but negative in oligodendroglial tumors (ODGs) and its expression was significantly higher in isocitrate dehydrogenase (IDH) wild-type tumors; 2.  High vimentin expression was correlated with poor prognosis (hazard ratio [HR]: 5.99), but it was dependent on the new WHO grade which reflects both histologic features and genetics (HR: 1.28);",Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
402,34344068,1,Submitted,0,NA,"1. Tissues were available in nine chordoid gliomas for Sanger sequencing to detect PRKCA and IDH gene mutation, and eight cases (8/9) showed PRKCA gene D463H mutation. None of these cases showed IDH1 R132 and IDH2 R172 mutation.",Chordoid glioma: a clinicopathological study,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
403,34470587,1,Submitted,0,EGFR; Glioblastoma; PI3K/AKT signaling pathway; miR-223-3p; pitpna-as1.,"1. PITPNA-AS1 was highly expressed in glioblastoma; 2. PITPNA-AS1 inhibited the proliferation and promoted the apoptosis of glioblastoma cells; 3. PITPNA-AS1 sponged miR-223-3p to promote EGFR expression, thus activating PI3K/AKT signaling pathway to accelerate proliferation and inhibit apoptosis of GBM cells;",LncRNA PITPNA-AS1 stimulates cell proliferation and suppresses cell apoptosis in glioblastoma via targeting miR-223-3p/EGFR axis and activating PI3K/AKT signaling pathway,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
404,34826036,1,Submitted,0,ATRX; Genetics; Glioma; Immunohistochemistry; Surrogate marker; WHO 5th CNS tumor classification 2021; p53.,"1. ATRX-IHC and p53-IHC should be supplementary to morphological diagnosis; 2. Rare IDH mutations other than IDH1 R132H should be considered; 3. There is no complete alternative test to detect molecular features of glioblastoma under the 2021 WHO classification;

",Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
405,34837760,1,Submitted,0,Biomarker; Exosomes; Extracellular vesicles; Glioblastoma; miRNAs.,"1. Seven DEMs were shared in two datasets, among which hsa-miR-183-5p and hsa-miR-98-5p as well as has-miR-323-3p or has-miR-19b-3p constituted a diagnostic signature to distinguish GBM from controls, with the area under the ROC curve nearly approximate to 1; 2. MAPK8IP1/FAM175B, OSMR/CASP3, PTPN2 and FBXO32 may be underlying targets for hsa-miR-183-5p, hsa-miR-98-5p, has-miR-323-3p and has-miR-19b-3p, respectively;","Identification of serum exosomal miR-98-5p, miR-183-5p, miR-323-3p and miR-19b-3p as potential biomarkers for glioblastoma patients and investigation of their mechanisms",English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
406,34871801,1,Submitted,0,BRAFV600E; Brain tumor; Central nervous system tumor; Subependymal giant cell astrocytoma (SEGA); TTF-1.,"1. TTF-1 immunopositivity was seen in all 38 cases (100%) of SEGAs, with 20 cases (52.6%) showing diffuse (>50% of tumor area) expression while focal (<50%) immunopositivity was seen in 18 cases (47.3%); 2. Barring 2 cases of neurocytoma (6.6%), all other cases including ependymoma, glioblastoma, and cortical tubers were immunonegative for TTF-1;",TTF-1: A Well-Favored Addition to the Immunohistochemistry Armamentarium as a Diagnostic Marker of SEGA,English,2022-06-09 15:37:00.665792+00:00,2022-06-09 15:37:00.665792+00:00
